JOURNAL TRANSCRIPT

---

MONDAY, OCTOBER 16, 2017 P1.01 ADVANCED NSCLC P1.01-001 – P1.01-023 P1.01-024 – P1.01-045 P1.01-046 – P1.01-049 P1.01-050 – P1.01-066 P1.01-067 – P1.01-070 P1.01-071 – P1.01-078a

ALK BIOMARKERS EGFR IMMUNOTHERAPY MISCELLANEOUS PRECLINICAL

P1.02 BIOLOGY/PATHOLOGY P1.02-001 – P1.02-006 P1.02-007 – P1.02-013 P1.02-014 – P1.02-039 P1.02-040 – P1.02-059 P1.02-060 – P1.02-064 P1.02-065 – P1.02-067 P1.02-068 – P1.02-071b

MISCELLANEOUS MISMATCH REPAIR AND MUTATION LOADS MORPHOLOGY OTHER MUTATIONS IN THORACIC MALIGNANCIES PROTEINS IN LUNG CANCER AND PROTEOMICS STEM CELLS IN LUNG CANCER TARGETS FOR TREATMENT PREDICTION

P1.03 CHEMOTHERAPY/TARGETED THERAPY P1.03-001 – P1.03-013 ALK P1.03-014 – P1.03-049 CHEMOTHERAPY P1.03-050 – P1.03-053 MISCELLANEOUS P1.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS P1.05 EARLY STAGE NSCLC P1.05-001 – P1.05-012 MISCELLANEOUS P1.05-013 – P1.05-015 NEOADJUVANT AND ADJUVANT CHEMOTHERAPY P1.05-016 – P1.05-022b RECURRENCE P1.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION P1.06-001 – P1.06-024 EPIDEMIOLOGY P1.07 IMMUNOLOGY AND IMMUNOTHERAPY P1.07-001 – P1.07-044c IMMUNOTHERAPY (BIOMARKERS) P1.08 LOCALLY ADVANCED NSCLC P1.09 MESOTHELIOMA P1.10 NURSING/PALLIATIVE CARE/ETHICS P1.11 PATIENT ADVOCACY P1.12 PULMONOLOGY/ENDOSCOPY P1.12-001 – P1.12-009 THERAPEUTIC ENDOSCOPY P1.13 RADIOLOGY/STAGING/SCREENING P1.13-001 – P1.13-011c STAGING P1.13-011a– P1.13-011b DIAGNOSTIC RADIOLOGY

P1.14 RADIOTHERAPY P1.15 SCLC/NEUROENDOCRINE TUMORS P1.16 SURGERY P1.16-001 – P1.16-028 MINIMAL INVASIVE SURGERY P1.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES P1.17-001 – P1.17-019 THYMOMA

2

Monday, October 16, 2017

Poster Setup Time: Monday, October 16, 08:00 – 10:00 Poster Takedown Time: Monday, October 16, 15:30 – 18:00 (Posters not taken down by 18:00 will be discarded by management) POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME) Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates. Monday, October 16 from 10:00 – 10:45 and 14:30 – 15:30 (Exhibit Hall B + C - Poster Area)

P1.01 ADVANCED NSCLC P1.01-001 – P1.01-023 ALK P1.01-001 Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK+ NSCLC in the ALTA Trial Ross Camidge, University of Colorado Cancer Center, US P1.01-002 TP53 Mutations Predict for Poor Survival in ALK Rearrangement Lung Adenocarcinoma Patients Treated with Crizotinib Gang Chen, Fujian Provincial Cancer Hospital, CN P1.01-003 Patients Harboring a Novel PIK3CA Point Mutation after Acquired Resistance to Crizotinib in ROS1 Rearrangement Adenocarcinoma: A Case Report Wu Zhuang, Fujian Provincial Cancer Hospital, CN P1.01-004 Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC Ross Camidge, University of Colorado Cancer Center, US P1.01-005 Overall Survival (OS) After Disease Progression (PD) on Brigatinib in Patients With Crizotinib-Refractory ALK+ NSCLC in ALTA Corey J Langer, Abramson Cancer Center, University of Pennsylvania, US P1.01-006 Effect of EML-Alk Fusion Variant and Fusion Abundance on the Efficacy of Crizotinib in Non-Small Cell Lung Cancer Tang Feng Lv, Jinling Hospital, CN P1.01-007 ALK Testing Trends and Patterns Among Community Practices in the United States Peter B Illei, Johns Hopkins University School of Medicine, US P1.01-008 Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC Matthew A Gubens, University of California, San Francisco, US P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer Jin Kang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, CN

3

P1.01-010 Circulating Cell-Free DNA of Cerebrospinal Fluid May Function as Liquid Biopsy for Leptomeningeal Metastases of ALK Rearrangement NSCLC Yangsi Li, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, CN P1.01-011 Pattern of Care and Survival of ALK Rearranged Non-Small Cell Lung Cancer in Two Australian Referral Centres Malinda Itchins, University of Sydney, AU P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis Alice Shaw, Massachusetts General Hospital, US P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC Julien Mazieres, Toulouse University Hospital, FR P1.01-014 Feasibility of Liquid Biopsy Using Plasma and Platelets for Detection of ALK Rearrangements in Non-Small Cell Lung Cancer Cheol-Kyu Park, Chonnam National University Medical School, Hwasun Hospital, KR P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial Lorenza Landi, OncoHematology Department, AUSL della Romagna, IT P1.01-016 Next-Generation Sequencing Shows Mechanisms of Intrinsic Resistance in ALK-Positive NSCLC Patients Treated with Crizotinib Ben J Solomon, Peter MacCallum Cancer Centre, AU P1.01-017 ALK-Rearranged May Promote VTE by Increasing the Expression of TF in Advanced Lung Adenocarcinoma Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, CN P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression Anna Li, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, CN P1.01-019 ALK+ Non-Small Cell Lung Cancer Treated with First Line Crizotinib: Patient Characteristics, Treatment Patterns, and Survival Claudio Martín, Fleming Institute, AR P1.01-020 Translocation ALK/EML4+ in Non-Squamous NSCLC Population and Crizotinib: What Can We Tell? Ana Barroso, Centro Hospitalar Vila Nova de Gaia/Espinho, PT P1.01-021 FISH and IHC Discordance in ALK Rearranged Non Small Cell Lung Cancer Akhil Kapoor, Tata Memorial Hospital, IN P1.01-022 Prediction of Central Nervous System Progression During Crizotinib Treatment in ALK+ NSCLC Among Hispanics Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, CO

4

P1.01-023 ALK-Positive NSCLC: A TMH Experience Vikas Talreja, Tata Memorial Hospital, IN P1.01-024 – P1.01-045 BIOMARKERS P1.01-024 Plasma Circulating cfDNA as a Potential Biomarker in Clinical Management of NSCLC: Experience of Tata Memorial Hospital, India Anuradha Choughule, Tata Memorial Hospital, IN P1.01-025 Biomarker Testing in Advanced NSCLC: A Simulation-Based Assessment of Medical Oncologists Tara Herrmann, Medscape Education, US P1.01-026 Circulating miR-206 in Advanced Stage Lung Cancer Patients and Its Association with Cancer Cachexia Noorwati Sutandyo, Dharmais National Cancer Hospital, ID P1.01-027 Combination of Biomarker and Clinicopathologic Characters May Circle out Beneficiaries through Second-Line Immunotherapy: A Meta Analyse Si-Yang Liu, Guangdong Lung Cancer Institute; Guangdong General Hospita & Guangdong Academy of Medical Sciences, CN P1.01-028 Characteristics of Cell Free DNA in Lung Cancer Patients Tomonori Abe, Saga University, JP P1.01-029 Lymphocyte Monocyte Ratio as a Prognostic Factor in Non Small Cell Lung Cancer Tarkan Yetisyigit, Namik Kemal University Hospital, TR P1.01-030 Predictive Biomarkers in Non-SmallCell Carcinoma and Their Clinical Association Anurag Mehta, RGCI&RC, IN P1.01-031 Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients Lisa Wang, Genentech, Inc, US P1.01-032 Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART) Tony SK Mok, The Chinese University of Hong Kong, HK P1.01-033 Thrombogenic Biomarkers in Patients with NSCLC – Associations with Thrombosis, Progression, and Survival Marliese Alexander, Monash University, AU P1.01-034 Cerebrospinal Fluid and Plasma Tumor DNA Profiling Reveals Heterogeneity of CNS Metastasis in Patients with Non-Small-Cell Lung Cancer Panwen Tian, Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, CN P1.01-035 A Next Generation Sequencing and Characteristics Based Model for Predict Clinical Benefit of Advanced NSCLC Patients Yongchang Zhang, Hunan Cancer Hospital, CN

5

P1.01-036 Identifying and Addressing Gaps in Molecular Testing for Patients with Lung Cancer Jennifer C King, Lung Cancer Alliance, US P1.01-037 Circulating Tumor DNA Clearance During Treatment Associates with Improved ProgressionFree Survival Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, CN P1.01-038 Identification and Characterization of Circulating Tumor Cells from Lung Cancer Patients for Selecting Target Anticancer Drugs for Relapse Bong-Seog Kim, Veterans Health Service Medical Center, KR P1.01-039 Survival Impact of Next-Generation Sequencing in Lung Cancer Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, IL P1.01-040 Clinical Utility of Plasma-Based NGS for Advanced-Stage NSCLC Patients with Insufficient or Unavailable Tumor Tissue Pilar Garrido, Hospital Universitario Ramón y Cajal, ES P1.01-041 Role of Re-Biopsy During Disease Progression Non-Small Cell Lung Cancer for Acquired Resistance Analysis and Directing Oncology Treatments Masatoshi Kakihana, Tokyo Medical University, JP P1.01-042 Dynamic ctDNA Assay by Next Generation Sequencing to Guide Targeted Therapy in Advanced Non-Small Cell Lung Cancer Xiaochun Zhang, The Affiliated Hospital of Qingdao University, CN P1.01-043 Molecular Testing for Non-Small Cell Lung Cancer in Latin American Ana Caroline Zimmer Gelatti, Grupo Brasileiro de Oncologia Torácica - GBOT, BR P1.01-044 Detection of Circulating Tumor Cells Is Associated with Disease Burden in Patients with Advanced Non-Small Cell Lung Cancer Kostas Syrigos, University of Athens, GR P1.01-045 Companion Diagnostic Tests for EGFR, ALK and ROS-1 vs NGS in Advanced NSCLC Patients Which Is the Best in Terms of Cost and Effective? Luciene Schluckebier, Fundação do Câncer, BR P1.01-046 – P1.01-049 EGFR P1.01-046 The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGFR-TKI Resistance: A Preliminary Study Lucheng Zhu, Hangzhou First People’s Hospital, Nanjing Medical University, CN P1.01-047 Analysis of EGFR Mutation Status in CSF and Blood in Lung Adenocarcinoma Patients with EGFR Mutation and CNS Metastasis Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, CN P1.01-048 Clinical Impact of EGFR Mutation on Brain Metastasis in NSCLC Patients: A Meta-Regression Analysis Chien-Chung Lin, National Cheng Kung University Hospital, TW

6

P1.01-049 Conformity of EGFR Mutation Status Between Blood Plasma and Tumor Tissue Samples Among NSCLC Adenocarcinoma Patients, at Dr. H. A. Rotinsulu Lung Hospital. A Preliminary Study Reza Kurniawan Tanuwihardja, RS Paru Dr. H. A. Rotinsulu, ID P1.01-050 – P1.01-066 IMMUNOTHERAPY P1.01-050 Cost-Effectiveness of PDL1 Based Test-And-Treat Strategy with Pembrolizumab as the 1st Line Treatment for NSCLC in Hong Kong Herbert H Loong, The Chinese University of Hong Kong, HK P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting Edward Brian Garon, Santa Monica Hematology Oncology, US P1.01-052: Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC) Marcus Ballinger, Genentech Inc., USA P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases Lucio Crinò, Medical Oncology- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, IT P1.01-054 PD-L1 Expression in Patients with Non-Small Cell Lung Cancer According to Underlying Pulmonary Disease: A Retrospective Study Sayaka Ohara, NTT Medical Center Tokyo, JP P1.01-055 Spectrum of Early Progression in Advanced NSCLC Patients Treated with PD-1 Inhibitors: Identifying Markers for Poor Outcome Mizuki Nishino, Dana-Farber Cancer Institute, US P1.01-056 Quality of Life and Clinical Outcomes of Nivolumab as 2+ Line Treatment in Advanced Refractory NSCLC Pts: Interim Analysis Tatiana I Ionova, Multinational Center for Quality of Life Research, RU P1.01-057 Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) José Miguel Sánchez-Torres, Hospital Universitario de La Princesa, ES P1.01-058 Real World Data with Nivolumab: Experience in Argentina Claudio Martin, Department of Clinical Oncology, Instituto Alexander Fleming, AR P1.01-059 Combination Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel for Patients with Recurrent/Metastatic NSCLC and PS of 2 Tamjeed Ahmed, Wake Forest Comprehensive Cancer Center, US P1.01-060 Nivolumab after Progression to Platinum- Based Chemotherapy in Advanced Non-SmallCell Lung Cancer (NSCLC) Mariana López Flores, Complejo Asistencial Universitario de León, ES

7

P1.01-061 The Efficacy and Safety of Anti-PD-1 in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Systematic Review Mingyi Di, Peking Union Medical College Hospital, CN P1.01-062 KRAS Mutations (KRAS-Mut) and antiPD1/PDL1 Therapy in a Cohort of Lung Cancer (LC) Patients (P). Experience from a Single Institution Enric Carcereny, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, ES P1.01-063 Are the Real World Patients with Advanced Non-Small Cell Lung Cancer Represented in Phase III Immunotherapy Trials? Ana Caroline Zimmer Gelatti, Grupo Brasileiro de Oncologia Toracica (GBOT), BR P1.01-064 Efficacy and Tolerability of Nivolumab in Elderly Patients with Advanced Non-Small Cell Lung Cancer Kohei Yamane, Tottori University Hospital, JP P1.01-065 Treatment Beyond Progression with Nivolumab in Patients with Advanced Non-Squamous NSCLC: Results from the Italian Expanded Access Program Enrico Cortesi, Policlinico Umberto I, IT P1.01-066 PDL-1 Expression of Tumor Cell, Macrophage, and Immune Cells on Pleural Effusion Yen-Han Tseng, Taipei Veterans General Hospital, TW P1.01-067 – P1.01-070 MISCELLANEOUS P1.01-067 Characteristics and Survival Rate of Non-Small Cell Lung Cancer in Patients 45 Years of Age or Younger Noorwati Sutandyo, Dharmais National Cancer Hospital, ID P1.01-068 Impact of Case-Based CME on Physician Performance in the Diagnosis and Management of NSCLC Elaine Hamarstrom, Medscape Education, US P1.01-069 Clinical Experience with IBM Watson for Oncology (WFO) Cognitive System for Lung Cancer Treatment in China Xiaochun Zhang, The Affiliated Hospital of Qingdao University, CN P1.01-070 BIW-8962, an Anti-GM2 Ganglioside Monoclonal Antibody, in Advanced/Recurrent Lung Cancer: A Phase I/II Study Joo-Hang Kim, Yonsei Cancer Center, KR P1.01-071 – P1.01-078a PRECLINICAL P1.01-071 High Dose IVAA Synergy with mEHT in Patients with Stage III-IV NSCLC: A Phase I Study Junwen Ou, Clifford Hospital, CN P1.01-072 Epithelial-To-Mesenchymal Transition (EMT) in Lung Cancer: Classic Reproduction Huibin Liu, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, People’s Republic of China, CN

8

P1.01-073 Over-Expression of GGPPs Contributes to Tumor Metastasis and Correlates with Poor Prognosis of Lung Adenocarcinoma Yong Song, Jinling Hospital, CN P1.01-074 Exosomal RNA-Profiling of Lung Pleural Effusions Identifies Adenocarcinoma Patients through Elevated miR-200 Expression Per Hydbring, Karolinska Institutet, SE P1.01-075 Simultaneous Multiplex Profiling of Gene Fusions, METe14 Mutations and Immune Genes in Advanced NSCLC by NCounter Technology Noemi Reguart, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES P1.01-076 Comparison of PANA Mutyper and PNA Clamping for Detecting KRAS Mutations in Tumor Tissue, Cell Block and Pleural Effusion from Cancer Chan Kwon Park, The Catholic University of Korea, Republic of Korea, KR P1.01-077 Oncogenic Potential of a Novel HER2 755PL In-Frame (HER2PL) Mutation in Lung Adenocarcinoma Anya Maan-Yuh Lin, Institute of Pharmacology, National Yang-Ming University, TW P1.01-078 Longitudinal Studies of Quality of Life in Advanced Non-Small Cell Lung Cancer Patients Undergoing First-Line Target Therapy Lin Zhi Xuan, Chi Mei Medical Center, Liouying, TW P1.01-078a The Construction and Clinical Application of an Integrated Microfluidic Device for CTCs Detection in Patients with NSCLC Qi Wang, The Second Affiliated Hospital, Dalian Medical University, CN

P1.02 BIOLOGY/PATHOLOGY P1.02-001 – P1.02-006 MISCELLANEOUS P1.02-001 SLFN11 Expression in Early Stage Non-Small Cell Lung Cancer Predicts Benefit from Adjuvant Chemotherapy with Taxane and Platinum Vamsidhar Velcheti, Cleveland Clinic, US P1.02-002 Diagnostic Utility of MUC4 Expression to Differentiate Epithelioid Mesothelioma from Lung Adenocarcinoma and Squamous Cell Carcinoma Vishwa Jeet Amatya, Department of Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, JP P1.02-003 Prevention of Adriamycin-induced Cardiac Damage by NAD-ModulationPrevention of Adriamycin-induced Cardiac Damage by NAD-Modulation Sei-Hoon Yang, Wonkwang University Hospital, KR P1.02-004 Long Non-Coding RNA XLOC_000090 Promotes Lung Cancer Migration Through Modulation of miR-4505 Bin Zhang, Tianjin Medical University Cancer Institute and Hospital, CN

9

P1.02-005 Solving the Interfering Problem of Tissue Embedding OCT Compound in Activity Based Multiplex Profiling of Tyrosine Kinase Substrates Sven Hillinger, University Hospital, CH P1.02-006 Arsenic Promotes Persistent Alterations in the Lung PiRNA Transcriptome to Target Epigenetic Pathways Victor D Martinez, BC Cancer Research Centre, CA P1.02-007 – P1.02-013 MISMATCH REPAIR AND MUTATION LOADS P1.02-007 TP53 and DNA-Repair Gene Polymorphisms as Risk Factors for the Development of Advanced Lung Adenocarcinoma in Serbia Jelena Spasic, Institute for Oncology and radiology of Serbia, RS P1.02-008 Expression of Mismatch Repair Proteins Associates with Survival and Response to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients Hsiang-Ling Ho, Taipei Veterans General Hospital, TW P1.02-009 Accumulation of Mutations in Background Normal Lung Tissue Constitutes a Major Lung Cancer Risk Emi Kubo, National Cancer Center Japan, JP P1.02-010 Novel Role of hSSB2 in the Base Excision Repair Pathway (BER) Mark Adams, Queensland University of Technology, AU P1.02-011 XRCC6BP1: A Key Player in the DNA Repair of Cisplatin Resistant NSCLC Cells Martin P Barr, St. James's Hospital & Trinity College Dublin, IE P1.02-012 Profiling DNA Repair in Lung Cancer Alexander Dobrovic, Olivia Newton-John Cancer Research Institute, AU P1.02-013 ATM Mutation as a Predictor for Mutation Burden in NSCLC D. Gwyn Bebb, University of Calgary, CA P1.02-014 – P1.02-039 MORPHOLOGY P1.02-014 TGFalpha Promotes Growth of Lung Tumors Carrying EGFR Mutation but not KRAS Mutation in Transgenic Mouse Models in Vivo Koichi Tomoshige, Cincinnati Children's Hospital Medical Center, US P1.02-015 Comparison of Study Models of Lung Cancer Yoshito Yamada, University Hospital Zurich, CH P1.02-016 Establishment of Lung Adenocarcinoma Organoid Cultures Hirotsugu Notsuda, University Health Network, CA P1.02-017 Freely Floating Cancer Cells in Lymph Node Sinuses of Hilar Lymph Node Positive Lung Cancer Patients Yusuke Nakamura, Tokai University Hachioji Hospital, JP

10

P1.02-018 Number of Cancer Cells in Lung Adenocarcinoma Specimen – Correlation with Noguchi's Classification, WHO Pathologic Type, and Prognosis Takashi Inoue, Dokkyo Medical University, JP P1.02-019 Dual Role of Notch in Lung Cancer Sara Sinicropi-Yao, The Ohio State University, US P1.02-020 Acinar-Predominant Pattern Correlates with Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung Gengpeng Lin, The First Affiliated Hospital of Sun Yat-sen University, CN P1.02-021 Can 18F-FDG PET/CT Predict the Pathological Necrosis and Microvessel Density in Lung Adenocarcinomas Young Wha Koh, Ajou University School of Medicine, KR P1.02-022 Spontaneous Regression of Primary Pulmonary Synovial Sarcoma; A Case Report Naoko Miyata, Kyoto Prefectural University of Medicine, JP P1.02-023 TGF-β Signaling Mediated by Fibroblasts is Associated with the Histological Subtypes of Lung Adenocarcinoma Ryo Sato, Keio University, JP P1.02-024 Correlation of Maximal Tumor Diameter between Pathology Specimen and CT in Nonsmall Cell Lung Cancer: A Pilot Study Heae Surng Park, Gangnam Severance Hospital, KR P1.02-025 A Case of Primary Peripheral Epithelial–Myoepithelial Carcinoma of the Lung Daisuke Eriguchi, Tokyo Medical University Hachioji Medical Center, JP P1.02-026 The Characteristics of Lymph Node Metastasis in Resected Adenosquamous Lung Cancer Xiuyu Cai, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, CN P1.02-027 Minute Pulmonary Meningothelial-Like Nodules Presenting as Multiple Ground-Glass Density Nodules (GGNs): A Case Report Yeon Bi Han, Department of Pathology Seoul National University Bundang Hospital, KR P1.02-028 Pathways Involved in Early Stage Lung Cancers Vilde D Haakensen, Oslo University Hospital, NO P1.02-029 Pulmonary Adenofibroma with Cystic Change: A Case Report Eunhyang Park, Seoul National University Bundang Hospital, KR P1.02-030 The Effect of Chronic Obstructive Pulmonary Disease on the Tumor Stroma in Non-Small Cell Lung Cancer Yasuhiko Ohshio, Shiga University of Medical Science, JP P1.02-031 Clinicopathological Study of 16 Cases with Pulmonary Pleomorphic Carcinoma Fumi Ohsawa, Maebashi Red Cross hospital, JP

11

P1.02-032 Clinicopathological Profile of Invasive Mucinous Adenocarcinoma Based on Evaluation of Invasive Components Yuichi Mitsui, Osaka General Medical Center, JP P1.02-033 Differentiating of Cytomorphological Characteristics in Non-Small Cell Lung Cancer Predicts Value of Radiologic Features Ryota Tanaka, Kyorin University School of Medicine, JP P1.02-034 Non-Invasive Qualitative Diagnosis of Lung Cancer Enabled by Spectrum Analysis of Ultrasound Takashi Anayama, Kochi Medical School, Kochi University, JP P1.02-035 Human Papillomavirus Infection in Lung Squamous Cell Carcinoma and Correlation to p16 INK4a Expression from an Argentine Population Valeria Cecilia Denninghoff, Centro de Educación Médica e Investigaciones Clínicas (CEMIC-CONICET), AR P1.02-036 Fine Needle Aspiration as a Diagnostic Tool in Lung Cancer: Worth Pursuing? Luiz H. Araujo, Instituto Nacional de Câncer (INCA), BR P1.02-037 Pulmonary Carcinoid Tumors: A Prognostic Implications of Ki-67 Proliferative Index Renata Langfort, National Institute of Tuberculosis and Lung Diseases, PL P1.02-038 Bilateral Combined Lymphangioleiomyomatosis and Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia with Typical Carcinoids Jan Hinrich Von Der Thüsen, Erasmus MC, NL P1.02-039 Preventive and Therapeutic Action of Id1 Inhibition in KRAS-Mutant (KM) Lung Adenocarcinoma (LAC) Tumors in a Xenograft Murine Model Marta Roman Moreno, Clinica Universidad de Navarra, ES

P1.02-040 – P1.02-059 OTHER MUTATIONS IN THORACIC MALIGNANCIES P1.02-040 Genetic Risk Evaluation in Families with Lung Cancer History in High Lung Cancer Mortality Region of Xuanwei, China Madiha Kanwal, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China., CN P1.02-041 Mutation of SWI/SNF Complex Genes Is Frequent in Poorly Differentiated, MesenchymalLike Lung Cancer without Major Driver Mutation Taichiro Yoshimoto, Jichi Medical University, JP P1.02-042 Circadian Clock Gene Per2 Over-Expression Inhibits Tumor Progression in Human NonSmall Cell Lung Cancer Li Qiang, Sichuan Cancer Hospital＆Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China, CN P1.02-043 A Comparison of Consistency of Detecting BRAF Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients Gang Chen, Fujian Provincial Cancer Hospital, CN

12

P1.02-044 Relationship between RET Rearrangement and Thymidylate Synthase mRNA Expression in Non-Small Cell Lung Cancer Tissues Gang Chen, Fujian Provincial Cancer Hospital, CN P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer Meiyu Fang, Zhejiang Cancer Hospital, CN P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations Gang Chen, Fujian Provincial Cancer Hospital, CN P1.02-047 Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations Meiyu Fang, Zhejiang Cancer Hospital, CN P1.02-048 Somatic Mutation Analysis of RB1 Gene in Chinese Non-Small Cell Lung Cancer Patients Meiyu Fang, Zhejiang Cancer Hospital, CN P1.02-049 Detection of CDKN2A Gene Mutations in Patients with Non-Small Cell Lung Cancer Patients Meiyu Fang, Zhejiang Cancer Hospital, CN P1.02-050 Pan-Can Analysis of miRNAs at the Imprinted Chromosome 14q32 Locus Reveals a Unique Pattern of Deregulation in NSCLC Jhon Ralph Enterina, British Columbia Cancer Research Centre, CA P1.02-051 Ultra-Deep Sequencing Depicts the Genomic Landscape of Ground-Glass Nodules in Early Stage Lung Adenocarcinoma Hongwei Duan, Beijing Institute of Genomics, Chinese Academy of Sciences, University of Chinese Academy of Sciences, CN P1.02-052 Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma Masatsugu Kuraoka, Hiroshima University Graduate School of Biomedical and Health Sciences, JP P1.02-053 A New Strategy of Adjuvant Chemotherapy for Lung Cancer Based on the Expression of Anti-Aging Gene Klotho Kyoshiro Takegahara, Nippon Medical School Hospital, JP P1.02-054 The Molecular Characterisation of Lung Adenocarcinoma Subgroups Elizabeth Starren, Imperial College London and the Royal Brompton and Harefield NHS Trust, GB P1.02-055 Genotyping Squamous Cell Lung Carcinoma Among Hispanics (Geno1.1-CLICaP) Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, CO P1.02-056 BRAF Non-V600E Mutations Recurrently Found in Non-Small Cell Lung Cancer in Chinese Patients Meiyu Fang, Zhejiang Cancer Hospital, CN P1.02-057 Analysis of C-MET Amplification Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion Gang Chen, Fujian Provincial Cancer Hospital, CN

13

P1.02-058 Molecular Characteristics and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NFE2L2 Mutations Gang Chen, Fujian Provincial Cancer Hospital, CN P1.02-059 Molecular Characteristics of SMARCA4 Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients Gang Chen, Fujian Provincial Cancer Hospital, CN P1.02-060 – P1.02-064 PROTEINS IN LUNG CANCER AND PROTEOMICS P1.02-060 Podoplanin Expression in Cancer-associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung Yohei Yurugi, Tottori University, Faculty of Medicine, JP P1.02-061 Podoplanin Expression in Cancer-Associated Fibroblasts Predicts Unfavourable Prognosis in Patients with Stage IA Adenocarcinoma Yasuaki Kubouchi, Tottori University, Faculty of Medicine, JP P1.02-062 Ring Finger Protein 38 Promote Non-Small Cell Lung Cancer Progression by Endowing Cell EMT Phenotype Jian-Yong Ding, Zhongshan Hospital, Fudan University, CN P1.02-063 Tumor Heterogeneity Analyses by Integrated Proteo-Genomics of Thoracic Tumors from Sequential Biopsies and Warm Autopsies Udayan Guha, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, NCI, NIH, US P1.02-064 Proteomic Analysis of Exosome Purified Using a Novel Reagent Ayako Kurimoto, Fujirebio Inc., JP P1.02-065 – P1.02-067 STEM CELLS IN LUNG CANCER P1.02-065 Histone Deacetylase Inhibition Alters Stem Cell Phenotype in Gefitinib-Resistant Lung Cancer Cells with EGFR Mutation Fariz Nurwidya, Universitas Indonesia, ID P1.02-066 Cancer Stem Cells in Pulmonary High Grade Neuroendocrine Carcinoma: a Series of 23 Cases from Eastern India Prasanta Raghab Mohapatra, All India Institute of Medical Sciences, IN P1.02-067 FGF1 and IGF1 Co-Stimulation Promoted the Amplification and Cancer Stemness of Lung Cancer Cells under 3D Culture Condition Rui Zhang, Tianjin Medical University Cancer Institute & Hospital, CN P1.02-068 – P1.02-071b TARGETS FOR TREATMENT PREDICTION P1.02-068 Effects of Pirfenidone Targeting EMT and Tumor-Stroma Interaction as Novel Treatment for Non-Small Cell Lung Cancer Ayako Fujiwara, Osaka National Hospital, JP

14

P1.02-069 Pemetrexed-Resistant Non-Small Cell Lung Cancer Cell Lines Have Novel Drug-Resistant Mechanisms Ryosuke Tanino, Shimane University, JP P1.02-070 Identification of Lung Cancer Specific Differentially Methylated Regions Using GenomeWide DNA Methylation Study Yoonki Hong, Kangwon National University Hospital, KR P1.02-071 SFN Stabilizes Oncoproteins through Binding with SKP1 to Block SCFFBW7 Ubiquiting Ligase Jeongmin Hong, University of Tsukuba, JP P1.02-071a Targeting Human Single Stranded DNA Binding Protein (hSSB) 1, a Novel Prognostic Factor, in Non-Small Cell Lung Cancer Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, AU P1.02-071b SASH1 Is a Prognostic Indicator and Future Target in NSCLC Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, AU

P1.03 CHEMOTHERAPY/TARGETED THERAPY P1.03-001 – P1.03-013 ALK P1.03-001 Verification and Implementation of the VENTANA Anti-ALK D5F3 Antibody in Detecting ALK Rearrangement in NSCLC Haider Al-Najjar, Central Manchester University Hospitals NHS Foundation Trust, GB P1.03-002 Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-Positive Advanced NSCLC Patient Shaoyu Yang, Hangzhou First People’s Hospital, CN P1.03-003 Clinical Implications of an Analysis of Crizotinib Pharmacokinetics Co-Administered with Dexamethasone in Patients with NSCLC Swan Lin, University of California, San Diego, US P1.03-004 Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status Hirotsugu Kenmotsu, Shizuoka Cancer Center, JP P1.03-005 Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9 Hidehito Horinouchi, National Cancer Center Hospital, JP P1.03-006 Clinicopathological Features and Poor Outcome for ALK Inhibitors of Squamous Cell Lung Cancer with ALK-Rearrangement Hiroaki Motomura, Juntendo University Faculty of Medicine & Graduate School of Medicine, JP P1.03-007 A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer Xiao Hu, Zhejiang Cancer Hospital, CN

15

P1.03-008 Analysis of Data on Interstitial Lung Disease Onset and Its Risk Following Treatment of ALK-positive NSCLC with Xalkori Akihiko Gemma, Graduate School of Medicine, Nippon Medical School, JP P1.03-009 A Lung Adenocarcinoma with a STRN-ALK Rearrangement Was Poorly Responsive to Alectinib Treatment Yuko Iida, Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, JP P1.03-010 Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer Reina Imase, Hiratsuka Kyosai Hospital, JP P1.03-011 Clinical Outcomes Correlated with Percentage of Positive Anaplastic-Lymphoma Kinase Cells Tested by FISH Analysis in NSCLC. Katy Louise Clarke, Leeds Cancer Centre, GB P1.03-012 Using Computational Modeling to Simulate Clinical Response of ALK Inhibitors to G1202R ALK and Possible Mechanisms of Resistance Chien-Ting Liu, Kaohsiung Chang Gung Memorial Hospital, Taiwan, TW P1.03-013 Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Laura Mezquita, Gustave Roussy, FR P1.03-014 – P1.03-049 CHEMOTHERAPY P1.03-014 Saline Alone vs Saline plus Mannitol Hydration for the Prevention of Acute Cisplatin Nephrotoxicity: A Randomized Trial Wilfred Dela Cruz, San Antonio Military Medical Center, US P1.03-015 The Relationship between the UGT1A1*27 and UGT1A1*7 Genetic Polymorphisms and Irinotecan-Related Toxicities in Patients with Lung Cancer Minoru Fukuda, Nagasaki University Hospital, JP P1.03-016 Video-Thoracoscopic Pulmonary Resection Avoids Delay and Increase Adjuvant Chemotherapy Compliance for Non-Small Cell Lung Carcinoma Akın Ozturk, Sureyyapasa Thoracic Diseases and Thoracic Surgery Training and Research Hospital, TR P1.03-017 Benzyl Isothiocyanate Induces Protective Autophagy in Human Lung Cancer Cells through Endoplasmic Reticulum Stress-Mediated Mechanism Ke Xu, Tianjin Medical University General Hospital, CN P1.03-018 Effectiveness of Supportive Care Drugs in Lung Cancer Patients Undergoing 1st Line Chemotherapy in a Resource Limited Setting Digambar Behera, Postgraduate Institute of Medical Education and Research (PGIMER), IN P1.03-019 Sophoridine Inhibits Lung Cancer Cell Proliferation through Activating Hippo Signaling and P53 Pathway Jiangping Xiong, The First Affiliated Hospital of Nanchang University, CN

16

P1.03-020 Detection of Hypoxia Using EF5 PET/CT in 10 Patients with Advanced NSCLC Receiving Chemotherapy with and without Bevacizumab Frederic Lacroix-Poisson, BC Cancer Agency, CA P1.03-021 A Prospective Observational Study to Evaluate Incidence of Thromboembolic Events during Platinum Based Chemotherapy in Lung Cancer Vikas Talreja, Tata Memorial Hospital, IN P1.03-022 A Phase 1B Study of TRC105 in Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer Brian Simpson, Tracon Pharmaceuticals, US P1.03-023 The Real-World Practice of Bevacizumab Plus Chemotherapy in Stage IV Lung Adenocarcinoma: A Single Institute Experience Yen-Hao Chen, Kaohsiung Chang Gung Memorial Hospital, TW P1.03-024 Efficacy of Carboplatin-Vinorelbine in Advanced NSCLC Patients at Persahabatan Hospital, Jakarta - Indonesia Putu Ayu Diah, Department of Pulmonology and Respiratory Medicine, ID P1.03-025 Combination Therapy with Carboplatin and Hyperoxia Synergistically Enhances Suppression of Benzo[a]Pyrene Induced Lung Cancer Sang Haak Lee, St. Paul’s Hospital, Catholic University of Korea, KR P1.03-026 Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC Jonathan W. Goldman, University of California at Los Angeles, US P1.03-027 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in TreatmentNaïve Advanced Non-Sq NSCLC (CLEAR Study) Shinji Atagi, National Hospital Organization Kinki-chuo Chest Medical Center, JP P1.03-028 A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Untreated Stage IV Squamous Cell Lung Cancers Paul K. Paik, Memorial Sloan Kettering Cancer Center, US P1.03-029 Study of Plasma Homocysteine as a Marker of Toxicity and Depression in Patients Treated with Pemetrexed-Based Chemotherapy Mary O’brien, Royal Marsden Hospital NHS Foundation Trust, GB P1.03-030 Prognostic Impact of the Presence of COPD in Patients with NSCLC under Conventional Systemic Chemotherapy Jin Woo Kim, Uijeongbu St. Mary's Hospital, Catholic University of Korea, KR P1.03-031 Adherence and Feasibility of 2 Treatment Schedules of S-1 as Adjuvant Chemotherapy in Completely Resected Lung Cancer Takaharu Kiribayashi, Division of Chest Surgery (Ohashi), Toho University School of Medicine, JP P1.03-032 Observation of Durative Infusion Endostar Combined with Chemotherapy Within Vascular Normalization Period in Advanced NSCLC Jia Chen, Jiangsu Cancer Hospital, CN

17

P1.03-033 Long-Term Outcome of Histoculture Drug Response Assay Guided Adjuvant Chemotherapy in Patients with Non-Small Cell Lung Cancer Yoshimitsu Hirai, Wakayama Medical University, JP P1.03-034 Therapeutic Effect of Novel Leucyl-tRNA Synthetase Inhibitor, B1206, in Non-Small Cell Lung Cancer Eun Young Kim, Yonsei University College of Medicine, KR P1.03-035 Efficacy of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC Joaquim Bosch Barrera, Catalan Institute of Oncology. Hospital Universitari Dr. Josep Trueta, ES P1.03-036 Adjuvant Chemotherapy with Uracil-Tegafur for Pathological T1aN0M0 Lung Adenocarcinoma with Lymphatic Vessel Invasion Yoshitaka Kitamura, Hyogo Cancer Center, JP P1.03-037 A Phase II Study of Adjuvant Chemotherapy with Docetaxel plus Nedaplatin for Completely Resected Non-Small Cell Lung Cancer Koji Teramoto, Shiga University of Medical Science, JP P1.03-038 A Phase I Trial of Afatinib and Bevacizumab in Untreated Patients with Advanced NSCLC Harboring EGFR-Mutations: OLCSG1404 Shoichi Kuyama, NHO Iwakuni Clinical Center, JP P1.03-039 Therapeutic Inhibition of the Cancer Stem Cell Marker, ALDH1, a Promising Mechanism by Which Cisplatin Sensitivity Can Be Restored in NSCLC Martin P Barr, St. James's Hospital & Trinity College Dublin, IE P1.03-040 Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single Center Experience Perran Fulden Yumuk, Marmara University Medical School, Marmara University Pendik Training & Research Hospital, TR P1.03-041 Exploitation of the Cancer Stem Cell Marker ALDH1 Within the Vitamin a/Retinoic Acid Axis Promotes Re-Sensitisation of Cisplatin Resistant NSCLC Martin P Barr, St. James's Hospital & Trinity College Dublin, IE P1.03-042 BBI608, a Small Molecule Stemness Inhibitor, Circumvents Cisplatin Resistance in NSCLC Martin P Barr, St. James's Hospital & Trinity College Dublin, IE P1.03-043 30-Day Mortality Following Systemic Anti-Cancer Treatment for NSCLC at a Single Canadian Cancer Centre Gwyn Bebb, Alberta Health Services, CA P1.03-044 Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine Lyudmila Bazhenova, University of California San Diego, Moores Cancer Center, US P1.03-045 HER-2 Mutation Is Not a Prognostic Factor Treated with First-Line Chemotherapy in NSCLC Patients

18

Tao Jiang, Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, CN P1.03-046 A Retrospective Analysis of Correlation Between Cytokines in TME and Therapeutic Effect of Advanced Lung Cancer Chemotherapy in China Chunxia Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, CN P1.03-047 Carboplatin/ Weekly Nab-PTX in Elderly Patients with Previously Untreated Advanced Squamous NSCLC Selected Based on MNA-SF So Takata, Osaka Habikino Medical Center, JP P1.03-048 miR-34a and the Micromanagement of Cancer Stemness and Resistance in NSCLC. Does It Hold Therapeutic Benefit? Martin P Barr, St. James's Hospital & Trinity College Dublin, IE P1.03-049 Phase II Study of S-1 plus Bevacizumab Combination Therapy for Patients Previously Treated for Non-Squamous Non–Small Cell Lung Cancer Kentaro Masuhiro, Osaka Habikino Medical Center, JP P1.03-050 – P1.03-053 MISCELLANEOUS P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial David S Ettinger, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, US P1.03-051 Development of a Novel Microfluidic Device for Studying the Chemotaxis Mechanism of Bacterial Cancer Targeting Qi Wang, The Second Affiliated Hospital of Dalian Medical University, CN P1.03-052 Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism Yayi He, Shanghai Pulmonary Hospital, Tongji University School of Medicine, CN P1.03-053 Taiwan Real Word Efficacy of 1st Line EGFR TKIs Treatment in EGFR Mutation Positive Advanced Non Small Cell Lung Cancer Chih-Yen Tu, China Medical University, TW

P1.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS P1.04-001 Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results Helena Yu, Memorial Sloan Kettering Cancer Center, US P1.04-002 Tolerability of Osimertinib and Its Impact on Quality of Life in Advanced Non-Small Cell Lung Cancer Patients: The ARPA Study Enrica Capelletto, Department of Oncology, University of Turin, IT P1.04-003 The International Lung Screen Trial: A Multi-Centre Study to Evaluate LDCT Screening Selection Criteria and Nodule Management Kuan Pin Lim, Sir Charles Gairdner Hospital, AU

19

P1.04-004 Phase I/Ib Study of Nivolumab and Veliparib in Advanced Solid Tumors and Lymphoma with and without Alterations in Selected DNA Repair Genes Wade Thomas Iams, McGaw Medical Center of Northwestern University, US P1.04-005 Phase 2 Study of Nivolumab and Metformin in Advanced Non-Small Cell Lung Cancer with and without Prior Treatment with PD-1/PD-L1 Inhibitors Wade Thomas Iams, McGaw Medical Center of Northwestern University, US P1.04-006 Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy Philip Komarnitsky, AbbVie Inc., US P1.04-007 Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy Small Cell Lung Cancer Philip Komarnitsky, AbbVie Inc., US P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC Tony SK Mok, The Chinese University of Hong Kong, HK P1.04-009 The First Study of BBSKE in Heavy Treated Advanced EGFR Wild Type and ALK Negative, Trxr1 High Expression NSCLC Patients. Yongchang Zhang, Hunan Cancer Hospital, CN P1.04-010 CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, CN P1.04-011 Development of Novel Blood-Based Biomarker Assays in 1L Advanced/ Metastatic NSCLC: Blood First Assay Screening Trial (BFAST) Tony SK Mok, Chinese University of Hong Kong, CN P1.04-012 A Phase 1b Dose-Escalation Study of TRC105 in Combination with Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer Brian Simpson, Tracon Pharmaceuticals, US P1.04-013 Phase 1b Multi-Indication Study of the Antibody Drug Conjugate Anetumab Ravtansine in Patients with Mesothelin-Expressing Advanced or Recurrent Malignancies Alex Adjei, Mayo Clinic, US

P1.05 EARLY STAGE NSCLC P1.05-001 – P1.05-012 MISCELLANEOUS P1.05-001 Microwave Ablation plus Recombinant Human Endostatin (Endostar) versus Microwave Ablation Alone in Inoperable Stage I Non Small Cell Lung Cancer Guanghui Huang, Shandong Provincial Hospital Affiliated to Shandong University, CN P1.05-002 Characteristics and Prognosis of Ground Glass Opacity Predominant Primary Lung Cancer Larger Than 3.0 Cm on Thin-Section Computed Tomography Shigeki Suzuki, National Cancer Center Hospital, JP

20

P1.05-003 Impact of Coexisting Pulmonary Diseases on Oncological Outcomes of Patients with pStage I Non-Small Cell Lung Cancer Hiroyuki Tao, Yamaguchi Ube Medical Center, JP P1.05-004 Adenocarcinoma Subtyping of Early Stage Lung Cancer in a Danish Cohort Petrine laier Sonne, Odense University Hospital, DK P1.05-005 Percutaneous Cryoablation for Lung Cancer Patients with Idiopathic Pulmonary Fibrosis Takashi Ohtsuka, Keio University, School of Medicine, JP P1.05-006 Clinicopathological Features of Small-Sized Peripheral Squamous Cell Lung Cancer Takayuki Kosaka, Gunma University Graduate School of Medicine, JP P1.05-007 A Retrospective Study to Compare Resection Rate and Survival Rate in Operable Stage I to III NSCLC After Introduction of Lung Cancer MDT Ying Ying Sum, Hospital Umum Sarawak,, MY P1.05-008 A Comparison of the Imaging Features of Early Stage Primary Lung Cancer in Patients Treated with Surgery, SABR and Microwave Ablation Ambika Talwar, Oxford University Hospitals NHS Foundation Trust, GB P1.05-009 Analysis of Postoperative Prognosis in Terms of the Difference Between the Invasive Growth Area and the Total Tumor Diameter Masaya Yotsukura, Keio University School of Medicine, JP P1.05-010 Curative Treatment Rates for Patients Diagnosed with Early Stage Non-Small Cell Lung Cancer (NSCLC) in England Neal Navani, Royal College of Physicians of London, GB P1.05-011 Comparison of Tumor Measurement Methods in Patients with Clinical Stage IA Non-Small Cell Lung Cancer Takuya Nagashima, Kanagawa Cancer Center, JP P1.05-012 Treatment Planning in Non-Small Cell Lung Cancer Shows Variable Utilization of Multidisciplinary Tumor Board Joshua Robert Rayburn, Swedish Cancer Institute, US P1.05-013 – P1.05-015 NEOADJUVANT AND ADJUVANT CHEMOTHERAPY P1.05-013 Induction Chemoradiation Is Associated with Improved Survival in Resected Non-Pancoast Lung Cancer with Chest Wall Invasion Kei Suzuki, Boston Medical Center, US P1.05-014 Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer Min Kwang Byun, Gangnam Severance Hospital, Yonsei University College of Medicine, KR P1.05-015 Major Pathological Response as a Predictive Value of Survival in Early-Stage NSCLC After Chemotherapy: Cohort of NATCH Phase III Trial Enric Carcereny, Catalan Institute of Oncology Badalona—Germans Trias I Pujol Hospital Badalona, ES

21

P1.05-016 – P1.05-022b RECURRENCE P1.05-016 The Prognosticator in Synchronous Multiple Primary Lung Cancer: A Comprehensive Analysis of 438 Cases Yi Liu, Beijing Chao Yang Hospital, CN P1.05-017 Prognostic Significance of Preoperative Plasma D-Dimer Level in Patients with Surgically Resected Clinical Stage I Non-Small Cell Lung Cancer Kaoru Kaseda, Sagamihara Kyodo Hospital, JP P1.05-018 Prognostic Impact of Tumor Shadow Disappearance Rate in Patients with Clinical IA Lung Adenocarcinoma Joji Samejima, Kanagawa Cancer Center, JP P1.05-019 Effects of Tumor Stroma and Inflammation on Survival of Stage I-IIp Lung Cancer Eduard Monsó, Hospital Parc Taulí, CIBERES, Universitat Autònoma de Barcelona, ES P1.05-020 Clues of Stromal Invasion of Pulmonary Adenocarcinoma on CT, Focusing on Cicatricial Change Ye Kyeong Jun, Department of Radiology, St. Vincent’s Hospital, The Catholic University of Korea, KR P1.05-021 Are Prognostic Factors Different from That Which Predicts Recurrence in Completely Resected Pathological Stage IB Adenocarcinoma? Hiroyuki Ito, Kanagawa Cancer Center, JP P1.05-022 Association Between Neutrophil/Lymphocyte Ratio and Lymphocyte/Monocyte Ratio with Disease Free Survival in Operated NSCLC Patients in Peru Rodrigo Motta, Edgardo Rebagliati Hospital, PE P1.05-022a Positive Pleural Lavage Cytology Is the Independent Prognostic Factor in Lung Cancer Patients with Pathological Stage I Disease Tomoko So, Iizuka hospital, JP P1.05-022b Identifying Novel Markers of Early Stage Lung Cancer Using a CRISPR/Cas9 Mouse Model Paola Marignani, Dalhousie University Tupper Medical Building 9F1, CA

P1.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION P1.06-001 – P1.06-024 EPIDEMIOLOGY P1.06-001 Does Access to Private Health Care Influence Potential Lung Cancer Cure Rates? Thadathilankal Jess John, Tygerberg Hospital, ZA P1.06-002 The Role of Comorbidity in the Management and Prognosis in Nonsmall Cell Lung Cancer: A Population-Based Study Jonas Nilsson, Radiation Sciences, SE P1.06-003 Preoperative Physical Function and Activity in Elderly Lung Cancer Patients Compared to General Elderly Sunga Kong, Sungkyunkwan University, KR

22

P1.06-004 Occurrence of Lung Cancer among Young Patients Below the Age of 50 – A Retrospective Analysis Anna Maria Romaszko-Wojtowicz, The Center for Pulmonary Diseases, Pulmonology Clinic, PL P1.06-005 Sex-Based Disparities in NSCLC: An Evidence-Based Study Noor Asaad Alsaadoun, University Of Calgary-Arnie Charbonneau Cancer Institute, CA P1.06-006 Survival Benefits and Associated Prognostic Factors among Young NSCLC Patients Gwyn Bebb, Alberta Health Services, CA P1.06-007 EGFR Status Evaluation and Epidemiological Profile in Patients with NSCLC in a Brazilian Public Health Instituition Carolina Dutra, CEPON Centro de Pesquisas Oncológicas, BR P1.06-008 Prevalence of Lung Cancer in Patients with Interstitial Lung Disease is Higher than in those with Chronic Obstructive Pulmonary Disease Wonil Choi, Keimyung University School of Medicine, KR P1.06-009 Barriers to Clinical Trial Participation in Lung Cancer Patients, a Single Institution Experience Christina S Baik, University of Washington/Seattle Cancer Care Alliance, US P1.06-010 Interaction between Treatment Delivery Delay and Stage on the Mortality from Non-Small Cell Lung Cancer Fernando Conrado Abrão, Hospital Santa Marcelina, BR P1.06-011 Hyponatremia - Evaluation of Prevalence in Hospitalized Lung Cancer Patients and Its Prognostic Significance Sharif Ahmed, United Hospital Limited, BD P1.06-012 Non-Small Cell Lung Cancer (NSCLC) Patient Characteristics and Clinical Care Insights in Sweden: The SCAN-LEAF Study Martin Sandelin, Uppsala University, SE P1.06-013 Latent Tuberculosis in Newly Diagnosed Lung Cancer Patients. An Spanish Prospective Study Ruth Alvarez Cabellos, Hospital Toledo, ES P1.06-014 Higher Body Mass Index Prolongs Survival Time in Non-Small Cell Lung Cancer with Good Performance Status Tomohiro Suzumura, Graduate school of Medicine, Osaka City University, JP P1.06-015 Analysis of Relationship Between Non-Small Cell Lung Cancer and Nicotine Dependence Yoon Ho Ko, Department of Internal Medicine, The Cancer Research Institute, College of Medicine, The Catholic University of Korea,, KR P1.06-016 Route to Lung Cancer Diagnosis in the UK: How Does This Affect Patient Outcome? Sher May Ng, Lewisham and Greenwich NHS Trust, GB

23

P1.06-017 Lung Cancer Detection Rates for National Comprehensive Cancer Network Group 2 High Risk Individuals Andrea Katalin Borondy Kitts, Lahey Hospital & Medical Center, US P1.06-018 EGFR Mutations and ALK Gene Rearrangements: Changing Patterns of Molecular Testing in Brazil Gilberto Lopes, Sylvester Comprehensive Cancer Center at the University of Miami, US P1.06-019 The Association Between HPV Presence and EGFR Mutations in Asian Patients with NSCLC: A Meta-Analysis Hengrui Liang, The First Affiliated Hospital of Guangzhou Medical University, CN P1.06-020 Unequal Access to Health Care System Have a Higher Impact in Upgrading Staging for 8th TNM Ed Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, BR P1.06-021 Lung Cancer Among Women Assisted in an Argentinean University Institution Carolina Gabay, Instituto de Oncología Angel H.Roffo, University of Buenos Aires, AR P1.06-022 Prognostic Value of NLR in Overall Survival of Patients with Advanced Lung Cancer Claudio Flores, Oncosalud - AUNA, PE P1.06-023 Spatio-Temporal Distribution of Lung Cancer Mortality Rate in Peru: 2005-2014 Claudio J. Flores, Oncosalud - AUNA, PE P1.06-024 Outcome of Non-Small Cell Lung Cancer Patients Treated in the Private Health Care in Brazil Luiz H. Araujo, Américas Centro de Oncologia Integrada, BR

P1.07 IMMUNOLOGY AND IMMUNOTHERAPY P1.07-001 – P1.07-044c IMMUNOTHERAPY (BIOMARKERS) P1.07-001 Clinical Value of Expression of PD-L1 and CD8 of 58 Cases with NSCLC Hongnian Wu, Fuzhou Lung Hospital, CN P1.07-002 The Expression of PD-L1 Protein as a Prognostic Factor in Lung Squamous Cell Carcinoma Kazuki Takada, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, JP P1.07-003 Cytolitic Tests with Hyperimmune Patient Sera Is a Good Prognostic Tool in Racotumomab Immunotherapy in Advanced Non-Small Cell Lung Cancer Necdet Ismail Hakkı Uskent, Anadolu Health Science Center, TR P1.07-004 Predictive Biomarkers of Response to Nivolumab in Non–Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study Yuki Kataoka, Hyogo Prefectural Amagasaki General Medical Center, JP P1.07-005 A Systematic and Genome-Wide Correlation Analysis of PD-L1 Expression and Common NSCLC Driver Genes

24

Xiaoshun Shi, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, CN P1.07-006 Altered Expression of Programmed Death-1 Receptor (PD-1) and Its Ligand PD-L1, PD-L2 after Neo-Adjuvant Chemotherapy in Lung Cancer Wenyu Sun, The First Hospital of Jinlin University, CN P1.07-007 Interleukin-17A Promotes Lung Tumor Progression Through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Esra A Akbay, University of Texas Southwestern Medical Center at Dallas, US P1.07-008 Microbiome & Immunotherapy: Antibiotic Use Is Associated with Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors Jonathan R Thompson, Medical College of Wisconsin, US P1.07-009 PD-L1 Expression in Circulating Tumor Cells and Response to PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer Patients Nicolas Guibert, Centre Hospitalier Universitaire, FR P1.07-010 Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab Junko Tanizaki, Kindai University Faculty of Medicine, JP P1.07-011 PD-L1 Expression and CD8+ T Cell Infiltration Associate with the Prognosis of Pulmonary Neuroendocrine Tumor Haiyue Wang, Peking University Cancer Hospital, CN P1.07-012 Prediction Sensitivity of PD-1 Checkpoint Blockade Using Pathological Tissues Specimens by Novel Computerized Analysis System Akira Saito, Tokyo Medical University, JP P1.07-013 Detection of Genomic Alterations in Plasma Circulating Tumor DNA in Patients with Metabolically Active Lung Cancers Tianhong Li, Veterans Affairs Northern California Health Care System, US P1.07-014 Association of Preoperative Serum CRP with PD-L1 Expression in NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers Takaki Akamine, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, JP P1.07-015 Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy Niki Karachaliou, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Sagrat Cor, ES P1.07-016 Comparison of PD-L1 Immunohistochemical Staining between EBUS-TBNA and Resected Non-Small Cell Lung Cancer Specimens Kenneth Kazuto Sakata, Mayo Clinic, US P1.07-017 Assessment of Cancer Immunity Status in Each Patient Using Immunogram Takahiro Karasaki, The University of Tokyo Hospital, JP

25

P1.07-018 A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced Non Small Cell Lung Cancer Johnathan Man, Westmead Hospital, AU P1.07-019 Immune Cell Infiltrates in Non-Small Cell Lung Cancer and Interleukin-22 Expression Rudolf M Huber, Ludwig Maximilian University of Munich and Thoracic Oncology Centre Munich, DE P1.07-020 Autoantibody Profiles of Cancer-Testis Genes in Non-Small Cell Lung Cancer Dijana Djureinovic, Uppsala University, SE P1.07-021 Multiplex Immune Profiling Identifies Prognostic Importance of the Spatial Co-Localization of Immune Cells in NSCLC Artur Mezheyeuski, Uppsala University, SE P1.07-022 Routine PD-L1 Immunohistochemistry Testing by 22C3 in a Canadian Reference Testing Centre Ming Sound Tsao, University Health Network, CA P1.07-023 The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab Francesco Grossi, Ospedale Policlinico San Martino, IT P1.07-024 ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors Wungki Park, University of Miami, Sylvester Comprehensive Cancer Center, US P1.07-025 Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab Wungki Park, University of Miami, Sylvester Comprehensive Cancer Center, US P1.07-026 Predicting Tumor Mutational Burden (TMB) and Tumor Neoantigen Burden (TNB) of East Asian ANSCLC Patients by a Targeted Genomic Profiling Likun Chen, Sun Yat-Sen University Cancer Center, CN P1.07-027 PD-L1 Expression Analysis in African American (AA) and Hispanic Lung Cancer Patients at a Minority-Based Academic Cancer Center Elaine Shum, Montefiore-Einstein Center for Cancer Care, US P1.07-028 Determination of Soluble PD-L1 as a Potential Biomaker for Anti-PD(L)1 Therapy in NonSmall Cell Lung Cancer (NSCLC) Margarita Majem Tarruella, Hospital de la Santa Creu i Sant Pau, ES P1.07-029 Correlation Study Between Plasma sPD-L1 and the Efficacy and Prognosis of Patients with Non-Small Cell Lung Cancer Xiaoyan Kang, Shanxi Cancer Hospital, CN P1.07-030 Prognostic Impact of PD-L1 Expression in Correlation with HLA Class I Expression Status in Adenocarcinoma of the Lung Kazue Yoneda, University of Occupational and Environmental Health, Japan, JP

26

P1.07-031 Autoantibodies Associated with Risk of Subclinical Autoimmunity and Immune-Related Adverse Events from Checkpoint Inhibitor Therapy David E Gerber, UT Southwestern, US P1.07-032 28-Color, 30 Parameter Flow Cytometry to Dissect the Complex Heterogeneity of Tumor Infiltrating T Cells in Lung Cancer Pierluigi Novellis, Humanitas Clinical and Research Center, IT P1.07-033 Differential Expression of Immune Inhibitory Markers in Association with the Immune Microenvironment in Resected Lung Adenocarcinomas Mingjuan Lisa Zhang, Massachusetts General Hospital, US P1.07-034 Pretreatment Neutrophil & Platelet Count as a Predictor for Unfavorable Clinical Outcome in Non-Small Cell Lung Cancer (NSCLC) Sarita Agte, Northwestern University, US P1.07-035 Lymphocytes and Neutrophils Count After Two Cycles and TTF1 Expression as Early Outcome Predictors During Immunotherapy Iosune Baraibar, CLINICA UNIVERSIDAD DE NAVARRA, ES P1.07-036 LC-HRMS Metabolomics Profiling in Advanced NSCLC Treated with Anti PD-1 Agents. Metabolic Features at Diagnosis and at Response Evaluation Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, ES P1.07-037 Testing the Positive and Negative Immune Checkpoint on PBMCs of Patients from Initiatory to Terminative Treatment of Anti PD-1 Antibody Wushuang Du, Chinese PLA General Hospital, CN P1.07-038 The Potential Clinical Application of Comprehensive Genomic Profiling in Targeted Therapy and Immunotherapy of Lung Cancer Mingwu Chen, The First Affiliated Hospital of Guangxi Medical University, CN P1.07-039 Blood Biomarkers Correlate with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti PD-1 Antibodies Yanyan Lou, Mayo Clinic, US P1.07-040 Prognosis-Relevant Subgroups in NSCLC According to Granulocytic Myeloid-Derived Suppressor Cell Frequency and Cytokine Levels Oscar Arrieta, Instituto Nacional de Cancerologia, MX P1.07-041 CD47 Expression and Prognosis in a Cohort of Patients with Lung Adenocarcinoma (NSCLC) Oscar Arrieta, Instituto Nacional de Cancerologia, MX P1.07-042 PD-L1 and CD8 Expression in EGFR-Mutant or ALK-Rearranged Patients with Lung Cancer Yi-Long Wu, , P1.07-043 Barrier Molecule Overexpression is Associated with Increased CD8 T Cells and Decreased B/Treg Cells in Human Lung Cancer Wooyoung Monica Choi, Robert H Lurie Comprehensive Cancer Center of Northwestern University, US

27

P1.07-044 The Impact of Neutrophil/Lymphocyte Ratio as the Predictive Marker to Anti-PD-1 Antibody Treatment in NSCLC Patients Keiko Tanimura, Department of Pulmonary Medicine, Kyoto Prefectural University, JP P1.07-044a Comparison of Tumor Mutational Burden (TMB) Derived from Whole Exome and Large Panel Sequencing in Lung Cancer Gang Cheng, Novogene Co., Ltd, CN P1.07-044b: Pretreatment Neutrophil/Lymphocyte Ratio and the Efficacy of Nivolumab Treatment in Non–Small-Cell Lung Cancer Hiroshi Kobayashi, Toho University School of Medicine, JP P1.07-044c: Neurological Complications Following Treatment with Anti-PD1 Immune Checkpoint Inhibitors Kenneth O’Byrne, Princess Alexandra Hospital, AU

P1.08 LOCALLY ADVANCED NSCLC P1.08-001 Surgical versus Non-Surgical Treatments for Resectable Stage III NSCLC: A Systematic Review and Meta-Analysis Wee Yao Koh, National University Cancer Institute Singapore, SG P1.08-002 Blood Supply to the Tumor Do Not Predict the Effect of Induction Therapy in Patients with Locally Advanced Lung Cancer Koji Kawaguchi, Nagoya University, JP P1.08-003 Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study Kristin A Higgins, Winship Cancer Institute, Emory University, US P1.08-004 Adjuvant Chemoradiotherapy vs. Chemotherapy for Completely Resected Unsuspected N2Positive Non-Small Cell Lung Cancer Jong-Mu Sun, Samsung Medical Center, KR P1.08-005 Preoperative Analysis of 18FDG-PET Features May Predict Loco-Regional Invasiveness in NSCLC Pietro Bertoglio, Sacro Cuore-Don Calabria Research Hospital and Cancer Care Centre, IT P1.08-006 Phase I/II Study of Carboplatin, nab-paclitaxel, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC. Yuko Kawano, Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, JP P1.08-007 Surgery versus Concurrent Chemoradiotherapy for Resectable CIIIA-N2 NSCLC: A Propensity Score Matched Analysis Xin Sun, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, CN P1.08-008 Chemoradiotherapy in the Regime of Accelerated Fractionation in the Treatment of Lung Cancer Yury Ragulin, Medical Radiological Research Center, RU

28

P1.08-009 Neutrophilia as Prognostic Biomarker in Locally Advanced Stage III Lung Cancer Angela Botticella, Gustave Roussy, FR P1.08-010 Unsuspected N2 Disease in Patients Undergoing Surgery for Non-Small Cell Lung Cancer: Role of Extent and Location of the Lymph Node Metastasis Saana Andersson, Heart and Lung Center, Helsinki University Hospital, FI

P1.09 MESOTHELIOMA P1.09-001 Multiplexed Biomarker Strategies Based on Targeted Proteomics for Detection of Malignant Pleural Mesothelioma in Blood Ferdinando Cerciello, The Ohio State University Medical Center, US P1.09-002 Cellular Noise and Positional Effects Determine the Cell Stem State in Malignant Mesothelioma Walter Blum, UMR-1162, FR P1.09-003 Malignant Mesothelioma Versus Synovial Sarcoma: An Analysis of 19 Cases with Molecular Diagnosis Sonja Klebe, Flinders University, AU P1.09-004 YB-1 Suppresses miR-137 via a Feed Forward Loop, Increasing YB-1 Levels, Migration and Invasion in Malignant Mesothelioma Karin Schelch, Asbestos Diseases Research Institute, AU P1.09-005 Targeting YB-1 Induces Either Drug Sensitisation or Resistance via Distinct Mechanisms in Malignant Pleural Mesothelioma Thomas George Johnson, Asbestos Diseases Research Institute, AU P1.09-006 JMJ and BRD Domain Family Members in Malignant Pleural Mesothelioma: Potential Therapeutic Targets or Not? Steven G. Gray, Trinity College Dublin/St. James's Hospital, IE P1.09-007 Targeting MET/TAM Receptors in Mesothelioma: Are Multi-TKIs Superior to Specific TKI? Steven G. Gray, Trinity College Dublin/St. James's Hospital, IE P1.09-008 A 4-microRNA Signature in Serum Can Discriminate Between Non-Small-Cell Lung Cancer and Malignant Pleural Mesothelioma Michaela B Kirschner, University Hospital Zurich, CH P1.09-009 Evaluation of a Combined MicroRNA-Clinical Score as Prognostic Factor for Malignant Pleural Mesothelioma Michaela B Kirschner, University Hospital Zurich, CH P1.09-010 PD-L1 Reactivity of Tumor Cells Can Successfully Be Determined in Malignant Mesothelioma Effusions Annika Dejmek, Lund University, SE P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma Anne Tsao, University of Texas M.D. Anderson Cancer Center, US

29

P1.09-012 A Pre-Clinical Investigation of Intrapleural Curcumin Treatments as an Adjunct Therapy for Malignant Pleural Mesothelioma Ashleigh Jean Hocking, Flinders University, AU P1.09-013 Profiling Response to Chemotherapy in Malignant Pleural Mesothelioma Among Hispanics (MeSO-CLICaP) Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, CO

P1.10 NURSING/PALLIATIVE CARE/ETHICS P1.10-002 Outcome of Pilot RCT in Lung Cancer Surgery Patients Receiving Either Preop Carbohydrate & Postop Nutritional Drinks or Water Amy Kerr, Heart of England NHS Foundation Trust, GB P1.10-003 Synergy in Motion: Transferring Nursing Knowledge from Clinical Trials to Standard Therapy to Enhance Care and Communication Dianne Zawisza, Princess Margaret Cancer Centre, CA P1.10-004 Testing Efficacy of a Pulmonary Rehabilitation Program for Post Lung Cancer Resection Surgery Wei Ling Hsiao, National Taiwan University Hospital, TW P1.10-005 Generation of Symptom Burden Patient-Reported Outcomes for Patients with Lung Cancer George R. Simon, The University of Texas MD Anderson Cancer Center, US P1.10-006 Adverse Events After First-Line Target Therapy for Non-Small Cell Lung Cancer Patients in a Case Management Model Lin Zhi Xuan, Chi Mei Medical Center, Liouying, TW P1.10-007 Preparing Mesothelioma Patients for Treatment: Providing Psychosocial Support Networks Gleneara Elizabeth Bates, Mesothelioma Applied Research Foundation, US P1.10-008 Palliative Care and Hospice Resources are Underutilized in Patients with Advanced NonSmall Cell Lung Cancer Joshua Robert Rayburn, Swedish Cancer Institute, US

P1.11 PATIENT ADVOCACY P1.11-001 Economic Impact of Immune Checkpoint Inhibitor Therapy in Brazil and Strategies to Improve Access Pedro Aguiar Jr, Faculdade de Medicina do ABC, BR P1.11-002 Lung Cancer in Nonagenarian Patients Cheng Chieh Hsu, Taipei Veterans General Hospital, TW P1.11-003 A Personalized Navigation Program to Increase Clinical Trial Participation of Lung Cancer Patients Jennifer C King, Lung Cancer Alliance, US P1.11-004 Impact of Liquid Biopsy on the Treatment of Low-Income Lung Cancer Patients Jorge Nieva, USC Norris Comprehensive Cancer Center, US

30

P1.12 PULMONOLOGY/ENDOSCOPY P1.12-001 – P1.12-009 THERAPEUTIC ENDOSCOPY P1.12-001 Flexible Bronchoscopic Cryotherapy in Patients with Malignant Central Airway Obstruction Sung Kyoung Kim, St. Vincent's Hospital, The Catholic University of Korea, KR P1.12-002 Nanoparticle Targeted Folate Receptor 1 Enhanced Photodynamic Therapy for Lung Cancer Tatsuya Kato, Toronto General Hospital, University Health Network, CA P1.12-003 Photothermal Ablation of Lung Cancer by Low Power Near-Infrared Laser and Topical Injection of Indocyanine Green; A Preliminary Animal Study Kentaro Hirohashi, Kochi Medical School, Kochi University, JP P1.12-005 Improvement of Performance Status After Therapeutic Bronchoscopy in Patients with Airway Malignancy: Single Center Experience Thitiwat Sriprasart, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, TH P1.12-006 The Efficacy of Electrocautery Using Wire Snare as the Primary Ablation Modality for Malignant and Benign Airway Obstruction Masahiko Harada, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, JP P1.12-007 Outcomes of Radiotherapy and Endoscopic Airway Stenting for Central Airway Obstruction in Non-Small Cell Lung Cancer Candice Leigh Wilshire, Swedish Cancer Institute, US P1.12-008 Photodynamic Therapy for Peripheral Lung Cancers Using Composite-Type Optical Fiberscope of 1.0 mm in Diameter Jitsuo Usuda, Nippon Medical School, JP P1.12-009 Experience with Fully Covered Metallic Stents in Patients with Malignant Airway Obstruction Antoni Rosell, Hospital Universitari de Bellvitge, ES

P1.13 RADIOLOGY/STAGING/SCREENING P1.13-001 – P1.13-011c STAGING P1.13-001 T1 Tumor(≪3cm) with Visceral Pleural Invasion Should Be Classified as T2a in the 8th TNM Classification for Lung Cancer Jia-Tao Zhang, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University., CN P1.13-002 New Clinical T Classification Is Associated with Pathological Stage I Invasive Adenocarcinoma with Solid Histologic Subtype Yutaka Sawai, The University of Tokyo, JP

31

P1.13-003 Recurrence Dynamics in Resected Pathological Stage I Lung Adenocarcinoma Depend on the IASLC/ATS/ERS Histological Subtype Yusuke Takahashi, Memorial Sloan Kettering Cancer Center, US P1.13-004 The Role of Lymph Node Staging by EBUS-TBNA in Stereotactic Body Radiation Therapy for patients with Non-Small Cell Lung Cancer. Kohei Hashimoto, University of Toronto, CA P1.13-005 Is Tumor Size for the T4 Descriptor in Lung Cancer Staging Appropriate? Junji Ichinose, Cancer Institute Hospital, Japanese Foundation for Cancer Research, JP P1.13-006 The Value of F-18 FDG PET/CT-guided EBUS-TBNA in Nodal Staging of NSCLC. Sung Yong Lee, College of Medicine, Korea University, KR P1.13-007 Is Central Lung Tumor Location Really Predictive for Occult Mediastinal Nodal Disease in (Suspected) NSCLC Staged cN0 on PET-CT? Herbert Decaluwe, University Hospitals Leuven, BE P1.13-008 Evaluation of Clinical Associated Factors for Lung Adenocarcinoma by TNM 8th Edition with Unexpected N2 disease Yoshiteru Kidokoro, Tottori University, JP P1.13-009 Macroscopic and Microscopic Lymphatic Remodeling Caused by VEGF-C Play a Key Role in Lymphatic Metastasis of Non-Small Cell Lung Cancer Hiromitsu Takizawa, Institute of Biomedical Sciences, Tokushima University Graduate School, JP P1.13-010 Is MRI Brain Mandatory in All Patients with Early Stage NSCLC? George Karimundackal, Tata Memorial Hospital, IN P1.13-011 Prospective Cohort Study of Patterns of Staging and Treatment Selection with or Without Multidisciplinary (MD) Care Raymond Osarogiagbon, Baptist Cancer Center, US P1.13-011c: A Study on the Prognosis of Hilar and Interpulmonary Lymph Nodes Patients with Pathologic T1N1M0 and T2N1M0 Disease in NSCLC Jun Suzuki, Yamagata University Faculty of Medicine, JP P1.13-011a – P1.13-011b DIAGNOSTIC RADIOLOGY P1.13-011a: Stratification Based on PET/CT Findings for Malignant Grade of Radiologically Pure Solid Small-Sized (≪ 2cm) Lung Cancer Norifumi Tsubokawa, Hiroshima City Asa Citizens Hospital, JP P1.-13-011b: Nodal Status Based on the Anatomical Location or the Number of Lymph Nodes Metastasis Kyohei Masai, Keio University, School of Medicine, JP

32

P1.14 RADIOTHERAPY P1.14-001 The Feasibility of Predicting Radiation Pneumonitis Using Lung Equivalent Uniform Dose (LEUD) in Volumetric-Modulated Arc Xiadong Li, Zhejiang University, CN P1.14-002 Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumors After Resection of Lung Cancer Shigeo Takahashi, Kagawa University Hospital, JP P1.14-003 Anesthesia Allows Safe Administration of SBRT for Early Stage Lung Cancer Patients with Advanced Cognitive Impairments Gregory M.M. Videtic, Cleveland Clinic, US P1.14-004 Outcomes of Stereotactic Body Radiotherapy and Surgery in Treating Early Stage NonSmall Cell Lung Cancer: A Meta-Analysis Liang Wang, Key Laboratory of Carcinogensis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Peking University Cancer Hospital and Institute, CN P1.14-005 Development of a Novel Spacer to Reduce Mediastinal Organ Toxicity from Stereotactic Body Radiotherapy Yusuke Muranishi, Kyoto University, JP P1.14-006 Carbon-Ion Radiotherapy for Isolated Lymph Node Metastasis from Lung Cancer Using a Regimen of 12 Fractions during 3 Weeks Katsuyuki Shirai, Gunma University Heavy Ion Medical Center, JP P1.14-007 Mesenchymal Stem Cells Labeled with Fluorescent Magnetic Nanoparticles for Targeted Imaging and Hyperthermia Therapy of Lung Cancer Runlei Hu, Hangzhou First People’s Hospital, CN P1.14-008 Elevated Platelet Levels Affect Prognosis in Patients with NSCLC Treated with Curatively Intended Chemoradiotherapy Georg Holgersson, Gävle Hospital, SE P1.14-009 Comparison of Dosimetric Parameters and Outcome in Non-Small Cell Lung Cancer Patients Having 3D Conformal or VMAT Plans Nur Abdul Satar, St Bartholomew's Hospital, GB P1.14-010 SGA Could Be a Predictive Factor for Radiation Pneumonitis in Lung Cancer Patients Treated by Concurrent Chemoradiotherapy Hui Liu, Sun Yat-sen University Cancer Center, CN P1.14-011 An Esophagus-Sparing Technique to Limit Radiation Esophagitis in Locally Advanced NSCLC Treated by SIB-IMRT and Concurrent Chemotherapy Hui Liu, Sun Yat-sen University Cancer Center, CN P1.14-012 Hypofractionated Simultaneous Integrated Boost IMRT Concurrent with Chemotherapy Improved Loco-Regional Control in Locally Advanced NSCLC Hui Liu, Sun Yat-sen University Cancer Center, CN

33

P1.14-013 High Dose Radiotherapy (74Gy) Improved Local Progression Free Survival in Patients with Inoperable Stage III NSCLC Young Il Kim, Chungnam National University Hospital, KR P1.14-014 Comparative Evaluation of VMAT & 3D-CRT in Locally Advanced NSCLC: Is There Any Radiobiological Advantage? Iulian Badragan, BC Cancer Agency, CA P1.14-015 Local Recurrence Rate and Timing after Stereotactic Body Radiotherapy for Lung Cancer: Need for Long-term Follow-up Takashi Shintani, Kyoto University Graduate School of Medicine, JP P1.14-016 Assessing the Feasibility of FLT-PET for Evaluation of Non-Small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiotherapy (SBRT) Meredith Elana Giuliani, University of Toronto and Princess Margaret Cancer Center, CA P1.14-017 Impact of Systematic EBUS-TBNA Mediastinal Staging on Radical Radiotherapy Planning in NSCLC Nicholas Hardcastle, Peter MacCallum Cancer Centre, AU P1.14-018 Construction and Evaluation of RapidPlanTM Models for Radical Lung Planning Timothy Mitchell, Beatson West Of Scotland Cancer Center, GB

P1.15 SCLC/NEUROENDOCRINE TUMORS P1.15-001 Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer Edurne Arriola, Hospital del Mar, ES P1.15-002 A Retrospective Study of Amrubicin Monotherapy for the Treatment of Relapsed Small Cell Lung Cancer in Elderly Patients Hiroyuki Minemura, Fukushima Medical University, JP P1.15-003 Survival by Response to First-line Platinum-Based Therapy Among Patients With Extensive Disease Small Cell Lung Cancer Yong Yuan, Bristol-Myers Squibb, US P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC Matthew G Krebs, The University of Manchester and The Christie NHS Foundation Trust, GB P1.15-005 Relationship Between MYC Family Status and Sensitivity to Aurora Kinase Inhibitors in Neuroendocrine and Other Lung Cancer Cell Lines Tomohiro Haruki, University of Texas Southwestern Medical Center, US P1.15-006 Enriched Environment and Anti-Depressants Enhance Platinum Chemosensitivity of Small Cell Lung Cancer Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, CN

34

P1.15-007 Randomized Phase III Trial of Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: The RASTEN Trial Emelie Gezelius, Lund University Cancer Center, SE P1.15-008 Clinical Features and Gene Mutation Profiling of Pulmonary Carcinoid Tumors Xiongfei Li, Tianjin Medical University General Hospital, CN P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897) Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, CN P1.15-010 Small Cell Lung Cancer: Experience of a Portuguese District Hospital Margarida Felizardo, Hospital Beatriz Angelo, PT P1.15-011 Longitudinal Mutation Monitoring in Plasma Without Matching Tumor Tissue by Deep Sequencing in Small Cell Lung Cancer (SCLC) André Rosenthal, Roche Sequencing Solutions, US P1.15-012 Clinical Prognostic Factors of Elderly Patients with Extensive Stage Small Cell Lung Cancer in Korea Jung Sun Kim, Korea University Medical Center, KR P1.15-013 Small Cell Lung Cancer. Methodology and Preliminary Results from the Small Cell Study Ángeles Rodríguez, Pontevedra Hospital Complex, ES P1.15-014 Can Limited Resection Be Accepted as an Alternative Treatment Option for Patients with Early-Stage Small Cell Lung Cancer? Takamasa Koga, National Hospital Organization Minami-kyushu Hospital, JP P1.15-015 Prognostic Implication of the FEV1/FVC Ratio in Limited-Stage Small Cell Lung Cancer Young-Taek Oh, Ajou University School of Medicine, KR P1.15-016 The Study of Population Pharmacokinetics and Individualized Dosage of Lobaplatin-Based Regimens in Elderly Patients with Small Cell Lung Cancer Ying Cheng, Jilin Provincial Cancer Hospital, CN P1.15-017 Adoption of Prophylactic Cranial Irradiation for Extensive Stage Small Cell Lung Cancer: A Population Based Outcomes Study Swee Peng Yap, National Cancer Centre Singapore, SG

P1.16 SURGERY P1.16-001 – P1.16-028 MINIMAL INVASIVE SURGERY P1.16-001 Characteristics of Resected Lung Cancer in Patients Aged under 60: A Single–Center Experience Jeong Su Cho, Pusan National University Hospital, KR P1.16-002 Management of Local Recurrence after Segmentectomy for Stage IA Lung Cancer Takeshi Mori, Kumamoto University Hospital, JP

35

P1.16-003 Learning Curve for Adoption of Robotic Lobectomy for Early Stage Non-Small Cell Lung Cancer by a Thoracic Surgeon Experienced in Open Lobectomy Shea Gallagher, University of California, Irvine, US P1.16-004 Intubated Versus Non-intubated Anesthesia for Lung Cancer VATS in Octogenerians Nenad Ilic, University Surgical Hospital, HR P1.16-005 Comparison Sublobar vs Lobar Resection in Early Stage Lung Cancer in Octagenarian Patients Sira Laohathai, Bundang Hospital, KR P1.16-006 Less Is More: video Assisted Thoracic Surgery (VATS) vs Open Thoracotomy in the Management of Resectable Lung Cancer Shagufta Shaheen, Loma Linda University Medical Center, US P1.16-007 Mobile Computed Tomography in Video-Assisted Thoracoscopic Surgery for Ground-Glass Opacity Lung Nodules Kouhei Tajima, Kiryu Kosei General hospital, JP P1.16-008 Near-Infrared Fluorescence-Guided Pulmonary Segmentectomy Following Endobronchial Indocyanine Green Injection Hironobu Wada, Chiba University Graduate School of Medicine, JP P1.16-009 Comparing Lymph Node Dissection in VATS versus Open Lung Cancer Surgery: How, How Long, and How Does It Matter? Alan D L Sihoe, The University of Hong Kong Shenzhen Hospital, CN P1.16-010 Development of a Novel Surgical Marking Method Using Low Power Laser Light Keishi Ohtani, Tokyo Medical University, JP P1.16-011 The Role of 3D-CT in Patients with Pulmonary Malignancies Undergoing Segmentectomy Ali Amiraliev, P. Hertzen Research Institute of Oncology, RU P1.16-012 Application of Fluorescent and Iodized Dual Marker for Pre-Operative Localization and Image-Guided Surgery of Pulmonary Nodule Jiyun Rho, Korea University Guro Hospital, KR P1.16-013 Video-Assisted Thoracoscopic Surgery (VATS) versus Thoracotomy in Locally-Advanced Lung Cancers – a Meta-Analysis Gerald Sng, National Cancer Centre Singapore, SG P1.16-014 The Efficacy of Thoracoscopic Right Upper Lobectomy Using Fissureless Technique in Patients with Dense Fissures Hitoshi Igai, Maebashi Red Cross Hospital, JP P1.16-015 miMRST Thoracotomy Cures Aged, Sickly Weak and/or Cardiopulmonary Dysfunction Patients with Lung Cancer Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, CN

36

P1.16-016 Comparing Safety and Effectiveness of Image-Guided VATS Versus Conventional VATS for Small or Deep Pulmonary Nodules Yin Kai Chao, Chang Gung memorial hospital, TW P1.16-017 Middle Term Survival Outcome of Single Port Video Assisted Thoracoscopic Anatomic Lung Resection: Two Center Experience Ching Feng Wu, Chang Gung Memorial Hospital, TW P1.16-018 Intraoperative Detection of Tumor Resection Margin via Inhalation of Fluorescent Imaging Agents Yu Hua Quan, Korea University Guro Hospital, KR P1.16-019 Three Dimensional CT Angio-Bronchography Doesn't Contribute to the Shortening of the Operation Time in Segmentectomy Hirohisa Horinouchi, Saitama-city hospital, JP P1.16-020 Outcomes of Pulmonary Metastasectomy in Hepatocellular Carcinoma According to Approach Method-Thoracoscopic Versus Open Approach Hyeong Ryul Kim, Asan Medical Center, University of Ulsan College of Medicine, KR P1.16-021 Midterm Oncologic Outcomes of Single Port Thoracoscopic Lobectomy for Lung Cancer by Propensity Matched Analysis Kook Nam Han, Korea University Guro Hospital, KR P1.16-022 Incorporating Robotics to the Surgical Treatment of Thoracic Neoplasms: 5-Year Experience at an Academic Center Dao Minh Nguyen, University of Miami, US P1.16-023 A Useful and Safe Method of Intraoperative Localization of Small-Sized Peripheral Pulmonary Lesions Yujiro Kubo, Iwakuni Clinical Center, JP P1.16-024 A Case of Bronchial Atresia Treated with Complete Thoracoscopy-Assisted Right S6 Segmentectomy Using Fluorescence Navigation Mototsugu Watanabe, Iwakuni Clinical Center, JP P1.16-025 Safety of Simultaneous TEVAR and Combined Aortic Wall Resection at the Time of Lung Resection for T4 Lung Cancer Infiltrating the Aorta Masanori Tsuchida, Niigata University Graduate School of Medical and Dental Sciences, JP P1.16-026 Multimodal Image-Guided VATS Resection of Sub-Centimeter Pulmonary Nodules by Cone Beam CT and Bronchoscopic NIR Fluorescence Marking Takashi Anayama, Kochi Medical School, Kochi University, JP P1.16-027 Robotic Surgery, VATS, and Open Surgery for Early Stage Lung Cancer: Comparison of Costs and Outcomes at a Single Institute Pierluigi Novellis, Humanitas Clinical and Research Center, IT P1.16-028 Is Video-Assisted Thoracic Surgery a Safer Procedure for Lung Cancer Patients? Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, BR

37

P1.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES P1.17-001 – P1.17-019 THYMOMA P1.17-001 The Optimal First-Line Treatment for Advanced Thymic Carcinomas Xue Yang, Peking University Cancer Hospital and Institute, CN P1.17-002 Clinicopathological Significance of Epithelial Mesenchymal Transition in Thymic Cancer Yasushi Shintani, Osaka University Graduate School of Medicine, JP P1.17-003 Identification of Differentially Expressed Genes between Thymoma and Paraneoplastic Thymic Tissue Lei Yu, Beijing Tongren Hospital, Capital Medical University, CN P1.17-004 Extrapleural Pneumonectomy for Patients with Stage IVa Thymoma: Pathological Evaluation of Disseminated Pleural Nodules Shota Nakamura, Nagoya University Graduate School of Medicine, JP P1.17-005 Pure Red Cell Aplasia Associated with Thymoma: A Report of a Single-Center Experience Satoru Moriyama, Nagoya City University Graduate School of Medical Sciences, JP P1.17-006 Radiographic Assessment for Tumor Responses of Thymic Carcinoma Using the ITMIG Modified Criteria Taiki Hakozaki, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, JP P1.17-007 Platinum Based Chemotherapy in Locally Advanced Non-Metastatic Thymic Carcinoma Tahir Mehmood, Northwest General Hospital and Research Centre, PK P1.17-008 Clinical and Oncological Outcomes on Resected Thymomas over a Decade at the National Cancer Institute at Mexico City Francisco Corona Cruz, National Cancer Institute, MX P1.17-009 Clinical Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients with Thymic Epithelial Tumor Undergoing Surgery Satoru Okada, Kyoto Prefectural University of Medicine, JP P1.17-010 The Diagnostic Value of Serum Cytokeratin Fragment 19 (CYFRA21-1) for Thymic Squamous Cell Carcinoma Haruhiko Shiiya, Hokkaido University Hospital, JP P1.17-011 Efficacy and Toxicities of Gemcitabine and Cisplatin Combination Chemotherapy in Advanced Thymoma and Thymic Carcinoma Jian Fang, Peking University Cancer Hospital and Institute, CN P1.17-012 Thymic Neoplasms: The Experience of a Cancer Institute Rita Vitorino, Instituto Português de Oncologia de Lisboa Francisco Gentil, PT P1.17-013 Prognostic Impact of Programmed Cell Death-1 (PD-1) and PD-Ligand 1 (PD-L1) Expression in Thymic Cancer Soichiro Funaki, Osaka University Graduate School of Medicine, JP

38

P1.17-014 Platinum Rechallenge in Advanced Thymic Epithelial Tumors: Still an Option in the Age of Target Therapy? A Monocentric Experience Margaret Ottaviano, CRTR Rare Tumours Reference Center, IT P1.17-015 Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience Margaret Ottaviano, CRTR Rare Tumours Reference Center, IT P1.17-016 Immunohistochemical Markers as Prognostic Factors in Malignant Thymic Epithelial Tumors Yoshito Yamada, University Hospital Zürich, CH P1.17-017 Usefulness of FDG-PET for Differentiating Thymic Epithelial Tumors from Malignant Lymphomas Hiroyuki Sakamaki, Keio University, School of Medicine, JP P1.17-018 Distribution of Ectopic Thymus in Chinese Patients: A Preliminary Study Jian-Yong Ding, Zhongshan Hospital, Fudan University, CN P1.17-019 B7-H3 Protein Expression in Thymic Epithelial Tumour Subtypes and Its Association with PD-L1 and Clinical Characteristics Spyridon Gennatas, Imperial College, London, GB

39

TUESDAY, OCTOBER 17, 2017 P2.01 ADVANCED NSCLC P2.01-001 – P2.01-058 CHEMOTHERAPY P2.01-059 – P2.01-075c MISCELLANEOUS P2.02 BIOLOGY/PATHOLOGY P2.02-001 – P2.02-024 GENOMICS P2.02-025 – P2.02-049 IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY P2.02-050 – P2.02-073 MARKER FOR PROGNOSIS, PREDICTION P2.03 CHEMOTHERAPY/TARGETED THERAPY P2.03-001 – P2.03-058a EGFR P2.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS P2.05 EARLY STAGE NSCLC P2.05-001 – P2.05-009 SBRT P2.05-010 – P2.05-021 SURGERY P2.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION P2.06-001 – P2.06-011 PREVENTION P2.07 IMMUNOLOGY AND IMMUNOTHERAPY P2.07-001 – P2.07-062c IMMUNOTHERAPY (CLINICAL) P2.08 LOCALLY ADVANCED NSCLC P2.09 MESOTHELIOMA P2.10 NURSING/PALLIATIVE CARE/ETHICS P2.11 PATIENT ADVOCACY P2.12 PULMONOLOGY/ENDOSCOPY P2.12-001 - P2.12-006 DIAGNOSTIC ENDOSCOPY P2.13 RADIOLOGY/STAGING/SCREENING P2.13-001 – P2.13-026a SCREENING P2.14 RADIOTHERAPY P2.15 SCLC/NEUROENDOCRINE TUMORS P2.16 SURGERY P2.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES

Tuesday, October 17, 2017

Poster Setup Time: Tuesday, October 17, 08:00 – 10:00 Poster Takedown Time: Tuesday, October 17, 15:30 – 18:00 (Posters not taken down by 18:00 will be discarded by management) POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME) Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates. Tuesday, October 17, 10:00 – 10:45 and 14:30 – 15:30 (Exhibit Hall B + C - Poster Area)

P2.01 ADVANCED NSCLC P2.01-001 – P2.01-058 CHEMOTHERAPY P2.01-001 Serum Albumin Level Predicts the Survival Benefit of Chemotherapy in Elderly Advanced NSCLC Patients with Poor Performance Status Satoshi Ikeda, Kanagawa Cardiovascular and Respiratory Center, JP P2.01-002 Survival of Patients with Advanced Non-Small Cell Lung Cancer at Single Institute in Eastern Thailand, 2013-2016 Sitthi Sukauichai, Chonburi Cancer Hospital, TH P2.01-003 Does Astragalus Membranaceus Root Extract Have Any Survival Benefit for Metastatic NonSmall Cell Lung Cancer? Adnan Aydiner, Istanbul University, Institute of Oncology, TR P2.01-004 Safety and Efficacy of Nab-Paclitaxel plus Carboplatin in Elderly Patients with NSCLC (ABOUND.70+) Corey J Langer, Abramson Cancer Center, University of Pennsylvania, US P2.01-005 A Randomized Phase II Trial of Erlotinib vs S-1 in Patients with NSCLC as Third- or FourthLine Therapy (HOT1002) Yasutaka Kawai, Oji General Hospital, JP P2.01-006 Effect of Maintenance Using Pemetrexed with and without Bevacizumad in Patients Advanced Lung Cancer in Non-Small Cells Mayra Galeana Hernandez, Hospital Central Militar, MX P2.01-007 Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population Valeria Cecilia Denninghoff, Centro de Educación Médica e Investigaciones Clínicas (CEMIC-CONICET), AR P2.01-008 Combination of Bavacizumab with Conventional Chemotherapy Shows Better Prognosis in Patients with Lung Cancer with Liver Metastasis Kim Ki-Up, Soon Chun Hyang University Hospital, KR P2.01-009 The Efficacy of Bevacizumab Adding in Standard First Line Chemotherapy and Maintenance Treatment in Advanced NSCLC: A Network Meta-Analysis Voralak Vichapat, Mahidol university, TH

41

P2.01-010 Risk Score for Predicting Acute Exacerbation after Chemotherapy in Lung Cancer Associated with Interstitial Pneumonia Kazutoshi Isobe, Toho University School of Medicine, JP P2.01-011 The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma Qingming Shi, Anhui Chest Hospital, CN P2.01-012 Impact of Brain Metastases on the Humanistic Burden Incurred by Patients with Advanced Non-small Cell Lung Cancer (A-nsclc) Oana Chirita, Bristol-Myers Squibb, GB P2.01-013 Nab-Paclitaxel/Carboplatin in Elderly Patients with NSCLC (ABOUND.70+): Analysis of Safety and Quality of Life (QoL) by Cycle Corey J Langer, Abramson Cancer Center, University of Pennsylvania, US P2.01-014 ABOUND.PS2: Safety and Efficacy of Nab-Paclitaxel–Based Therapy in Patients with NSCLC and ECOG PS 2 Ajeet Gajra, Upstate Medical University, State University of New York, US P2.01-015 Longitudinal Assessment of Performance Status (PS) in Patients with NSCLC and ECOG PS 2 on Nab-Paclitaxel–Based Therapy Nagla Abdel Karim, University of Cincinnati Medical Center, US P2.01-016 Prognostic Impact of a New Score Using Neutrophil-To-Lymphocyte Ratios in the Serum and Malignant Pleural Effusion in Lung Cancer Patients Hae-Seong Nam, Inha University Hospital, KR P2.01-017 Study on the Effect of Apatinib Salvage Treatment of Advanced Non-Small Cell Lung Cancer Meiyu Fang, Zhejiang Cancer Hospital, CN P2.01-018 Risk Factors in Patients with Pathological N1 or N2 Non-Small Cell Lung Cancer Yoshimasa Tokunaga, Kochi Health Sciences Center, Japan, JP P2.01-019 The Necessity of Contrast-enhanced CT before CT-Guided Percutaneous Transthoracic Needle Biopsy for Lung Lesions Tang Feng Lv, Jinling Hospital, CN P2.01-020 Continuous Intravenous Infusion Endostar Combined with Pemetrexed plus Cisplatin in Chinese Treatment-Naïve Metastatic Non-Squamous NSCLC Li Chen, The First Affiliated Hospital of Nanchang University, CN P2.01-021 Efficacy of Single-Agent Chemotherapy after Exposure to Nivolumab in Advanced NonSmall Cell Lung Cancer Yuto Yasuda, Kyoto University, JP P2.01-022 Nintedanib/Docetaxel Efficacy in Advanced Lung Adenocarcinoma Treated with 1L Chemotherapy/2L Immunotherapy in Nintedanib NPU Jesus Corral, Hospital Virgen del Rocío-Oncoavanze, ES

42

P2.01-023 Reasons for Withholding Systemic Therapy in Stage IV NSCLC: Comparison of Years 2004 to 2007 and 2010 to 2013 Gouri Shankar Bhattacharyya, Fortis Hospital, Anandapur, Kolkata, IN P2.01-024 Prognostic Value of Body Fat Mass Ratio in Lung Cancer Patients Abdurrahman İsikdogan, Dicle University Diyarbakır/turkey, TR P2.01-025 Evaluation of Calculating Carboplatin Dosage in Carboplatin–Pemetrexed Therapy in Chinese Patients with Advanced NSCLC Yixiang Zhu, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, CN P2.01-026 Distribution of Metastatic Disease in Survival Outliers with Stage IV Non-Small Cell Lung Cancer D. Gwyn Bebb, University of Calgary, CA P2.01-027 Clinical Significance of Topoisomerase-II Expression in Patients with Non-Small Cell Lung Cancer Treated with Amrubicin Reiko Sakurai, Gunma University Hospital, JP P2.01-028 Clinical Correlation between CTCs Enumeration Based on New Detection Method and Chemotherapy Efficacy in Human Advanced Lung Cancer Honglei Chen, Wuhan University, CN P2.01-029 Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC Yalei Wang, Cancer Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, CN P2.01-030 Real World Study of Bevacizumab-Contained Regimen as First Line Therapy in Chinese Patients with Advanced NSCLC Yuxin Mu, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, CN P2.01-031 Use of Geriatric Assessment (GA) in Clinical Practice for Stage IV Non-Small Cell Lung Cancer (NSCLC). The GIDO Experience Regina Gironés, Hospital Lluis Alcanyís, ES P2.01-032 A Randomized Phase Ii Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219 Barbara Melosky, British Columbia Cancer Agency, CA P2.01-033 Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: A Single Center Experience in Chinese Patients Junling Li, Cancer Institute and Hospital Chinese Academy of Medical Sciences Peking Union Medical College, CN P2.01-034 Phase I/II Trial of Weekly Nab-Paclitaxel as 2nd or 3rd Line Treatment in NSCLC Without Driver Mutations. (OLCSG1303) Kenichiro Kudo, National Hospital Organization Iwakuni Clinical Center, JP

43

P2.01-035 Phase II Study: Weekly Docetaxel as First Line Chemotherapy for Elderly Patients with Squamous-Cell Non-Small-Cell Lung Cancer Kyung Ho Kang, College of Medicine, Korea University, KR P2.01-036 Symptom Trajectories During Chemotherapy Predict Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer Qiuling Shi, University of Texas MD Anderson Cancer Center, US P2.01-037 Clinical Impact of Interstitial Lung Disease on Advanced Non-Small Cell Lung Cancer Hajime Oi, Tosei General Hospital, JP P2.01-038 Determinants of Frailty and Treatment Toxicity in Non-Small Cell Lung Cancer Patient Marie-Eve Boucher, Institut Gustave Roussy, FR P2.01-039 Erythropoiesis-Stimulating Agents for Chemotherapy-Induced Anaemia Efficacy, Toxicity and Effect on Survival Kostas Syrigos, University of Athens, GR

in Lung Cancer:

P2.01-040 Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in NonSquamous NSCLC: Descriptive Safety Analysis Vassiliki A Papadimitrakopoulou, MD Anderson Cancer Center, US P2.01-041 Pemetrexed plus Platinum Chemotherapy with or Without ImmunoResponses of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusionstherapy in Non-Squamous NSCLC: Descriptive Safety Analysis Xue Li, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, CN P2.01-042 Perioperative Chemotherapy with Pemetrexed and Cisplatin for Pulmonary LCNEC: A Case Report and Literature Review Hong Tang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, CN P2.01-043 PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients James Rigas, AstraZeneca, US P2.01-044 The Correlation Between One Year Survival and the Affecting Factors of Lung Cancer Patients at Dr. Moewardi Hospital Surakarta Ana Rima, Moewardi Hospital, ID P2.01-045 The Efficiency of Apatinib plus S-1 as Laterline Chemotherapy for Advanced Non-SmallCell Lung Cancer Zhiyong Wu, PLA General Hospital, CN P2.01-046 Clinical Characteristics of Survival with De Novo Versus Relapsed Metastatic Non-Small Cell Lung Cancer Gwyn Bebb, Alberta Health Services, CA P2.01-047 A Phase 1 Trial of Dose Escalated BGB324 in Combination with Docetaxel for Previously Treated Advanced NSCLC David E Gerber, UT Southwestern, US

44

P2.01-048 Early Changes in Body Composition in Metastatic Non-Small Cell Lung Cancer (NSCLC) Are Predictive for Poor Overall Survival Anne-Marie C. Dingemans, Maastricht University Medical Center, NL P2.01-049 Long Progression Free Survival and Overall Survival in Advanced NSCLC Patients with EGFR Mutation and Complete Response with TKI Treatment Omar Macedo-Pérez, Instituto Nacional de Cancerología, MX P2.01-050 Predicting Risk of Hospitalization in Patients with NSCLC Receiving Chemotherapy Using the LCSS 3-Item Global Index (3-IGI) Richard J Gralla, Albert Einstein College of Medicine, US P2.01-051 Randomized Study of Pemetrexed Versus Erlotinib as Maintenance Therapy in Metastatic /Locally Advanced EGFR Mutation Negative NSCLC Vikas Talreja, Tata Memorial Hospital, IN P2.01-052 Does Radiomics Improves the Survival Prediction in Non Small Cell Lung Cancer? Ravindra Patil, University of Maastricht, NL P2.01-053 Outcome of Clinical Management of Elderly and Younger Patients with NSCLC Inside a Private Institution (Oncosalud-AUNA) Jose Maria Gutierrez Castañeda, Oncosalud, PE P2.01-054 Inclusion of Central Nervous System Metastasis in Lung Cancer Early Phase Clinical Trials Narjust Duma, Mayo Clinic, US P2.01-055 Examining Metabolomics as a Prognostic Marker in Metastatic Non–Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy Desiree Hao, University of Calgary & Tom Baker Cancer Centre, CA P2.01-056 Use of Cell-Free Circulating RNA (cfRNA) Expression of PD-L1 and ERCC1 in Plasma to Monitor Response to Therapy in NSCLC Luis E Raez, Memorial Cancer Institute, US P2.01-057 Activity of Pemetrexed on Wild-Type and Unknown Status EGFR Genes with Brain Metastases from Non-Small Cell Lung Cancer Yun Fan, Zhejiang Cancer Hospital, CN P2.01-058 Pharmacokinetic Parameter Variability of Docetaxel between Individuals and Its Relationship with Hematological Toxicity Qisen Guo, Shandong Cancer Hospital, CN P2.01-058a Dose Serum Lactate Dehydrogenase Have a Significant Prognostic Value in Lung Cancer? Sharareh Seifi, National Institute of Tuberculosis and Lung Disease(NRITLD), IR

45

P2.01-059 – P2.01-075c MISCELLANEOUS P2.01-059 Breast Metastasis from Pulmonary Cancer: A Case Report. University Hospital "Shefqet Ndroqi" Tirana Albania 2008 Fadil Gradica, University Hospital Shefqet Ndroqi, AL P2.01-060 Outcomes Following Gamma Knife Radiosurgery in Patients with Non-Small Cell Lung Cancer with Brain Metastases Oliver Coen, Leeds Cancer Centre, GB P2.01-061 Mode of Lung and Airway Metastasis of NSCLC: Review of Chest CT Findings Mi Young Kim, Asan Medical Center, KR P2.01-062 Primary Lung Adenocarcinoma in the Young with Multiple Metastases: An Autopsy Report of 2 Cases Randell Santos Arias, Philippine Heart Center, PH P2.01-063 Outcomes of Patients with Oligometastatic Non-Small Cell Lung Cancer Who Were Treated with Radical Treatment Ahmet Bilici, Istanbul Medipol University, Medical Faculty, Department of Medical Oncology, TR P2.01-064 Co-Existing Mutations and Their Clinical Implications in Non-Small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01) Bo Mi Ku, Samsung Biomedical Research Institute, Samsung Medical Center, KR P2.01-065 Clinico-Radiological and Pathological Evaluation of Lung Adenocarcinoma with Infiltration on the Computed Tomography of the Chest Asuka Okada, Saiseikai Suita Hospital, JP P2.01-066 Targeted Therapy for Lung Cancer: Liquid Biopsy or Tumor Sampling? A Case-Control Study Zhen-Yu Ding, West China Hospital, Sichuan University, CN P2.01-067 Treatment of the Patients with Oncological Emergencies with Massive Pleural Effusion at the First Hospital Visit Kazuhiro Ito, Kyoto Yamashiro Medical Center, JP P2.01-068 Lobectomy Improve the Survival of Non-Small Cell Lung Cancer Patients with Occult Malignant Pleural Disease First Detected at Thoracotomy Shaolei Li, Peking University Cancer Hospital & Institute, CN P2.01-069 Radiologists' Considerations to Determine the Origin of Tumor on Chest CT: Lung vs Mediastinum Junghwa Choi, Uijeongbu St. Mary's Hospital, KR P2.01-070 FAACT- Anorexia Cachexia Scale: Cut-Off Value for the Anorexia Diagnosis in NSCLC Patients Jenny Turcott, Instituto Nacional de Cancerología, MX

46

P2.01-071 Efficacy of Thoracic Radiotherapy in Oligometastatic Non-Small-Cell Lung Cancer Harboring Wild-Type EGFR After First-Line Chemotherapy Congying Xie, the 1st Affiliated Hospital of Wenzhou Medical University, CN P2.01-072 Local Management of Oligometastasis in Non-Small Cell Lung Cancer (NSCLC) Margarita Majem Tarruella, Hospital de la Santa Creu i Sant Pau, ES P2.01-073 Prognostic Factors Analysis of Non-Small Cell Lung Cancer with Brain Metastases Jiancheng Li, Fujian Cancer Hospital, CN P2.01-074 Wait and See: A Favorable Alternative for R-M1a and S-M1a NSCLC Patients Ying Chen, Guangdong Lung Cancer Institute, CN P2.01-075 Genomic Changes and Clinical Characteristics Associated with Wood-Smoke Exposure in Patients with Non-Small Cell Lung Cancer Norma Yanet Hernandez-Pedro, Instituto Nacional de Cancerologia, MX P2.01-075a Incidence of Hippocampal Metastases in Non-Small Cell Lung Cancer Sophia Ly, Princess Alexandra Hospital, AU P2.01-075b Analysis of the Safety and Usefulness of Nab-Paclitaxel Therapy in Patients with NonSmall Cell Carcinoma Ikeya Eriko, Saiseikai Yokohamashi Tobu Hospital, JP P2.01-075c FGFR1 as an Intrinsic Resistance Mechanism in Erlotinib Treated EGFR Mutated NSCLC Kristine Raaby, Aarhus University Hospital, DK

P2.02 BIOLOGY/PATHOLOGY P2.02-001 – P2.02-024 GENOMICS P2.02-001 Detection of Gene Fusions in NSCLC Using NGS Fusion Assay Yoon-La Choi, Samsung Medical Center, Sungkyunkwan University School of Medicine, KR P2.02-002 Digital Multiplexed Detection of Single Nucleotide Variants (SNV) in Non-Small Cell Lung Cancer Using NanoString Technology Brielle Parris, University of Queensland Thoracic Research Centre, The Prince Charles Hospital, AU P2.02-003 A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma Xiaoshun Shi, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, CN P2.02-004 Gene Mutational Feature in Lung Enteric Adenocarcinoma by the Next Generation Sequencing Gang Chen, Fujian Provincial Cancer Hospital, CN P2.02-005 13 Cases of Molecular Features Analysis in Pulmonary Mucoepidermoid Carcinoma Gang Chen, Fujian Provincial Cancer Hospital, CN P2.02-006 NovoSV: Identify and Parse the Pattern of Chromosomal Structural Variation Gang Chen, Fujian Provincial Cancer Hospital, CN

47

P2.02-007 Molecular Spectrum of STK11 Gene Mutations in Patients with Non-Small-Cell Lung Cancer in Chinese Patients Gang Chen, Fujian Provincial Cancer Hospital, CN P2.02-008 Snai1-Expression Cancer-Associated Fibroblast Induce Epithelial-Mesenchymal Transition of Lungcancer Cells through miR-33b Min Li, Xiangya Hospital, The Central South University, CN P2.02-009 Metabolomic Analysis in Lung Cancer Naohiro Kajiwara, Tokyo Medical University, JP P2.02-010 Oncogenic Role of PKP1 in Non-Small-Cell Lung Cancer. Pedro P Medina, University of Granada, ES P2.02-011 Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number Terry L. Ng, University of Colorado Cancer Center, US P2.02-012 The Epigenetic Role of LSD1+8a in Small Cell Lung Cancer Aditya Wirawan, Juntendo University Graduate School of Medicine, JP P2.02-013 Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multiregion Exome and TCR Sequencing Jianjun Zhang, The University of Texas MD Anderson Cancer Center, US P2.02-014 Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D™ Technology Cristina Teixidó, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES P2.02-015 Mutation Patterns in a Swedish Non-Small Cell Lung Cancer Cohort Linnea La Fleur, Uppsala University, SE P2.02-016 Pulmonary Sarcomas: A Comprehensive Genomic Profiling Study Jeffrey S. Ross, Albany Medical College, US P2.02-017 Aberrant Expression of Long Non-Coding RNAs from Pseudogene Loci Highlights Alternative Mechanisms of Cancer Gene Regulation Greg L. Stewart, BC Cancer Research Centre, CA P2.02-018 Genomic Profiling of Driver Gene Mutations in 498 Chinese NSCLC Patients Minghui Wang, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, CN P2.02-019 Utility of Circulating Tumor DNA (CtDNA) in Prognostication of Lung Cancer vs. Other Cancer Types Francisco III Maramara Heralde, University of the Philippines - Manila, PH P2.02-020 Molecular Characteristics of Patients with PTEN Mutations in Chinese Non-Small Cell Lung Cancer Meiyu Fang, Zhejiang Cancer Hospital, CN

48

P2.02-021 Prevalence of PTPRD Gene Mutations in Chinese Non-Small Cell Lung Cancer Patients Meiyu Fang, Zhejiang Cancer Hospital, CN P2.02-022 Alternative Regulation of Cancer-Associated Genes through Modulation of Long NonCoding RNAs Adam P Sage, British Columbia Cancer Research Centre, CA P2.02-023 Targeted Gene Expression Profiling to Evaluate Minimal Diagnostic FFPE-Biopsies from NSCLC-Patients Johanna Sofia Margareta Mattsson, Uppsala University, SE P2.02-024 False Positivity Due to Polysomy in Fluorescence in Situ Hybridization Erik Thunnissen, VU University Medical Center, NL\ P2.02-025 – P2.02-049 IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY P2.02-025 Histological Difference of Tumor-Infiltrate Lymphocytes in Non-Small Cell Lung Cancer Naohiro Kobayashi, University of Tsukuba, JP P2.02-026 Impact of PD-L1 Expression on 18F-FDG-PET in Pulmonary Squamous Cell Carcinoma Norimitsu Kasahara, Gunma University Graduate School of Medicine, JP P2.02-027 Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)? José Miguel Sánchez-Torres, Hospital Universitario de La Princesa, ES P2.02-028 Prognostic Value of Cox-2 Expression Differs Depending on CD8+ T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma Katsuhiko Shimizu, Kawasaki Medical School, JP P2.02-029 Morphologic Features of Lung Adenocarcinoma Expressing PD-L1 Protein in Small Biopsy Specimens Eun Su Park, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, KR P2.02-030 Bavituximab in Combination With Nivolumab Enhances Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients Joseph Shan, Peregrine Pharmaceuticals, Inc, US P2.02-031 Relationship between PD-L1 Expression and EGFR/HER2 Signaling in Non-Small-Cell Lung Cancer Riki Okita, Kawasaki Medical School, JP P2.02-032 Interplaying between Gamma-H2AX and Autophagy in A549 Cells Treated with Cisplatin and Etoposide Jong Wook Shin, Chung-Ang University Hospital, KR P2.02-033 The Association of PD-L1 Expression with Clinical Characteristics and EGFR and ALK Status in Lung Adenocarcinoma Jinghui Wang, Beijing Chest Hospital, CN

49

P2.02-034 PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib Niki Karachaliou, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Sagrat Cor, ES P2.02-035 PD-L1 IHC Test on Cytological Cell Block Specimen; Potential Utility and Practical Issues Michiko Sugiyama, National Cancer Center Hospital, JP P2.02-036 The Expression Pattern of CD26/DPP4 in Human Lung Cancer Ignacio Gil-Bazo, Clinica Universidad de Navarra, ES P2.02-037 CD14+ Cell Tumor Microenvironment Infiltration Correlates with Poor Overall Survival in Patients with Early Stage Lung Cancer Erin Schenk, Mayo Clinic, US P2.02-038 Imaging Platform for the Quantification of Cell-Cell Spatial Organization within the Tumour-Immune Microenvironment Katey S.S. Enfield, British Columbia Cancer Research Centre, CA P2.02-039 Spatial Heterogeneity of Immunological Markers Between Cores and Complete NSCLC Sections Using Multispectral Fluorescent IHC Geoffrey Peters, Olivia Newton-John Cancer Research Institute, AU P2.02-040 Cytology Cell Block Is Suitable for Immunohistochemical Testing for PD-L1 in Lung Cancer Hangjun Wang, McGill University Health Center & McGill University, CA P2.02-041 Update on Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer (ICON Project) Jianjun Zhang, MD Anderson, US P2.02-042 Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study Cristian Ortiz -Villalón, Karolinska University Hospital, SE P2.02-043 Multicentre Assessment of PD-L1 Immunohistochemistry: Challenges for Establishing the Concordance Between Four Different Antibodies Cristian Ortiz -Villalón, Karolinska University Hospital, SE P2.02-044 Pulmonary Findings in 7 Autopsy Cases of Patients Treated with Immune Checkpoint Inhibitors Peter B Illei, Johns Hopkins University School of Medicine, US P2.02-045 PD-L1 Assessment in Cytology Samples Peter B Illei, Johns Hopkins University School of Medicine, US P2.02-046 Assessment of PDL1 and Immunoprofiling Using Multiplex Quantitative Immunofluorescence in Lung Cancer: Clinical Implications Vera Luiza Capelozzi, Faculdade de Medicina da USP, BR P2.02-047 Comparison of PD-L1 Immunohistochemistry Assays and Response to PD-L1 Inhibitors Sanja Dacic, University of Pittsburgh Medical Center, US

50

P2.02-048 Survival Correlation Between TP53 Gene and PD-L1 Tumour Expression in Resected NonSmall Cell Lung Carcinoma Jane Sze Yin Sui, St. James's Hospital, IE P2.02-049 Immunohistochemical Approach in Predicting Primary Lung Cancer Outcome: A Single Center Study Gulrukh Komiljonovna Botiralieva, National Cancer Research Center, UZ P2.02-050 – P2.02-073 MARKER FOR PROGNOSIS, PREDICTION P2.02-050 Weighted Genes Co-expression Network Analysis of Lung Cancers Concerning Patients Overall Survival and Cancer Stage Haolong Qi, Chinese University of Hong Kong, HK P2.02-051 Bevacizumab Prevents Growth of Established Non-Small Cell Lung Cancer Brain Metastases in Hematogenous Brain Metastasis Model Chinami Masuda, Chugai Pharmaceutical Co., Ltd., JP P2.02-052 A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care James Sun, Foundation Medicine, US P2.02-053 The Prognostic Value of 18 Circulating Markers of Inflammation, Endothelial Activation and Extracellular Matrix Remodelling in Non-small Cell Lung Cancer Patients Janna Berg, Vestfold Hospital Trust, NO P2.02-054 Thymidylate Synthase Promotes Epithelial-To-Mesenchymal Transition and Aggressiveness in NSCLC Paolo Ceppi, IZKF Erlangen, DE P2.02-055 Stratifin Regulates Stabilization of Receptor Tyrosine Kinases via Activation of UbiquitinSpecific Protease 8 in Lung Adenocarcinoma Aya Shiba, Univerysity of Tsukuba, JP P2.02-056 Regulatory Variants in Cancer-Related Pathway Genes Predict Survival of Patients with Surgically Resected Non-Small Cell Lung Cancer Eungbae Lee, Kyungpook National University Medical Center, KR P2.02-057 Expression of MGAT4a and MGAT5 Are Correlated with Poorer Outcome in Advanced Lung Adenocarcinoma Yoko Nakanishi, Nihon University School of Medicine, JP P2.02-058 Endogenous Arginase 2 as a Biomarker for PEGylated Arginase 1 Treatment in Squamous Cell Lung Carcinoma Xenograft Models Sze Kwan Lam, The University of Hong Kong, HK P2.02-059 Genomic Mutation Patterns Detected with Cancer Panel Can Predict Postoperative Prognosis in Clinical Stage I Adenocarcinoma Kwanyong Hyun, Seoul National University Hospital, KR

51

P2.02-060 Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma Young Wha Koh, Ajou University School of Medicine, KR P2.02-061 Two Novel Protein-Based Prognostic Signatures Improve Risk Stratification of Early Lung ADC and SCC Patients Luis M Montuenga, CIMA-University of Navarra, IDISNA, CIBERONC, ES P2.02-062 The MicroRNAs Associated with Recurrence and Metastasis of Stage I Lung Adenocarcinoma Yanning Gao, Cancer Hospital, Peking Union Medical College, CN P2.02-063 Oncogenic microRNAs Associated with Poor Prognosis Are Up-Regulated on the Amplicon in Squamous Cell Lung Carcinoma Sana Yokoi, Chiba Cancer Center Research Institute, JP P2.02-064 A Novel 5-miR Signature Shows Potential as a Diagnostic Tool and as a Predictive Biomarker of Cisplatin Response in NSCLC Martin P Barr, St. James's Hospital & Trinity College Dublin, IE P2.02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors Anna Tessari, The Ohio State University, US P2.02-066 Identification of Crucial Gene Targets in the in Situ Environment of Cancer by Google Network Ranking Victor Pontén, Uppsala University, SE P2.02-067 LKB1 Loss Is Associated with DNA Hypomethylation in Human Lung Adenocarcinoma Michael John Koenig, The Ohio State University, US P2.02-068 BRG1 and p53 Expression in Resected Stage I – III Non-Small Cell Lung Cancer Gwyn Bebb, University of Calgary and Alberta Health Services, CA P2.02-069 Targeting Neuropilin-1 in NSCLC Martin P Barr, St James's Hospital & Trinity College Dublin, IE P2.02-070 C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer Georgios Tsakonas, Karolinska Institutet, SE P2.02-071 Prospective Molecular Study of 22 Genes by NGS in Patients with Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Single Institution Experience Valeria Cecilia Denninghoff, Centro de Educación Médica e Investigaciones Clínicas (CEMIC-CONICET), AR P2.02-072 Reliability of Small Biopsy Samples for Tumor PD-L1 Expression in Non-Small-Cell Lung Cancer Akihito Tsunoda, St. Marianna University School Of Medicine, Department Of Internal Medicine, Division Of Respiratory Diseases, JP

52

P2.02-073 Cytoplasmic Mislocalization of ECT2 Protein Is Associated with Poor Prognosis in Lung Adenocarcinoma Zeinab Kosibaty, Graduate School of Comprehensive Human Sciences, University of Tsukuba, JP

P2.03 CHEMOTHERAPY/TARGETED THERAPY P2.03-001 – P2.03-058a EGFR P2.03-001 Survivors and Adverse Events After First-Line Target Therapy for Advanced Non-Small Cell Lung Cancer Patients in Taiwan Lin Zhi Xuan, Chi Mei Medical Center, Liouying, TW P2.03-002 Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations Satoshi Igawa, Kitasato University School of Medicine, JP P2.03-003 Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor Chun-Ru Chien, China Medical University Hospital, TW P2.03-004 Recurrent Response to Advanced NSCLC with Erlotinib Developing Central Nervous System Failure during Gefitinib or Icotinib Treatment Di Ma, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, CN P2.03-005 Overall Survival Results from a Prospective, Multicenter Phase II Trial of Low-Dose Erlotinib as Maintenance in NSCLC Harboring EGFR Mutation Satoshi Hirano, Funabashi Municipal Medical Center, JP P2.03-006 How Many Years of Life Have We Lost in Brazil Due to the Lack of Access to Anti-EGFR TKIs in the National Public Health System? Pedro Aguiar Jr, Faculdade de Medicina do ABC, BR P2.03-007 Loxoprofen Prevents EGFR-TKI-Related Skin Rash in Non-Small Cell Lung Cancer Patients: A Single-Center Retrospective Study Yohei Iimura, Chemotherapy Research Institute, Kaken Hospital, JP P2.03-008 Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L Tatsuo Kimura, Osaka City University, JP P2.03-009 Clarification of Mechanisms of Acquired Resistance for Afatinib Using Plasma Samples Tomomi Nakamura, Saga University, JP P2.03-010 Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC Tatsuro Fukuhara, Miyagi Cancer Center, JP P2.03-011 Correlation and Problems of Re-Biopsy and Liquid Biopsy for Detecting T790M Mutation Kazutoshi Komiya, Saga University, JP

53

P2.03-012 Characterization of the Efficacies of Osimertinib and Nazartinib against Cells Expressing Epidermal Growth Factor Receptor Mutations Keita Masuzawa, Keio University, JP P2.03-013 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients Yun Fan, Zhejiang Cancer Hospital, CN P2.03-014 A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced NSCLC Harboring EGFR Mutations Hisashi Tanaka, Hirosaki University, JP P2.03-015 Efficacy of EGFR-TKIs for EGFR Mutatnt NSCLC Patients with Central Nervous System Metastases: A Retrospective Analysis Kenichi Koyama, Niigata Cancer Center Hospital, JP P2.03-016 Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited Tomohiro Sakamoto, Tottori University Hospital, JP P2.03-017 Clinical Features and Treatment with Afatinib in Patients with Squamous Cell Lung Cancer with Sensitive EGFR Mutations Yuri Taniguchi, NTT Medical Center Tokyo, JP P2.03-018 Diagnostic Yield of Fine-Needle Aspiration and Core-Needle Biopsy in Assessment of EGFR and ALK Mutation Status in Non–Small Cell Lung Cancer Junghoon Kim, Seoul National University Bundang Hospital, KR P2.03-019 Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer Eiji Nakajima, Tokyo Medical University Ibaraki Medical Center, JP P2.03-020 Pemetrexed Continuation Maintenance versus Conventional Platinum-based Doublet Chemotherapy in EGFR-negative Lung Adenocarcinoma: Retrospective Analysis Seung Hyeun Lee, Kyung Hee University Medical Center, KR P2.03-021 A Phase I Study Evaluating the Combination of Afatinib, Carboplatin and Pemetrexed after Failure of 1St Generation EGFR-TKIs Ou Yamaguchi, Saitama Medical University International Medical Center, JP P2.03-022 Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC) Jin-Hyoung Kang, Seoul St. Mary's hospital, KR P2.03-023 Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic Jana Skrickova, University Hospital Brno and Faculty of Medicine, Masaryk University, CZ P2.03-024 Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA Young-Chul Kim, Chonnam National University Hwasun Hospital, KR

54

P2.03-025 Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib Maximilian Johannes Hochmair, Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, AT P2.03-026 Managing EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancers in THAILAND Thongbliew - Prempree, Chularat3 Hospital, TH P2.03-027 Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib Mansi Sharma, Tata Memorial Hospital, IN P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial Yuankai Shi, National cancer center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, CN P2.03-029 A Case of a Patient Harboring an EGFR Insertion of Exon 20 and Long Lasting Clinical Response to Afatinib Ana Caroline Zimmer Gelatti, Hospital do Câncer Mãe de Deus, BR P2.03-030 Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs In Ae Kim, Konkuk University medical center, KR P2.03-031 Efficacy of Gefitinib and Radiotherapy Combination in Lung Adenocarcinoma Elisna Syahruddin, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Refferal Hospital, ID P2.03-032 Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer Hiroyuki Shimada, Hiratsuka Kyosai Hospital, JP P2.03-033 Propensity Score-Adjusted Survival Analysis of Non-Small Cell Lung Cancer Patients with Acquired Resistance to EGFR-TKI Sho Watanabe, National Center for Global Health and Medicine, JP P2.03-034 EGFR Exon 19 Deletion Is Associated with Favorable Overall Survival After First-Line Icotinib Therapy in Advanced NSCLC Patients Xiaochun Zhang, The Affiliated Hospital of Qingdao University, CN P2.03-035 Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study Inger Johanne Zwicky Eide, Oslo University Hospital, NO P2.03-036 Comparing the Efficacy/Toxicity of Osimertinib and First Line EGFR-TKI by Individual Patient Analysis Shoko Narita, National Cancer Center Hospital, JP

55

P2.03-037 Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study Inger Johanne Zwicky Eide, Oslo University Hospital, NO P2.03-038 Early Serum Tumor Markers After 14 Days of Tyrosine Kinase Inhibitor Target Therapy Predicts Outcomes in Patients with Lung Adenocarcinoma Kuo-Yang Huang, Yuanlin Christian Hospital, TW P2.03-039 Compassionate Use of Osimertinib: Argentine Experience Jose Nicolas Minatta, Hospital Italiano, AR P2.03-040 EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients Chenguang Li, Tianjin Medical University Cancer Institute and Hospital, CN P2.03-041 The Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients with T790M Mutation Hanping Wang, Peking Union Medical College Hospital, CN P2.03-042 EGFR Mutation and Erlotinib Efficacy in Turkish Oncoregistry Mahmut Gumus, Istanbul Medeniyet University, TR P2.03-043 A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Sukhmani Kaur Padda, Stanford Cancer Institute/Stanford University School of Medicine, US P2.03-044 OSCILLATE - Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFRT790M Mutation Positive Advanced NSCLC Ben J Solomon, Peter MacCallum Cancer Centre, AU P2.03-045 Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 8114LTR) Hidetoshi Hayashi, Kindai University Faculty of Medicine, JP P2.03-046 Lymhocyte-To-Monocyte Ratio and Mean Platelet Volume as Prognostic Factor in EGFR Mutant NSCLC Treated with EGFR TKI Kousuke Watanabe, University of Tokyo Hospital, JP P2.03-047 The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFRMutation Positive Lung Cancer Songtao Xu, Zhongshan Hospital Fudan University, CN P2.03-048 Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib Yuki Shinno, National Cancer Center Hospital, JP P2.03-049 Pulmonary Adenoid Cystic Carcinoma with EGFR Activating Mutation and Responds Well with Tyrosine Kinase Inhibitor Jamal Zaini, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia – Persahabatan National Respiratory Referral Hospital, ID

56

P2.03-050 The Efficacy of EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Harboring G719X Mutation Hanping Wang, Peking Union Medical College Hospital, CN P2.03-051 The Impact of EGFR Mutations. Treatment with ITKs in Non Small Cell Lung Cancer Patients Teresa García Manrique, Hospital Virgen Macarena, ES P2.03-052 Local Ablative Therapy for Oligoprogressive, EGFR-Mutant, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib Udayan Guha, Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, US P2.03-053 A Five-Year Audit of EGFR and ALK Testing at a Tertiary Care Centre in North India: More Sensitive Methods Do Make a Difference! Valliappan Muthu, Postgraduate Institute of Medical Education and Research (PGIMER), IN P2.03-054 EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities Shan Su, Guangdong Lung Cancer Institute,Guangdong General Hospital & Guangdong Academy of Medical Sciences, CN P2.03-055 Comparison of Afatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI Yuichi Sakamori, Graduate School of Medicine, Kyoto University, JP P2.03-056 Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 in Slovakiab NSCLC Patients - Updated Survival Data Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, SK P2.03-057 Effectiveness of Icotinib on Uncommon EGFR Exon 20 Insert Mutations: A763_Y 764insFQEA in Non-Small-Cell Lung Cancer Meiyu Fang, Zhejiang Cancer Hospital, CN P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC) James Chih-Hsin Yang, National Taiwan University Hospital, TW P2.03-058a T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive NSCLC Takeshi Yoshida, Kindai University Faculty of Medicine, JP

P2.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS P2.04-001 BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC Ihor Vynnychenko, Sumy State University, UA P2.04-002 CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC Luis Paz-Ares, Hospital Universitario 12 de Octubre, ES

57

P2.04-003 Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib Li Zhang, Sun Yat-sen University Cancer Center, CN P2.04-004 IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC Enriqueta Felip, Vall d’Hebron University Hospital, ES P2.04-005 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC Jürgen Wolf, University of Cologne, DE P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Roy S. Herbst, Yale Cancer Center, US P2.04-007 KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC Charles M Rudin, Memorial Sloan Kettering Cancer Center, US P2.04-008 ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy Jose Antonio Lopez-Vilariño, PharmaMar, ES P2.04-009 Randomized, Single-Blind Phase 1 Study of Pharmacokinetic Equivalence of ABP 215 Relative to Bevacizumab in Japanese Subjects Valdimir Hanes, Amgen, Inc., US P2.04-010 Afatinib in Combination with Pembrolizumab in Patients with Stage IIIB/IV Squamous Cell Carcinoma (SCC) of the Lung Jonathan W Riess, University of California Davis Comprehensive Cancer Center, US P2.04-011 The Using of LungCare Electromagnetic Navigated Bronchoscopy System in Lung Lesions, a New Project in China Baohui Han, Shanghai Chest Hospital, CN P2.04-012 First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, CN P2.04-013 ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PDL1 Unselected, Metastatic NSCLC Patients Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, ES P2.04-014 Computing the Impact of Immunotherapy on NSCLC Landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR) George R. Simon, The University of Texas MD Anderson Cancer Center, US

P2.05 EARLY STAGE NSCLC P2.05-001 – P2.05-009 SBRT

58

P2.05-001 Does CGA Impact QoL and Overall Survival in NSCLC Patients Treated with SBRT - Results of a Randomized Pilot Study Stefan Starup Jeppesen, Odense University Hospital, DK P2.05-002 A Pilot Study on the Safety and the Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumor Takamasa Mitsuyoshi, Kyoto University Graduate School of Medicine, JP P2.05-003 Stage by Stage Comparison of Radiotherapy versus Surgery in NSCLC: The Influence of Prognostic Factors on Survival Outcome Sara Moore, British Columbia Cancer Agency, CA P2.05-004 Radiotherapy Patterns of Care for Stage I and II Non-small-cell Lung Cancer in Sydney, Australia Andrew Duy Duc Nguyen, University of NSW, AU P2.05-005 Proton Beam Therapy for Early Stage Lung Cancer: A Multi-Institutional Retrospective Study in Japan Kayoko Ohnishi, University of Tsukuba Hospital, JP P2.05-006 Credentialing of Radiotherapy Centres in Australasia for a Phase III Clinical Trial on SABR (TROG 09.02 CHISEL) Nicholas Hardcastle, Peter MacCallum Cancer Centre, AU P2.05-007 Sterotactic-Body-Radiotherapy for Early-Lung Cancer: Is FDG-PET/TC a Predictor of Outcome? Margarita Majem, Hospital de la Santa Creu i Sant Pau, ES P2.05-008 Stereotactic Body Radiotherapy (SBRT) for Early Stage I Lung Cancer: A Review from an Oncology Center in Hong Kong Lim Mei Ying, Princess Margaret Hospital, HK P2.05-009 Outcome of Stereotactic Body Radiotherapy for Clinical Stage I Non Small Cell Lung Cancer and CT Findings: Comparison with Surgical Resection Yuho Maki, Shikoku Cancer Center, JP P2.05-010 – P2.05-021 SURGERY P2.05-010 Changes between Pre- and Post-Operative AICS (Lung) in NSCLC Patients: Predictability of High-Risk Cases with Recurrence Masahiko Higashiyama, Osaka International Cancer Institute, JP P2.05-011 Segmentectomy versus Wedge Resection in Patients with Clinical Stage I Non-Small Cell Lung Cancer Who Were Unfit for Lobectomy Yasuhiro Tsutani, Hiroshima University, JP P2.05-012 Prognostic Factors for Surgically Resected Non-Small Cell Lung Cancer with Cavity Formation Shunsuke Shigefuku, Tokyo Medical University, JP

59

P2.05-013 The Result of Preoperative Lipiodol Markings for 121 Small Pulmonary Nodules in 115 Patients Hirofumi Suzuki, Saiseikai Suita Hospital, JP P2.05-014 Factors Associated with Recovery Time to Predicted FEV1 in Non-Small-Cell Lung Cancer Patients after Lobectomy Shin Ah Young, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, KR P2.05-015 Wedge Resection Is Enough for Curing GGO Patients with Minimally Invasive Adenocarcinoma (MIA) of the Lung? Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, CN P2.05-016 Clinical Importance and Application of New T Descriptors in the 8th TNM Classification for Pathological T0-1 Lung Adenocarcinoma Masayuki Nakao, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, JP P2.05-017 Prognostic Impact of the Clinical T Descriptor in the Eighth Edition of the TNM Staging System of Non-Small Cell Lung Cancer Tatsuro Okamoto, Oita University Faculty of Medicine, JP P2.05-018 Video-Assisted Thoracoscopic Surgery vs Thoracotomy for Early-Stage Non-Small Cell Lung Cancer: Short-Term Outcomes of a Randomized Trial Dongrong Situ, Lung Cancer Research Institute, Sun Yat-sen University, CN P2.05-019 Overall Survival (OS) of Pathological T1N0 Non-Small Cell Lung Cancer (NSCLC) After Resection. Etienne Bourdages-Pageau, Laval University, CA P2.05-020 Prognostic Factors in Patients with Completely Resected Subsolid Node-Negative Lung Adenocarcinoma of 3cm or Smaller Jung-Jyh Hung, Taipei Veterans General Hospital and National Yang-Ming University, TW P2.05-021 Occult Nodal Metastasis Following Lobectomy for Clinical Stage I Lung Adenocarcinoma: Implications for Sublobar Resection Yusuke Takahashi, Memorial Sloan Kettering Cancer Center, US

P2.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION P2.06-001 – P2.06-011 PREVENTION P2.06-001 Circulating Cotinine Concentrations, Self-Reported Smoking, and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3) Tricia L. Larose, Norwegian University of Science and Technology, NO P2.06-002 Tobacco Use and Prevalence of Head and Neck Cancers among Malayali Tribes, Yelagiri Hills, Tamil Nadu, India Delfin Lovelina Francis, Tagore Dental College and Hospital, IN

60

P2.06-003 Retrospective Study of Cerebral Thromboembolism Occurring before and after Detection of Lung Cancer (Trousseau Syndrome) Kinnosuke Matsumoto, Osaka General Medical Center, JP P2.06-004 Role of Polymorphic Variants of BER and DSBR Pathway Genes in Modulating Lung Cancer Susceptibility and Prognosis of North Indian Population Amrita Singh, Thapar University, IN P2.06-005 An Exploration of Attitudes and Barriers to Uptake of Lung Cancer Screening in at Risk Adults in the United Kingdom David Raymond Baldwin, Nottingham University Hospitals, GB P2.06-006 Screening Values of CEA and Cyfra 21-1 for Lung Cancer in Combination with Low Dose CT (LDCT) in High-Risk Populations Natthaya Triphuridet, Chulabhorn Hospital, TH P2.06-007 Demographic Characteristics of Lung Cancer and Association with Wood Smoke in Mexican Population Jeronimo Rafael Rodriguez-Cid, Instituto Nacional de Enfermedades Respiratorias, MX P2.06-008 Diagnosis of Incidental Disease in Medicaid Recipients During Lung Cancer Screening Marisa Bittoni, The Ohio State University Wexner Medical Center, US P2.06-009 Trace Elements Affect Lung Cancer Subtypes Ryosuke Chiba, Iwate Medical University, JP P2.06-010 Association of Vitamin D Receptor BsmI Polymorphism with Lung Cancer Risk: Evidence from a Meta-Analysis Minhua Shi, the Second Affiliated Hospital of Soochow University, CN P2.06-011 Assessing and Addressing Knowledge Gaps to Improve Lung Cancer Screening Rates Lawrence Eric Feldman, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, US

P2.07 IMMUNOLOGY AND IMMUNOTHERAPY P2.07-001 – P2.07-062c IMMUNOTHERAPY (CLINICAL) P2.07-001 Clinicopathological Characteristics of NSCLC Patients with Nivolumab-Induced Pneumonitis Nobuyuki Koyama, Tokyo Medical University Hachioji Medical Center, JP P2.07-002 Drug-Related Pneumonitis in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Commercial PD-1 Inhibitors Mizuki Nishino, Dana-Farber Cancer Institute, US P2.07-003 Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer Hironori Yoshida, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, JP

61

P2.07-004 Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients Yukihiro Toi, Sendai kousei Hospital, JP P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Laura Mezquita, Gustave Roussy, FR P2.07-006 Irinotecan Augmented Anti-Tumor Activity of Anti-PD-L1 through Enhancing CD8 Proliferation Regardless of Its Hematotoxicity Toshiki Iwai, Chugai Pharmaceutical Co., Ltd., JP P2.07-007 Retrospective Analysis of Antitumor Effects and Biomarkers of Nivolumab in NSCLC Patients with EGFR Mutations Satoshi Watanabe, Niigata University Graduate School of Medical and Dental Sciences, JP P2.07-008 Does PD-L1 Expression of the Archive Surgical Specimen of Primary Tumor Predict the Sensitivity of Recurrence to Nivolumab in Patients with NSCLC? Yuki Shiina, Chiba University Graduate School of Medicine, JP P2.07-009 Monitoring Nivolumab Binding as a Method to Clarify the Residual Therapeutic Effects in Previously Treated Lung Cancer Patients Akio Osa, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, JP P2.07-010 Impact of Clinicopathological Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients with Previously Treated Non-Small Cell Lung Cancer Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, CN P2.07-011 Long Follow up from Phase I Study of Nivolumab and Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Shintaro Kanda, National Cancer Center Hospital, JP P2.07-012 Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC) Martin Früh, Cantonal Hospital St. Gallen, CH P2.07-013 Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer with Preexisting Interstitial Lung Disease Osamu Kanai, National Hospital Organization Kyoto Medical Center, JP P2.07-014 Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer Hironori Ashinuma, Chiba Cancer Center, JP P2.07-015 Reviving Chemotherapy Sensitivity after Anti-CCR4 mAb (Mogamulizumab) Treatment in Lung Cancer Patients Koji Kurose, Kawasaki Medical School, JP P2.07-016 Inmunotherapy: Which Is More Important, Choosing Patients Who Will Respond or Identifying Those Who Will Die Early? Inmaculada Ramos García, Hospital Universitario VIrgen de la Victoria, ES

62

P2.07-017 Association between Thyroid Dysfunction and Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Received Nivolumab Tomoko Funazo, Kyoto University, JP P2.07-018 Correlation of Clinical Response and XAGE1 Immunity in Lung Adenocarcinoma Yoshihiro Ohue, Kawasaki Medical School, JP P2.07-019 Role of Anti-Angiogenesis on the Prognosis in Advanced Non-Small Cell Lung Cancer Who Are Treated with Immunotherapy Takefumi Komiya, Tulane University School of Medicine, US P2.07-020 Distinct Immune Status in Patients with Adenocarcinoma and Squamous Cell Carcinoma: Implication for Immunotherapy of NSCLC Nada Hradilova, Sotio a.s., CZ P2.07-021 A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC) Kimio Yonesaka, Kindai University Faculty of Medicine, JP P2.07-022 Inflammatory Cytokine Induction after Anti-PD-1 Ab Administration Relates to the Efficacy and Safety in Patients with Non-Small Cell Lung Cancer Yuichi Ozawa, Seirei Mikatahara General Hospital, JP P2.07-023 Safety of Immune Checkpoint Inhibitors in Patients with Preexisting Autoimmune Disease Margaux Geier, CHU Brest, FR P2.07-024 Real-World Data of Nivolumab for Previously Treated Non-Small Cell Lung Cancer Patients in Japan: A Multicenter Retrospective Cohort Study Daichi Fujimoto, Kobe City Medical Center General Hospital, JP P2.07-025 Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer Song Ee Park, Samsung Medical Center, KR P2.07-026 Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality Sivan Shamai, Tel Aviv Medical Center, IL P2.07-027 Efficacy and Safety of Nivolumab Therapy for Advanced NSCLC in the Expanded Access Named Patient Program in Taiwan Bin-Chi Liao, National Taiwan University Hospital, TW P2.07-028 Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer Patients Who Relapse after Thoracic Radiotherapy Teppei Yamaguchi, Aichi Cancer Center Hospital, JP P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients Rosalyn J. Juergens, Juravinski Cancer Centre, CA

63

P2.07-030 Real Life Second-Line Nivolumab in Advanced Non-Small-Cell-Lung Cancer: A French Observational Multicenter Study of 259 Patients Margaux Geier, CHRU Morvan, FR P2.07-031 Relationship between Clinical Factors and the Expression of Programmed Death Ligand 1 in Lung Cancer Yasuhiro Kato, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, JP P2.07-032 Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centres. Kenneth O’byrne, Princess Alexandra Hospital and Queensland University of Technology, AU P2.07-033 Anti-PD1-Induced Rotator Cuff Injury: A Case Series Kenneth O’byrne, Princess Alexandra Hospital and Queensland University of Technology, AU P2.07-034 Health Status in Patients with Small-Cell Lung Cancer Treated with Nivolumab Alone or Combined with Ipilimumab: CheckMate 032 D. Ross Camidge, University of Colorado, US P2.07-035 Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab Koichi Sato, Third Department of Internal Medicine, Wakayama Medical University, JP P2.07-036 Appropriate Use of Immune Checkpoint Inhibitors in Advanced NSCLC: Effectiveness of Unique Case-Based Education on Clinical Decision-Making Tara Herrmann, Medscape Education, US P2.07-037 Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab Wungki Park, University of Miami, Sylvester Comprehensive Cancer Center, US P2.07-038 Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA Aaron Lisberg, University of California, Los Angeles, US P2.07-039 Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain Antonio Irigoyen Medina, HOSPITAL TOLEDO, ES P2.07-040 Pre-Treatment Tumor Volume in Non-Small Cell Lung Cancer (NSCLC) as a Predictor of Response to PD-1 Inhibitors Misako Nagasaka, Karmanos Cancer Institute/ Wayne State University, US P2.07-041 Immuno-Related Cutaneous Adverse Events (IRcutAEs) in Patients (P) with Advanced NSCLC: A Single-Institution Prospective Study Enric Carcereny, Catalan Institute of Oncology-Hospital Germans Trias i Pujol, ES P2.07-042 Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer Tsuneo Shimokawa, Yokohama Municipal Citizen's Hospital, JP

64

P2.07-043 Efficacy and Safety of Anti-PD-1 Antibody as the First Line Treatment in Elderly Patient with Advanced Lung Squamous Cell Carcinoma: A Case Report Hua min Shi, The Second Affiliated Hospital of Soochow University, CN P2.07-044 Thyroid Disfunction in Advanced NSCLC Patients Treated with Nivolumab out of Clinical Trial: A Real-World Data Analysis Ramon Palmero, Catalan Institute of Oncology, ES P2.07-045 A Retrospective Analysis of Nivolumab-Related Pneumonitis in Non-Small Cell Lung Cancer Patients Shuhei Tsujino, Nagasaki University Hospital, JP P2.07-046 Nivolumab Exerts Remarkable Antitumor Activity in NSCLC After an Immune-Modulating Biochemotherapy Regimen Pierpaolo Correale, Unit of Medical Oncology, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, Reggio Calabria;, IT P2.07-047 Poor Performance Status and BRAF Mutation Predict Grade 3-5 Immune-Related Adverse Events in Pts with Advanced NSCLC Yan Wang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, CN P2.07-048 Immunotherapy vs. Targeted Therapy - Who Wins? A Case Series Inbar Finkel, Beilinson Medical Center, IL P2.07-049 Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer David P Walder, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, GB P2.07-050 Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors Neil J Shah, Medstar Georgetown University Hospital, US P2.07-051 Immune Checkpoint Associated Cardiotoxicity: An Update Zin War Mynt, Division of Hematology and Oncology, University of Kentucky, US P2.07-052 Detection of KRAS Mutation in Blood Predicts Favorable Response to Immunotherapy in NSCLC Martin Frederik Dietrich, Memorial Cancer Institute, US P2.07-053 A Case of Small Cell Lung Cancer Complicated During Nivolumab Administration as Second Line Treatment for Squamous Cell Lung Cancer Tomoki Kimura, Tosei General Hospital, JP P2.07-054 Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer Pedro Aguiar Jr, Faculdade de Medicina do ABC, BR P2.07-055 Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer – a Network Meta-Analysis Pedro Aguiar Jr, Faculdade de Medicina do ABC, BR

65

P2.07-056 SAKK 16/14 – Perioperative Anti-PD-L1 Antibody Durvalumab in Patients with Stage IIIA(N2) Non-Small Cell Lung Cancer (NSCLC) Sacha I Rothschild, University Hospital Basel, CH P2.07-057 Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for FirstLine Treatment of Advanced Lung Cancer Yun Fan, Zhejiang Cancer Hospital, CN P2.07-058 First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Cancer Julie R Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, US P2.07-059 Phase I Trial of Gene Mediated Cytotoxic Immunotherapy (GMCI) for Malignant Pleural Effusion (MPE) and Malignant Pleural Mesothelioma (MPM) Daniel H. Sterman, NYU Langone Medical Center, US P2.07-060 Response Assessment and Subgroups Analysis According to the Lung Immune Prognostic Index (LIPI) for Immunotherapy in Advanced NSCLC Patients Laura Mezquita, Gustave Roussy, FR P2.07-061 Nivolumab for Patients with Non-Small Cell Lung Carcinoma in Patients with Progression to One or More Lines of Chemotherapy in Mexican Population Jeronimo Rafael Rodriguez-Cid, Instituto Nacional de Enfermedades Respiratorias, MX P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR‐214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies Vassiliki A Papadimitrakopoulou, The University of Texas MD Anderson Cancer Center, US P2.07-062a Single Institutional Experience of the Use of PD-1 Inhibitors to Non-Small Cell Lung Cancer Patients with Preexisting Autoimmune Diseases Mehmet Altan, MD Anderson Cancer Center, US P2.07-062b DNA Damage Repair Targeting Upregulates PD-L1 Level and Potentiates the Effect of PDL1 Blockade in Small Cell Lung Cancer Triparna Sen, University of Texas MD Anderson Cancer Center, US P2.07-062c A Phase II Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Lung Adenocarcinoma Murray Yule, BerGenBio ASA, NO

P2.08 LOCALLY ADVANCED NSCLC P2.08-001 Hand Grip Strength Is an Independent Prognostic Factor for Mortality in Patients with NSCLC Undergoing Radiotherapy Dirk K De Ruysscher, Maastricht University Medical Center, NL P2.08-002 A Nomogram for Predicting Underlying Beneficiaries for Resectable IIIA/N2 NSCLC Patients Chao Zhang, Guangdong Lung Cancer Institute, CN

66

P2.08-003 An Audit of Concurrent Chemoradiotherapy for Non-Small Cell Lung Cancer at the Leeds Cancer Centre (LCC) Katy Louise Clarke, Leeds Cancer Centre, GB P2.08-004 Pathologic Complete Response as an Independed Prognostic Factor in Patients with Locally Advanced Non-Small Cell Lung Cancer Waldemar Schreiner, Friedrich-Alexander-University, DE P2.08-005 Salvage Lung Surgery Following Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer Waldemar Schreiner, Friedrich-Alexander-University, DE P2.08-006 Immunological Biomarkers Characterization in Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemo-Radiotherapy Ernest Nadal, Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet, ES P2.08-007 Five-Year Results of Concurrent Chemotherapy and Isotoxic Radiotherapy Dose-Escalation with IMRT in Stage III NSCLC (NCT01166204) Dirk K De Ruysscher, Maastricht University Medical Center, NL

P2.09 MESOTHELIOMA P2.09-001 Effects of Tumor Burden Reduction on Survival in Epithelioid Pleural Mesothelioma Aaron S. Mansfield, Mayo Clinic, US P2.09-001a TNM or Tumor Volume for Predicting Prognosis in Malignant Pleural Mesothelioma: Still an Open Debate Marina Chiara Garassino, IRCCS Istituto Nazionale dei Tumori, IT P2.09-002 Prevalence and Survival of Malignant Pleural Mesothelioma Patients Treated in a Single Brazilian Cancer Center João Navarro Reolon, A.C. Camargo Cancer Center, BR P2.09-003 Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment Silvia Novello, University of Torino, IT P2.09-004 PD-L1 Protein Expression Is Negative Prognostic Factor in Malignant Pleural Mesothelioma in Central Europe Luka Brcic, Medical University of Graz, AT P2.09-005 The C-reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma Shinkichi Takamori, Graduate School of Medical Sciences, Kyushu University, JP P2.09-005a Clinical Characteristics of Early Stage, Malignant Pleural Mesothelioma Kozo Kuribayashi, Hyogo College of Medicine, JP P2.09-006 FISH Analysis of p16 and BAP1 Immunohistochemistry for the Diagnosis of Mesothelioma Kenzo Hiroshima, Tokyo Women's Medical University, JP

67

P2.09-007 Pleural Biopsy in Patients Suspected of Malignant Pleural Mesothelioma Consecutive 377 Cases Masaki Hashimoto, Hyogo College of Medicine, JP P2.09-008 Usefulness of Immunohistochemistry in the Differential Diagnosis of Epithelioid Mesothelioma and Lung Squamous Cell Carcinoma Kei Kushitani, Hiroshima University, JP

P2.10 NURSING/PALLIATIVE CARE/ETHICS P2.10-001 Factors Associated with Quality of Life among Patients with Lung Cancer Yi-Lin Wu, National Cheng Kung University, TW P2.10-002 A Study on the Relation between Gender and Quality of Life for Lung Cancer Patients Yi-Lin Wu, National Cheng Kung University Hospital, TW P2.10-003 The Deterioration and Prognostic Value of Functional Capacity in Patients with Lung Cancer: A Systematic Review Laerke Winther, University of Copenhagen, DK P2.10-004 Efficacy and Safety of Viscum Album (Helixor M) to Treat Malignant Pleural Effusion in Patients with Advanced Lung Cancer Yun-Gyoo Lee, Kangbuk Samsung Hospital, KR P2.10-005 Overall Survival of Lung Cancer Patients with Brain Metastases in a Developing Country Tomi Kovacevic, Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, RS P2.10-006 Prognostic Factors of Mortality and Recurrence of Malignant Pleural Effusion in High-Risk Tumors According to the LENT Score Study Fernando Conrado Abrão, Hospital Santa Marcelina, BR P2.10-007 Quality of Life across Various Treatment Lines in Metastatic Lung Cancer Patients Aseem Rai Bhatnagar, SMS Hospital, IN

P2.11 PATIENT ADVOCACY P2.11-001 Evaluation of a Cultural Notebook of Self-Expression and Follow-Up Among Patients with Lung Cancer in French Polynesia Eric Parrat, CHPf Taaone, PF P2.11-002 To Live and Work with Lung Cancer: Coping Strategies of a Stage 4 Patient Satoko Kono, Arun, JP

P2.12 PULMONOLOGY/ENDOSCOPY P2.12-001 - P2.12-006 DIAGNOSTIC ENDOSCOPY P2.12-001 Early Experience with Radial Endobronchial Ultrasound with Guide Sheath For Diagnosis of Peripheral Pulmonary Lesion Sze Shyang Kho, Sarawak General Hospital, MY

68

P2.12-002 Radial Probe Endobronchial Ultrasound (R-EBUS) Guided Transbronchial Cryobiopsy In The Diagnosis of Peripheral Lung Mass Sze Shyang Kho, Sarawak General Hospital, MY P2.12-003 The History of EBUS TBNA Mark Krasnik, Copenhagen University Hospital Rigshospitalet / Gentofte Hospital, DK P2.12-004 Lung Cancer Detection Rate of Conventional Bronchoscopic Techniques: A Tertiary Hospital Experience June 2011- December 2016 Marlo Pasco Bagano, Perpetual Succour Hospital - Cebu Lung Institute, PH P2.12-005 Comparison of Needle Gauge Used to Obtain Specimens During EBUS-TBNA in Patients with Lung Cancer Goohyeon Hong, Dankook University Hospital, Dankook University College of Medicine, KR P2.12-006 Evaluation of New 25G Needle in EBUS-TBNA Comparing Conventional 22G Needle in Diagnosis for Nodal Metastasis of Lung Cancer Yuichi Sakairi, Chiba University Graduate School of Medicine, JP

P2.13 RADIOLOGY/STAGING/SCREENING P2.13-001 – P2.13-026a SCREENING P2.13-001 Herbal Compound as a Potential Lead Targets Lung Cancer Stem Cells Pei-Jung Lee, National Taiwan University, College of Medicine, TW P2.13-002 The LungScreen WA Project: Feasibility of LDCT Screening with the PLCOm2012 Risk Model and PanCan Nodule Risk Calculator Kuan Pin Lim, Sir Charles Gairdner Hospital, AU P2.13-004 Role of Low-Dose Chest Computerized Tomography in Lung Cancer Screening among Never-Smokers Hye-Rin Kang, Seoul National University College of Medicine, KR P2.13-005 Early Results of Lung Cancer Screening in an African American Population Cherie Parungo Erkmen, Temple University Hospital, US P2.13-006 Enhanced Shared Decision Making in Lung Cancer Screening: Addressing Questions of Willingness and Ability to Undergo Lung Cancer Treatment Cherie Parungo Erkmen, Temple University Hospital, US P2.13-007 Relationship of Nodule Count and Lung Cancer Probability in New Nodules Detected after Baseline in CT Lung Cancer Screening Joan E Walter, University of Groningen, University Medical Center Groningen, NL P2.13-008 Lung Cancer Screening Improves Mortality: Examining Screening Patterns in an Urban Underserved Community Haiying Cheng, Albert Einstein College of Medicine/Montefiore Medical Center, US

69

P2.13-009 Results of Low-Dose CT Lung Cancer Screening at a Non-University Tertiary Hospital System in Oregon, USA John R Handy, Providence Cancer Center, US P2.13-010 Five-Year-Long Follow-Up of the Low-Dose Computed Tomography Screening Programme in Gdansk, Poland Marcin Ostrowski, Medical University of Gdańsk, PL P2.13-011 Optimal Selection Criteria for LDCT Lung Cancer Screening Renelle L Myers, British Columbia Cancer Agency, CA P2.13-012 Recruitment for Lung Cancer Screening Renelle L Myers, British Columbia Cancer Agency, CA P2.13-013 Determination of the Detection Lead Time for Autoantibody Biomarkers in Early Stage Lung Cancer Using the UKCTOCS Cohort Jim Jett, Oncimmune PLC, US P2.13-014 Computed Tomography-Based Radiomic Classifier Distinguishes Malignant from Benign Pulmonary Nodules in the National Lung Screening Trial Tobias Peikert, Mayo Clinic, US P2.13-015 The Primary Care Provider Role in the US Screening Context: Current Practices and Strategies for Physician Engagement Angela Meredith Criswell, Lung Cancer Alliance, US P2.13-016 Self-Reported Program Barriers to Increasing Lung Cancer Screening Rates in the US and Implications for the Screening Community Angela Meredith Criswell, Lung Cancer Alliance, US P2.13-017 Four Years of Data in an Established Low Dose CT (LDCT) Screening Program Jacob Sands, Lahey Hospital & Medical Center, US P2.13-018 Clinical Outcomes Stage I/0 Adenocarcinoma Lung Diagnosed by Low Dose CT (LDCT) Screening vs Incidentally Discovered Jacob Sands, Lahey Hospital & Medical Center, US P2.13-019 Attrition Rate in Community-Based Lung Cancer Screening: One and Done Candice L. Wilshire, Swedish Cancer Institute, US P2.13-020 Lung-RADS Used in Lung Cancer Screening: Does Granulomatous Disease Intereferes with the Results? Initial Findings at a Brazilian Cancer Center Fabio Jose Haddad, A.C.Camargo Cancer Center, BR P2.13-021 Community Network Lung Cancer Screening Experience Underrepresents Medically Underserved and Geographically Remote Individuals Candice Leigh Wilshire, Swedish Medical Center and Cancer Institute, US P2.13-022 Lung Nodule Survey: One Pathology, Perspectives from Thoracic Surgeon, Pulmonologist and Radiology Point of View Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, BR

70

P2.13-023 Lung Cancer Risk and Eligibility for Lung Cancer Screening in Patients Undergoing Computed Tomography Coronary Angiography Daniel P Steinfort, Royal Melbourne Hospital, AU P2.13-025 Selecting the Risk Cut off for the LLP Model Kevin Ten Haaf, Erasmus MC, NL P2.13-026 Determining the Effect of Screening on Lung Cancer Mortality Claudia I Henschke, Icahn School of Medicine at Mount Sinai, US P2.13-026a A Validated Clinical Lung Cancer Risk-Prediction Model for Light-, Heavy- and ExSmokers: the Lung-HUNT Model Oluf Dimitri Røe, Norwegian University of Science and Technology, NO

P2.14 RADIOTHERAPY P2.14-001 Mid-Treatment Perfusion PET/CT Is More Effective Than Ventilation PET/CT in Functionally-Adapted Radiotherapy for NSCLC Roshini Thomas, Peter MacCallum Cancer Centre, AU P2.14-002 Impact of Pre-Existing Cardiac Disease and Heart Doses on Survival in Nsclc Treated with Post-Operative Thoracic Radiotherapy Chia Ching Lee, National University Cancer Institute Singapore, SG P2.14-003 Clinical Outcomes of SBRT in Inoperable Elderly Patients with NSCLC: Experience from a Developing Country Fabio Y Moraes, Hospital Sirio Libanes, BR P2.14-004 Comparable Local Controls after Twice-Daily and Once-Daily Chest Radiotherapy in Extensive Stage Small Cell Lung Cancer Bo Qiu, Sun Yat-sen University Cancer Center, CN P2.14-005 Determination of Optimal Cut off SUV Threshold for Auto-Contouring of GTV Using PETCT for Early Stage NSCLC Mangesh Babarao Patil, Tata Memorial Hospital, IN P2.14-006 A Pilot, Randomized Trial of Daily Lisinopril vs Placebo to Prevent Radiation-Induced Pulmonary Distress (Alliance MC1221) Terence Tai Weng Sio, Mayo Clinic Arizona, US P2.14-007 Histological Difference in Outcomes of Definitive Chemoradiotherapy for non-small cell Lung Cancer Ito Hitoshi, Kyoto Katsura Hospital, JP P2.14-008 Partial and Full Arc VMAT in Lung Cancer SBRT with Different Definitions of Internal Target Volume Based on 4D CT Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, CN P2.14-009 Assessing the Value of Radiotherapy for Lung Cancer in the Intensive Care Unit – A Population-based analysis Alexander Vincent Louie, London Regional Cancer Program, CA

71

P2.14-010 The Time-Weighted Mid-Ventilation Technique: Reducing Planning Target Volumes For Patients Undergoing Lung Stereotactic Body Radiotherapy. Charlotte Emily Louise Atkinson, St George Cancer Centre, AU P2.14-011 Recombinant Human Endostatin (Endostar) Combined with Concurrent Intensity Modulated Radiation Therapy for Elderly Local Advanced NSCLC Qun Chen, Fuzhou Pulmonary Hospital of Fujian, CN P2.14-012 Clinical Outcomes of the Largest UK Cohort of Cyberknife-Delivered Stereotactic Ablative Body Radiotherapy (SABR) for Primary Lung Cancers Qamar Ghafoor, Queen Elizabeth Hospital Birmingham, GB P2.14-013 Effect of Stereotactic Radiotherapy (SABR) on Pulmonary Function and Quality of Life: Results from a Tertiary Oncology Unit Qamar Ghafoor, Queen Elizabeth Hospital, GB P2.14-014 Does Histological Subtype Affect Outcomes in Stereotactic Ablative Body Radiotherapy (SABR) for Lung Tumours? Qamar Ghafoor, University Hospitals Birmingham NHS Foundation Trust, GB P2.14-015 Outcomes for Stereotactic Ablative Body Radiotherapy (SABR) for Early Primary Lung Cancers: Cyberknife Versus VMAT Platform Qamar Ghafoor, University Hospitals Birmingham NHS Foundation Trust, GB P2.14-016 Pulomonary Resection After Curative Intent Chemoradiation for NSCLC Gamze Cetinkaya, Uludag University, TR P2.14-017 Postoperative Radiotherapy in Completely Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Sung-Ja Ahn, Chonnam National University Hwasun Hospital, KR P2.14-018 Treatment Outcome and Lung Toxicities of Volumetric Modulated Arc Therapy in the Treatment of Inoperable Non-Small-Cell Lung Cancer Patients Congying Xie, the 1st Affiliated Hospital of Wenzhou Medical University, CN P2.14-019 Magnetic Resonance (MR)-Guided Adaptive Stereotactic Ablative Radiotherapy for Adrenal Metastases Suresh Senan, VU University Medical Center, NL P2.14-020 Clinical Validation of NTCP-Models for Esophagus Toxicity in Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiation Iris Walraven, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, NL P2.14-020a Retrospective Research on Radiofrequency Ablation (RFA) for Liver Metastasis Due to NSCLC: A Single Institutional Experience Kentaro Ito, Matsusaka Municipal Hospital, JP P2.14-020b Prognostic Factors in Unresectable Stage III NSCLC Treated with Concurrent Chemoradiotherapy Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, AU

72

P2.15 SCLC/NEUROENDOCRINE TUMORS P2.15-001 NHWD-870, a Novel BET Family Bromodomain Inhibitor Targeting BRD2/3/4, Proved to Be Effective and Promising for Treatment of Small Cell Lung Cancer Yongchang Zhang, Hunan Cancer Hospital, CN P2.15-002 Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC): An Experience From Eastern Indian Hospital Prasanta Raghab Mohapatra, All India Institute of Medical Sciences, IN P2.15-003 A Long Non-Coding RNA HOTTIP Expression Is Associated with Disease Progression and Predicts Outcome in Small Cell Lung Cancer Patients Linlang Guo, Zhujiang Hospital, Southern Medical University, CN P2.15-004 Underrepresentation of Elderly Patients with ED-SCLC as Clinical Trial Candidates (JCOG1201/TORG1528) Yuki Misumi, Yokohama Municipal Citizen's Hospital, JP P2.15-005 Post-Progression Survival Is Strongly Linked to Overall Survival in Refractory Small-Cell Lung Cancer Patients Who Received Amrubicin Hisao Imai, Gunma Prefectural Cancer Center, JP P2.15-006 The Effects of Pegylated Arginase on Small Cell Lung Cancer in vitro and in vivo Shi Xu, The University of Hong Kong, HK P2.15-007 Extensive Stage Small Cell Lung Cancer: Patterns of Care and Outcomes of a Single Institution over 15 Years Eunji Hwang, Radiation Oncology Prince of Wales Hospital, AU P2.15-008 Genomic Analysis to Assess a Molecular Signature in Japanese Patients with Pulmonary High Grade Neuroendocrine Carcinoma Hideaki Kojima, Shizuoka Cancer Center, JP P2.15-009 Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Functioning as a Competing Endogenous RNA to Regulate Etk Expression Fanrui Zeng, Zhujiang Hospital, Southern Medical University, CN P2.15-010 Etk Interacting with PFKFB4 Modulates Chemoresistance of Small Cell Lung Cancer by Regulating Autophagy Qiongyao Wang, Zhujiang Hospital, Southern Medical University, CN P2.15-011 Therapeutic Strategies and Genetic Comparisons in SCLC and LCNEC of the Lung Using Next-Generation Sequencing Masaoki Ito, Hiroshima University Hospital, JP P2.15-012 Analysis of Small Cell Lung Cancer with Paraneoplastic Limbic Encephalitis Mingyi Di, Peking Union Medical College Hospital, CN P2.15-013 Doxorubicin and Topotecan for Relapsed/Refractory Small Cell Lung Cancer (SCLC): A FPBCC Clinical Trials Network Phase I Study

73

Apar Kishor Ganti, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center/Fred & Pamela Buffett Cancer Center, US P2.15-014 Extensive Stage Small Cell Lung Cancer: Is Primary Growth Factor Support Warranted in Patients Having Doublet Chemotherapy? Tasha Mackie, Auckland District Health Board, NZ P2.15-015 Negativity for Thyroid Transcription Factor 1 Was Correlated with Less Neuroendocrine Differentiation in Small Cell Lung Cancers Yuko Iida, Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, JP P2.15-016 Clinical Significance of Topoisomerase-II Expression in Patients with Relapsed HGNEC of the Lung Treated with Amrubicin Yosuke Miura, Department of Respiratory Medicine, Gunma University Graduate School of Medicine, JP P2.15-016a Exploiting G2-M Cell Cycle Checkpoint Dependency in Small Cell Lung Cancer (SCLC) by Targeting Checkpoint Kinase 1 (CHK1) Triparna Sen, University of Texas MD Anderson Cancer Center, US

P2.16 SURGERY P2.16-001 Liposomal Bupivacaine (Exparel) Reduces Thoracic Surgery Post-Operative Pain and Reduces Length of Stay, a Retrospetive Study Joseph Aisner, Rutgers Cancer Institute of New Jersey, US P2.16-002 Adequacy of Lymph Node Sampling during Lobectomy in a Small Community Teaching Hospital Mark A Kryskow, Berkshire Medical Center, US P2.16-003 Diagnostic Lobectomy for Indeterminate Pulmonary Tumor Noritoshi Nishiyama, Osaka City University, JP P2.16-004 Alternative Subpreural Lymph Flow Pathways in Human Lung – a Hundred Cases Experience and Analysis Takuya Tokunaga, Kagoshima University, JP P2.16-005 Is There Any Oncological Concern about Preoperative Biopsy for Resectable Lung Cancer Patients? Hideyuki Kozuka, Kansai Medical University, JP P2.16-006 Locking of the Scapula after Lobectomy with Rib Resection Motohiro Nishimura, Saiseikai Suita Hospital, JP P2.16-007 Two Cases of VATS Resection for Endobronchial Protruded Tumors Kunihiko Terauchi, Nara City Hospital, JP P2.16-008 Collapsed Lung Index Ten Minutes after Thoracotomy and Pre-Operative Pulmonary Function Tests Junichi Shimada, Kyoto Prefectural University of Medicine, JP

74

P2.16-009 Strategy for Oncologic Emergency in Thoracic Disease Ryohei Yoshikawa, Maebashi Red Cross Hospital, JP P2.16-010 Removing the Chest Tube on the First Day after Surgery Does Not Contribute to the Early Discharge from the Hospital Takuya Ohashi, Wakayama Medical University, JP P2.16-011 Unsuspectedly Detected Isolated Fibrinogen Deficiency in a Patient with Lung Adenocarcinoma after Surgery Jeong Su Cho, Pusan National University Hospital, KR P2.16-012 Does Percutaneous Ultrasound Predict Tumor Site and Internal Tumor Properties? Gaku Yamaguchi, Chemotherapy Research Institute, Kaken Hospital, JP P2.16-013 Peripheral or Central Lung Nodules: How do Thoracic Surgeons Define it? Rowena Yip, Icahn School of Medicine at Mount Sinai, US P2.16-014 Deconstructing Surgical Decision Making Rowena Yip, Icahn School of Medicine at Mount Sinai, US P2.16-015 Log Data of Digital Drainage System Is a Potential Predictive Factor of Pleurodesis Efficacy for Postoperative Air Leak After Pulmonary Resection Tomonari Oki, National Cancer Center Hospital East, JP P2.16-016 Surgical Treatment of Indeterminate Lung Nodules Masashi Yanada, Japanese Red Cross Kyoto Daini Hospital, JP P2.16-017 Surgical Treatment of Bronchial Carcinoid Tumors: Evaluation of Survival and Prognostic Factors. A Single-Center Experience Piotr Rudzinski, National Institute of Tuberculosis and Lung Diseases, PL P2.16-018 Phrenic Nerve Injury After Lung Surgery: An Underestimated Problem Luigi Ventura, University Hospital of Parma, IT P2.16-019 Improving Survival with a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resections Raymond U. Osarogiagbon, Baptist Cancer Center, US P2.16-020 Surgical Strategy for Synchronous Multiple Lung Cancer with Ground Glass Opacity Toshihiko Moroga, Fukuoka University Chikushi Hospital, JP P2.16-021 Malignant Melanocytic Neoplasm: A Rare Presentation of a Large Mediastinal Mass Tina Koh, National Cancer Centre, SG P2.16-022 Initiative for Early Lung Cancer Research on Treatment: Pilot Implementation Claudia I Henschke, Icahn School of Medicine at Mount Sinai, US P2.16-023 Changes of the Pulmonary Artery After Resection of Stage I Lung Cancer Michael Chung, Mount Sinai Hospital, US

75

P2.16-024 Effect of Resection of Stage 1 Lung Cancer on Lung Volume Artit Jirapatnakul, Icahn School of Medicine at Mount Sinai, US P2.16-025 Accuracy of Multidisciplinary Evaluation of Small Solitary Pulmonary Nodules in a Portuguese Private Hospital Joao Reis, Hospital da Luz, PT P2.16-026 Surgical Treatment for Metastatic Lung Tumors from Various Sarcomas Hiromasa Yamamoto, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, JP P2.16-027 Comparison of Single Chest Tube Versus Double Chest Tube Drainage After Lung Resection for the Treatment of Non-Small Cell Lung Cancer Tomasz Gil, Jagiellonian University, John Paul II Hospital, PL P2.16-028 Are We Doing the Right Thing? Overall Survival & Intermediate Outcomes Following Lung Metastasectomy Prakash Balakrishnan, Wellington Regional Hospital, NZ

P2.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES P2.17-001 Pulmonary Inflammatory Myofibroblastic Tumor with TPM4-ALK Translocation Katsuhiro Okuda, Nagoya City University Graduate School of Medical Sciences, JP P2.17-002 Pulmonary and Mediastinal Paragangliomas: Rare Endothoracic Malignancies with Challenging Diagnosis and Treatment Angela De Palma, University of Bari "Aldo Moro", IT P2.17-003 Is Complete Resection Mandatory for Mediastinal Germ Cell Tumor Which Shows Severe Adhesion to Greater Vessels? Hiroyuki Ito, Kanagawa Cancer Center, JP P2.17-004 Salvage Surgery for Pulmonary Metastases in Patients with Testicular Germ Cell Tumors Shinji Kikuchi, University of Tsukuba, J

76

WEDNESDAY, OCTOBER 18, 2017 P3.01 ADVANCED NSCLC P3.01-001 – P3.01-076 EGFR P3.01-077 – P3.01-088h OTHER GROUPS AND TARGETS P3.02 BIOLOGY/PATHOLOGY P3.02-001 – P3.02-014a P3.02-015 – P3.02-017 P3.02-018 – P3.02-070 P3.02-071 – P3.02-097h

ANALYSIS OF BODY FLUIDS IN CANCER APOPTOSIS IN LUNG CANCER DRIVER GENES IN NSCLC,RESISTANCE, AND OTHER FUNCTIONAL BIOLOGY IN LUNG CANCER

P3.03 CHEMOTHERAPY/TARGETED THERAPY P3.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS P3.05 EARLY STAGE NSCLC P3.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION P3.07 IMMUNOLOGY AND IMMUNOTHERAPY P3.08 LOCALLY ADVANCED NSCLC P3.09 MESOTHELIOMA P3.10 NURSING/PALLIATIVE CARE/ETHICS P3.11 PATIENT ADVOCACY P3.12 PULMONOLOGY/ENDOSCOPY P3.13 RADIOLOGY/STAGING/SCREENING P3.13-001 – P3.13.038 DIAGNOSTIC RADIOLOGY P3.14 RADIOTHERAPY P3.15 SCLC/NEUROENDOCRINE TUMORS P3.16 SURGERY P3.16-001 – P3.16-036 RISK ASSESSMENT AND PROGNOSTIC FACTORS P3.16-037 – P3.16-049 SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC P3.16-050 – P3.16-053 TRANSLATIONAL STUDIES P3.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES

Wednesday, October 18, 2017

Poster Setup Time: Wednesday, October 18, 08:00 – 10:00 Poster Takedown Time: Wednesday, October 18, 15:30 – 18:00 (Posters not taken down by 18:00 will be discarded by management) POSTER SESSION WITH PRESENTERS PRESENT (PRESENTING AUTHOR STAND BY TIME) Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates. Wednesday, October 18 from 10:00 – 10:45 and 14:30 – 15:30 (Exhibit Hall B + C - Poster Area)

P3.01 ADVANCED NSCLC P3.01-001 – P3.01-076 EGFR P3.01-001 Comparisons of Two Plasma EGFR Platforms (ddPCR and Cobas) in Patients with Radiological Metastatic Lung Cancer Jacky Yu Chung Li, Queen Elizabeth Hospital, HK P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient with EGFR TKI Drug Resistance Renwang Liu, Tianjin Medical University General Hospital, CN P3.01-003 Study of the Relationship between EGFR Mutation Status and Bone Metastasis in Advanced Lung Adenocarcinoma Zhao Bing, Affiliated Tumor Hospital of Xinjiang Medical University, CN P3.01-004 The Underestimated Role of Bronchial Washing Fluid in the Detection of EGFR Mutation from Lung Cancer Patients Jie Hu, Zhongshan Hospital, CN P3.01-005 ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis Sang-We Kim, Asan Medical Center, University of Ulsan College of Medicine, KR P3.01-006 Osimertinib in Pretreated EGFR T790M-Positive Non-Small Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao, National Taiwan University Hospital, TW P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations Edyta Maria Urbanska, University of Copenhagen, Rigshospitalet, Finsens Center, DK P3.01-008 Association between Icotinib Efficacy and Circulating Tumor Cell Levels in Advanced NonSmall Cell Lung Cancer Meiyu Fang, Zhejiang Cancer Hospital, CN P3.01-009 Clinical Efficacy of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 18 E709X Mutations Meiyu Fang, Zhejiang Cancer Hospital, CN

78

P3.01-010 High Probability and Frequency of EGFR Mutations in Non-Small Cell Lung Cancer with Brain Metastases Xiaohua Liang, Huashan Hospital, CN P3.01-011 Comparision of EGFR and ALK-Driven Lung Adenocarcinoma with Brain Metastases for Prognostic Factors in Chinese Patients Fengnan Wang, The First Affiliated Hospital of Guangzhou Medical University, CN P3.01-012 Symptom Impact of First-Line Dacomitinib versus Gefitinib in EGFR-Positive NSCLC: Results from a Randomized Phase 3 Study Rickard Sandin, Pfizer Oncology, SE P3.01-013 CNS Metastases in EGFR Mutation Positive NSCLC: Impact on Health Resource Utilization Negar Chooback, British Columbia Cancer Agency, CA P3.01-015 Differential Outcomes between First and Second Generation TKIs in Patients with Activating EGFR Mutations in NSCLC Sally C Lau, British Columbia Cancer Agency, CA P3.01-016 Factors Associated with Symptoms Improvement and HRQoL for First-Line EGFR-TKIs in NSCLC: A Multicenter Prospective SMILE Study Yu-Feng Wei, E-Da hospital/I-Shou University, TW P3.01-017 Clinical Outcomes of Patients with EGFR T790M + NSCLC on Osimertinib Wan Ling Tan, National Cancer Centre Singapore, SG P3.01-018 Mutation Abundance Affects the Therapeutic Efficacy of EGFR-TKI in Patients with Advanced Lung Adenocarcinoma: A Retrospective Analysis Huijuan Wang, Henan Cancer Hospital, CN P3.01-019 Canadian Multicentre Validation Study of Plasma Circulating Tumour DNA for Epidermal Growth Factor (EGFR) T790M Testing Ming Sound Tsao, University Health Network Princess Margaret Cancer Centre, CA P3.01-020 Clinical Features of Patients with Non-Small Cell Lung Cancer (NSCLC) Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations in Brunei Shir Kiong Lu, The Brunei Cancer Centre, BN P3.01-021 A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China Ying Cheng, Jilin Provincial Cancer Hospital, CN P3.01-022 Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs Isaac Kah Siang Ng, NUS Yong Loo Lin School of Medicine, SG P3.01-023 First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice Youjin Kim, Samsung Medical Center, KR

79

P3.01-024 Characterization of PD-L1 Expression and Its Predictive and Prognostic Significance in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, CN P3.01-025 Treatment Outcomes of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status: A Retrospective Analysis of 140 Patients Cheng Xiao, The first affiliated hospital, School of medicine, Zhejiang university, CN P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC Martin Schuler, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, DE P3.01-027 TET2 Mutation as a Novel Mechanism of Acquired Resistance to EGFR TKIs Identified by a Mutational Profiling Using NGS Xiao Hu, Zhejiang Cancer Hospital, CN P3.01-028 Efficacy of Osimertinib for Brain Metastasis in Advanced NSCLC: Data from Single Center in ASTRIS Trial Jee Hung Kim, Yonsei Cancer Center, KR P3.01-029 Transient Asymptomatic Pulmonary Opacities (TAPOs) during Osimertinib Treatment and Its Clinical Implication Hansang Lee, Samsung Medical Center, KR P3.01-030 CNS Metastases in EGFR Mutation Positive (EGFRm) NSCLC Patients: The Prognostic Relevance of Presenting Symptoms Negar Chooback, British Columbia Cancer Agency, CA P3.01-031 ctDNA Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non–SmallCell Lung Cancer in Read World Setting Shirong Zhang, Affiliated Hangzhou Hospital of Nanjing Medical University, CN P3.01-032 Preliminary study of Lung Cancer Adenocarcinoma with De-novo EGFR T790M Mutation in Persahabatan Hospital-Jakarta, Indonesia. Hapsari Dewanti, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia – Persahabatan National Respiratory Referral Hospital, ID P3.01-033 Detection of Epidermal Growth Factor Receptor Mutations with Plasma Sample Compared with Tumor Tissue Biopsy in Advanced Lung Adenocarcinoma Taewon Jang, Kosin Univeristy Gosepel Hospital, KR P3.01-034 Liquid Biopsy for EGFR Genotyping Using Cell-Free DNA and Extracellular Vesicular DNA of Pleural Effusion in Pulmonary Adenocarcinoma Patients Jong Sik Lee, Konkuk University School of Medicine, KR P3.01-035 Post-Marketing Observational Study of Japanese Patients with EGFR Mutation-Positive (EGFRm+) NSCLC Treated with Daily Afatinib (Final Report) Nobuyuki Yamamoto, Third Department of Internal Medicine, Division of Pulmonology and Medical Oncology, Wakayama Medical University, JP

80

P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis Yi-Long Wu, , P3.01-037 Understanding Mechanisms of Resistance to Osimertinib by Circulating Tumor DNA Genotyping in Advanced Non-Small-Cell Lung Cancer Gang Cheng, Novogene Co., Ltd., CN P3.01-038 Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network Julia Roeper, Pius Hospital Oldenburg/University of Oldenburg, DE P3.01-040 Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US Apar Kishor Ganti, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Centre, US P3.01-041 The Robustness of Allele-Specific qPCR Assays for Detection of EGFR Mutations in Plasma Cell-Free DNA from NSCLC Patients Joanna Chorostowska-Wynimko, National Institute of Tuberculosis and Lung Diseases, PL P3.01-042 Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study Thanyanan Reungwetwattana, Ramathibodi Hospital, TH P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung Glenwood Goss, University of Ottawa, CA P3.01-044 Erlotinib vs Chemotherapy in EGFR Mut+ NSCLC: OS in Three Phase III Trials Adjusting for Post-Progression Treatment Crossover Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, CN P3.01-045 Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution Noemi Reguart, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab Philip Christopher Mack, UC Davis Comprehensive Cancer Center, US P3.01-047 Erlotinib Induced Ectropion Followed by Papulo-Erythemato Skin Rash Abdolali Shahrasbi, Bouali Hospital, Tehran Medical unit, azad University, IR P3.01-048 CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib Lyudmila A Bazhenova, University of California San Diego Moores Cancer Center, US P3.01-049 T790M Mutation Detection, Clinical Characteristics and Impact in NSCLC Patients Treated with EGFR Tyrosine Kinase Inhibitors Júlio Oliveira, Instituto Português de Oncologia do Porto, PT

81

P3.01-050 A Real World Treatment Study of Osimertinib: ASTRIS Study Korean Subgroup Analysis Byoung Chul Cho, Yonsei Cancer Center, KR P3.01-051 Dramatic Response to Afatinib in EGFR-Mutant Lung Adenocarcinomas After Resistance to First-Generation EGFR Inhibitors: A Brief Report Wen -Feng Li, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, CN P3.01-052 The Prevalence and Genotype Distribution of Dual in Cis EGFR Mutations in Chinese Advanced Non-Small Cell Lung Cancer Patients Min Li, Xiangya Hospital, Central South University, CN P3.01-053 Detection of Common EGFR Mutation in Cytological Smears Using Reversed Dot Blot (RDB) Hybridization Method Najmiatul Masykura, Stem-cell and Cancer Institute, ID P3.01-054 Urinary ct-DNA Testing of EGFR Common Mutation in Non-Small Cell Lung Cancer Patients Asep Muhamad Ridwanuloh, Indonesian Institute of Sciences, ID P3.01-055 The Usefulness of Liquid Biopsy for ctDNA in Patients with EGFR-Mutant NSCLC During and After Treatment with EGFR-TKIs Takuma Yokoyama, Kyorin University Hospital, JP P3.01-056 Intracranial Activity of Osimertinib in Naïve EGFRm T790M(-)And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases Nir Peled, Rabin Medical Center, Davidoff Cancer Center, IL P3.01-057 Comparison of EGFR Mutations in Matched Tumor Tissues, Cell Blocks, Pleural Effusions and Bloods with NSCLC, by PANA Mutyper and PNA Clamping Seung Joon Kim, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea, KR P3.01-058 Impact of Different Timing of Radiotherapy in Patients with Brain Metastases from Epidermal Growth Factor Receptor-Mutant NSCLC Yaping Xu, Zhejiang Cancer Hospital, CN P3.01-059 First Experience with Osimertinib in Patients with Newly Developed T790M Mutation Previously Treated with EGFR – TKIs in Croatia Marko Jakopovic, University Hospital Centre Zagreb, HR P3.01-060 The Clinical Utility of ctDNA Gene Analysis in Lung Cancer Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, IL P3.01-061 Endostar Combined with Re-Challenged Gefitinib in Previous Treatment Failed NSCLC: A Retrospective Study Huijuan Wang, Henan Cancer Hospital, CN P3.01-062 The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumour DNA T790M Testing Tristan Alexandra Barnes, Princess Margaret Cancer Centre, CA

82

P3.01-063 Concomitant EGFR Mutation and ALK Rearrangement in Non-Small-Cell Lung Cancer Rui-Lian Chen, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, CN P3.01-064 Detection of EGFR Mutations in Circulating Tumor DNA Using Plasma Samples: Clinical Validation of Cobas EGFR Mutation Test V2 Hidetoshi Itani, Ise Red Cross Hospital, JP P3.01-065 Advanced NSCLC with EGFR Mutations in Elderly Patients. Single-Centre Experience Angel Artal Cortes, Hospital Universitario Miguel Servet, ES P3.01-066 CNS Metastases of Pulmonary Adenocarcinoma Harboring EGFR-Activating Mutations: a Multidisciplinary Approach, Including EGFR-TKis Renata Rodrigues da Cunha Colombo Bonadio, Instituto do Cancer do Estado de Sao Paulo, BR P3.01-067 TP53 Mutations Could Involved in EGFR-TKI Primary Resistance in Advanced Non-Small Cell Lung Cancer Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, CN P3.01-068 Investigation of Low Plasma/Tissue EGFR Concordance in Russia: Follow-up to the IGNITE Global Diagnostic Study Brian B Lentrichia, AstraZeneca Pharmaceuticals, US P3.01-069 Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases Yun Fan, Zhejiang Cancer Hospital, CN P3.01-070 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations Shun Lu, Shanghai Chest Hospital, CN P3.01-071 Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR MutationPositive Stage IV NSCLC: Phase 1b Outcomes Kazuhiko Nakagawa, Kindai University School of Medicine, JP P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050) Kazuhiko Nakagawa, Kindai University Hospital, JP P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC Rafael Rosell, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, ES P3.01-074 Genomic Analysis of Tumor and Plasma in T790M Mutant Positive EGFR Lung Cancer Patients before and after Osimertinib Treatment James Chih-Hsin Yang, National Taiwan University, TW P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC Vera Hirsh, McGill University, CA

83

P3.01-076 QTWiST Analysis to Compare the Benefit of Gefitinib Versus Pemetrexed Platinum for Patients with EGFR Mutated NSCLC Vijay Patil, Tata Memorial Hospital, IN P3.01-076a Lung Cancer Stem Cell (LCSC) Markers and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Resistance Shinnosuke Takemoto, Nagasaki Medical Center, JP P3.01-077 – P3.01-088h OTHER GROUPS AND TARGETS P3.01-077 Effectiveness of Methylnaltrexone Bromide in Opioid-Induced Constipation in Advanced NSCLC Patients Ioannis Dimitroulis, Sotiria Hospital for Thoracic Diseases, GR P3.01-078 Outcome of Stage IIIb Non-small Cell Lung Cancer (NSCLC) Patients – A Single Tertiary Center Experience Tahir Mehmood, Northwest General Hospital and Research Centre, PK P3.01-079 Evaluating the Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Stage IIIa (N2) Lung Cancer Luo-Sheng Yong, National Taiwan University, TW P3.01-080 Overall Survival (OS) of Pathological N2 Non-Small Cell Lung Cancer (NSCLC) After Surgical Resection Etienne Bourdages-Pageau, Laval University, CA P3.01-081 Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging Arthur Vieira, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), CA P3.01-082 Surgical Rebiopsy in Advanced Non-Small Cell Lung Cancer Resistant to Previous Chemotherapy Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, KR P3.01-083 Clinical Characteristics and Survival Outcomes for Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations Min Peng, Renmin Hospital of Wuhan University, CN P3.01-084 Analysis on ALTER0303 Trial: aCECs Level May Correlate with Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC Kai Li, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, CN P3.01-085 A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression Fengying Wu, Shanghai Pulmonary Hospital, Tongji University, CN P3.01-086 Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States Laura Chu, Genentech, US

84

P3.01-087 Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303 Kai Li, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, CN P3.01-088 Molecular Testing and First-Line Treatment of Patients with NSCLC. First Results from the German CRISP Study (AIO-TRK-0315) Frank Griesinger, Pius-Hospital Oldenburg, DE P3.01-088a Phase II Study of Nab-Paclitaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: SNIPER Study Naruo Yoshimura, Graduate school of Medicine, Osaka City University, JP P3.01-088b Is Efficacy Result in Phase 2 Trial Replicated in Phase 3 Trial in Advanced NSCLC: A MetaAnalysis Ryota Shibaki, Minami Wakayama Medical Center, JP P3.01-088c Exosomal Amphiregulin Induce Osteoclastogenesis Through Osteoclast Differentiation Mediated by EGFR Pathway Christian Rolfo, Antwerp University Hospital & Antwerp University, BE P3.01-088d TTFields Combined with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of NonSmall-Cell Lung Cancer (NSCLC): Phase 3 LUNAR Study Uri Weinberg, Novocure, US P3.01-088e TTFields Delivery to the Brain: An Overview of Computational Studies and Implications When Treating Brain Metastases Uri Weinberg, Novocure, US P3.01-088f Droplet Digital PCR-Based EGFR Mutation Detection with an Internal Quality Control Index to Determine the Quality of DNA Sung Su Kim, Seoul National University, KR P3.01-088g Variation in Treatment Recommendations for NSCLC Patients by Multidisciplinary Tumor Board Meetings Across the Netherlands Margriet Kwint, Netherlands Cancer Institute, NL P3.01-088h Resistance Mechanisms Causing First-line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment Failure Chong-Kin Liam, University of Malaya, MY

P3.02 BIOLOGY/PATHOLOGY P3.02-001 – P3.02-014a ANALYSIS OF BODY FLUIDS IN CANCER P3.02-001 Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary LymphoepitheliomaLike Carcinoma (LELC) Patients Mian Xie, The First Affiliated Hospital of Guangzhou Medical University, CN P3.02-002 Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients Alexis B Cortot, Lille University Hospital, FR

85

P3.02-003 Tissue and Serum Levels of Galectin-3 in NSCLC Patients Yoko Kataoka, Shiga University of Medical Science, JP P3.02-004 Analysis of MET in Liquid Biopsy and Tissue Biopsy in Patients with Advanced NSCLC: Incidence and Pattern. Edgardo S. Santos, Thoracic and Head and Neck Cancer Programs, Eugene M. & Christine E. Lynn Cancer Institute, Florida Atlantic University, Boca Raton, FL, US P3.02-005 Applicability of Ion Torrent Colon and Lung Sequencing Panel on Circulating Cell-Free DNA Christina Demuth, Aarhus University Hospital, DK P3.02-006 Monitoring Genetic Alterations in Plasma during Anti-Cancer Treatment in Advanced NSCLC (MAGIC1-Validation Cohort: Preliminary Results) Laura Bonanno, 1. Medical Oncology 2, Istituto Oncologico Veneto IRCCS, IT P3.02-007 Circulating miRNAs as Prognostic Biomarkers in Resected Early-Stages Non-Small-Cell Lung Cancer Lucio Crinò, Medical Oncology- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, IT P3.02-008 Non-Invasive Diagnosis of Solitary Pulmonary Nodules Using High-Throughput Targeted DNA Methylation Sequencing of Circulating Tumor DNA Wenhua Liang, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China State Key Laboratory of Respiratory Disease, CN P3.02-009 Mutation Detection in Cell-Free DNA from Patients with Lung Adenocarcinoma by NextGeneration Sequencing Hana Khairina Putri Faisal, Natural Science Center for Basic Research Development, Graduate School of Biomedical and Health Sciences, JP P3.02-010 Significant Increase of Blood Extracellular Vesicles in Pulmonary Vein as Potential Prognostic Biomarker for Lung Cancer Patients Byeon Hyeon Choi, Korea University Guro Hospital, KR P3.02-011 A Prospective Study of Serial Circulating Tumor DNA Assessment in Detecting Recurrence of Resected Early-stage Lung Cancer Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, KR P3.02-012 Liquid Based Cytology (LBC) Specimens Were Useful for EGFR Mutation Test Tatsuo Ohira, Tokyo Medical University, JP P3.02-013 Prognostic Role of Circulating Tumor DNA (ctDNA) and Immune Cell Biomarkers in NonSmall Cell Lung Cancer (NSCLC) Young Kwang Chae, Robert H Lurie Comprehensive Cancer Center of Northwestern University, US P3.02-014 Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC Nicolas Marie Guibert, Dana Farber Cancer Institute, US

86

P3.02-014a Diagnostic Value of FR+-CTCs Detected by LT-PCR for Lung Cancer in SPN and Tumor Invasiveness in Adenocarcinoma (T≪3cm) Qianjun Zhou, Shanghai Chest Hospital, Shanghai Jiaotong University school of medicine, CN P3.02-015 – P3.02-017 APOPTOSIS IN LUNG CANCER P3.02-015 433MHz Microwave Radiation Induces G2/M Checkpoint Arrest and Promotes Apoptosis under Hyperthermia in Non-Small Cell Lung Cancer Cells Yanyan Zhao, Hangzhou First People’s Hospital, Nanjing Medical University, CN P3.02-016 Correlation of Programmed Cell Death Ligand-1 Messenger RNA and Protein Expression in Non-Small Cell Lung Cancer Hyun Jung Kwon, Seoul National University Bundang Hospital, KR P3.02-017 Apoptosis-Related Protein in Non Small Cell Lung Cancer: Correlation of Clinicopathologic, Molecular Characteristics and Prognosis Ping-Li Sun, Jilin University Second Hospital, CN P3.02-018 – P3.02-070 DRIVER GENES IN NSCLC,RESISTANCE, AND OTHER P3.02-018 Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report Meiyu Fang, Zhejiang Cancer Hospital, CN P3.02-019 Clinical Validation of a Real Time PCR Assay for the Detection of ROS1 Fusion in Chinese Non-Small Cell Lung Cancer Guanshan Zhu, Amoy Diagnostics Co., Ltd., CN P3.02-020 Comparison of Diagnostic Ability for EGFR Mutation of the Specimen Groups: Histology – Cytology – Plasma Nguyen Son Lam, Pham Ngoc Thach Hospital, VN P3.02-021 Secondary EGFR Exon 20 T790m Mutation for Therapy of Non Small Cell Lung Cancer at Phat Ngoc Thach - Ho Chi Minh City - Vietnam Nguyen Son Lam, Pham Ngoc Thach Hospital, VN P3.02-022 Protein Tyrosine Phosphatase Interacting Protein 51 Might Improve EGFR-TKI Sensitivity in Non-Small-Cell Lung Cancer Xing Wang, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), CN P3.02-023 Semaphorin 7A Reduces Response to EGFR-TKI Treatment via Apoptosis in Human Lung Adenocarcinoma Yuhei Kinehara, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, JP P3.02-024 Role of FBXW7 in the Maintenance of Quiescent Cancer Stem Cells Resistant to Gefitinib in EGFR Mutation-Positive Non-Small Cell Lung Cancer Moulid Hidayat, Juntendo University Graduate School of Medicine, JP

87

P3.02-025 65 Cases of Molecular Profiling Anaysis in Surgical Resected Pulmonary Neuroendocrine Carcinoma Gang Chen, Fujian Provincial Cancer Hospital, CN P3.02-026 The Study of ROS1 Rearrangement in Advanced Primary Non-Small Cell Lung Cancer and Associated Metastatic Lesions Gang Chen, Fujian Provincial Cancer Hospital, CN P3.02-027 Lung Adenocarcinoma Patient with EGFR 19 Exon Insert Mutation: I740_K745insIPVAIK and Its Response to Icotinib: A Case Report Gang Chen, Fujian Provincial Cancer Hospital, CN P3.02-028 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma Gang Chen, Fujian Provincial Cancer Hospital, CN P3.02-029 218 Cases of EGFR/ALK Gene Status Anaysis in Chinese Lung Squamous Cell Carcinoma Gang Chen, Fujian Provincial Cancer Hospital, CN P3.02-030 Inhibitory Effects of Mitochondrial TRAP1 on Gefitinib-Resistance in Non-Small Lung Cancer Cells Euntaik Jeong, Wonkwang University Hospital, KR P3.02-031 Detection of Activating EGFR Mutations and Resistant T790M Mutation from cfDNA in Malignant Pleural Effusion(MPE-DNA) Kirsty Wai Chung Lee, Chinese University of Hong Kong, HK P3.02-032 Spatial Heterogeneity of EGFR and KRAS Variant Allele Frequencies Correlates with Histological Patterns of Lung Adenocarcinomas Steffen Dietz, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), DE P3.02-033 Pathological and Molecular Alterations after First and Second Generation EGFR-TKI Therapy in Patients with EGFR-Mutated Lung Adenocarcinomas Hironori Uruga, Toranomon Hospital, JP P3.02-034 Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma Wade Thomas Iams, McGaw Medical Center of Northwestern University, US P3.02-035 Mutational Signatures and Their Association with Clinicopathological Features in Lung Adenocarcinoma of Smokers Takayuki Honda, National Cancer Center Research Institute, JP P3.02-036 Feasibility Study to Evaluate Patterns of Metastases and Effect of Surgery on Lung Cancer Xenografts with Differing Sensitivity to EGFR TKI Sabita Jiwnani, Tata Memorial Hospital, IN P3.02-038 Diagnosis of Leptomeningeal Disease and Clonal Heterogeneity with Digital Droplet PCR (ddPCR) in EGFR Mutated NSCLC Gareth Rivalland, University of Melbourne, AU

88

P3.02-039 Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S Atsushi Osoegawa, Oita University Faculty of Medicine, JP P3.02-040 Driver Gene Detection in Chinese NSCLC Patients Using cSMART and Prognosis Analysis Xueqin Chen, Hangzhou First People’s Hospital, CN P3.02-041 EGFR Amplification Mediates Resistance to TAS121, A Third-Generation EGFR-TKI, in EGFR T790M-Positive Non-Small Cell Lung Cancer Sho Watanabe, National Cancer Center Hospital, JP P3.02-042 DS-1205b, a Novel, Selective, Inhibitor of AXL, Delays the Onset of Resistance and Overcomes Acquired Resistance to EGFR-TKIs Takeshi Jimbo, Daiichi-Sankyo Co., Ltd., JP P3.02-043 Clinical and Genetic Features in Lung Adenocarcinoma Without EGFR Mutation and ALK Rearrangement in Taiwan Tsu-Hui Shiao, Taipei Veterans General Hospital, TW P3.02-044 Diagnosis and Monitoring of EGFR Mutation Status with cfDNA in Advanced NSCLC: A Prospective Single Institution Study in Asia Teh-Ying Chou, Taipei Veterans General Hospital, TW P3.02-045 Prevalence of ALK Gene Abnormalities in Routine Diagnostics of Polish NSCLC Patients Kamila Wojas-Krawczyk, Medical University of Lublin, PL P3.02-046 EGFR-Grb2-GEP100 Complex Promoted Its Invasive and Metastatic Potential via Arf6 Pathway in Lung Adenocarcinoma Toshi Menju, Graduate School of Medicine, Kyoto University, JP P3.02-047 Testing EGFR and ALK in Large Cell Neuroendocrine Carcinoma of the Lung. Looking for Biological Features in Rare Tumors Teresa García Manrique, Hospital Virgen Macarena, ES P3.02-048 Clinicopathologic Characteristics of Non-Small Cell Lung Carcinomas Habouring MET Exon 14 Skipping Mutations Takeshi Fujii, Toranomon Hospital, JP P3.02-049 The Evaluation of Circulating miRNA Expression in Plasma as the Epigenetic Marker of EGFR Mutation Status in NSCLC Patients Mateusz Florczuk, National Institute of Tuberculosis and Lung Diseases, PL P3.02-050 Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines Anne Tranberg Madsen, Aarhus University Hospital, DK P3.02-051 Low Consistency Between FGFR1 Gene Amplification and Protein Expression in Squamous Cell Lung Cancer (SQCLC) Joanna Chorostowska-Wynimko, National Institute of Tuberculosis and Lung Diseases, PL P3.02-052 Stability of EGFR Mutations in Whole Blood and Plasma in Patients with NSCLC Johanne Andersen Højbjerg, Aarhus University Hospital, DK

89

P3.02-053 Optimization and Characterization of Assays to Identify Met Exon 14 Skipping in FFPE Embedded NSCLC Samples Steven G. Gray, Trinity College Dublin, IE P3.02-054 Prognostic Implications of ROS1 Positivity in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Published Literature Anchit Khanna, Pfizer Oncology, AU P3.02-055 Detecting ALK, ROS1 and RET Gene Translocations in Non-Small Cell Lung Cancer (NSCLC) with the NanoString Platform Hangjun Wang, McGill University Health Center & McGill University, CA P3.02-056 EGFR Mutation Profile of NSCLC Patients Tested at the Lung Center of the Philippines Maria Teresa Alhambra Barzaga, Lung Center of the Philippines, PH P3.02-057 Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples Kurtis D Davies, University of Colorado - Anschutz Medical Campus, US P3.02-058 Detection of ROS1 Rearrangements in 508 Russian Patients with Non-Small Cell Lung Cancer (NSCLC) Irina Demidova, Moscow Oncological Hospital 62, RU P3.02-059 T790M and C797S as Mechanisms of Acquired Resistance to Dacomitinib in Cell Models Yoshihisa Kobayashi, Kindai University Faculty of Medicine, JP P3.02-060 EGFR Mutation Status by Three Sequencing Platforms in 704 Non-Small Cell Lung Cancer (NSCLC) Brazilian Patients Helano Carioca Freitas, A.C. Camargo Cancer Center, BR P3.02-061 An ALK Follow-On Companion Diagnostic Using CGP for Clinical Care of Patients with NSCLC James Sun, Foundation Medicine, US P3.02-062 An EGFR Follow-On Companion Diagnostic for Clinical Care of Patients with NSCLC James Sun, Foundation Medicine, US P3.02-063 EGFR Exon 20 Insertions in Lung Adenocarcinomas: Molecular and Clinicopathologic Characteristics Among Hispanics (Geno1.2-CLICaP) Oscar Arrieta, Instituto Nacional de Cancerologia, MX P3.02-064 Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases Takashi Inoue, Dokkyo Medical University, JP P3.02-065 Lung Adenocarcinoma Patient with EGFR Kinase Domain Duplication(KDD) and Its Response to Icotinib: A Case Report Chunwei Xu, Fujian Provincial Cancer Hospital, CN

90

P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma Chiara Ambrogio, Dana Farber Cancer Institute, US P3.02-067 Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: A Case Report Meiyu Fang, Zhejiang Cancer Hospital, CN P3.02-068 95 Cases of EGFR/ALK Gene Status Anaysis in Lung Adenosquamous Carcinoma Meiyu Fang, Zhejiang Cancer Hospital, CN P3.02-069 58 Cases of EGFR/ALK Gene Status Anaysis in Pulmonary Sarcomatoid Carcinoma Meiyu Fang, Zhejiang Cancer Hospital, CN P3.02-070 Investigation of Whether HIF-1α Inhibitors Can Increase EGFR-TKI Effect for Non-Small Cell Lung Cancer Cell Lines Yung-Hung Luo, Taipei Veterans General Hospital, TW P3.02-071 – P3.02-097h FUNCTIONAL BIOLOGY IN LUNG CANCER P3.02-071 Statins May Improve the Prognosis of Patients with Lung Adenocarcinoma by Suppressing Mutant p53-Induced EMT Shigeto Nishikawa, Graduate School of Medicine, Kyoto University, JP P3.02-072 MiR-33b Inhibits Lung Adenocarcinoma Cell Epithelial-Mesenchymal Transition Through CeRNA Regulatory Network Min Li, Xiangya Hospital Central South University, CN P3.02-073 Stromal Hedgehog Pathway Activation Suppresses Growth and Metastasis of Lung Adenocarcinoma James Kim, University of Texas Southwestern, US P3.02-074 Podoplanin-Positive CAF Is Associated with a Higher Number of Single Nucleotide Variants in Cancer Cells in Lung Adenocarcinoma Shoko Nakasone, National Cancer Center Hospital East, JP P3.02-075 Molecular Disorders of the Genes of Intracellular Signal Pathways in Patients with NonSmall Cell Lung Cancer Anna Shchayuk, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, BY P3.02-076 Glutaminase Inhibitor CB-839 Radiosensitizes KRAS-Mutant Lung Cancer Cells in a LKB1and KEAP1/NRF2-Pathway Dependent Manner Piyada Sitthideatphaiboon, The University of Texas MD Anderson Cancer Center, US P3.02-077 Platin Sensitivity and ATM-Deficiency in Non-Small Cell Lung Cancer D. Gwyn Bebb, University of Calgary, CA P3.02-078 Establishing Malignant Pleural Mesothelioma Primary Cell Lines Using the 3D Spheroid Method Produces a Model with Better Tumour Architecture Yuen Yee Cheng, The University of Sydney, AU

91

P3.02-079 A 3D Spheroid Culture Represents an Improved in Vitro Model of Malignant Plural Mesothelioma (MPM) Yuen Yee Cheng, The University of Sydney, AU P3.02-080 DNMT3A Defines a Unique Molecular Class of Chinese Non-Small Cell Lung Cancer Patients Gang Chen, Fujian Provincial Cancer Hospital, CN P3.02-081 Nutritional Status Assessment in Treatment Naïve Patients with Lung Cancer Sabita Jiwnani, Tata Memorial Hospital, IN P3.02-082 High Mobility Group Box 1 Antagonist Limits Metastatic Seeding in the Lungs via Reduction of Cell-Cel Adhesion Adi Karsch-Bluman, The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel., IL P3.02-083 DKK1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via β-Catenin Signaling Pathway Jinjing Tan, Beijing Chest Hospital, Capital Medical University / Beijing Tuberculosis and Thoracic Tumor Research Institute, CN P3.02-084 FGF9-FGFR Pathway Induce Neuroendocrine Differentiation in Lung Epithelial Cells Kota Ishioka, Keio University School of Medicine, JP P3.02-085 Sphingosine Kinase 1 (SPHK1) Promotes Proliferation and Survival in Non-Small Cell Lung Cancer Nozomu Motono, Kanazawa Medical University, JP P3.02-086 MGA Suppresses the MYC Pathway in Lung Adeocarcinoma Paula Llabata, Bellvitge Biomedical Research Institute, ES P3.02-087 Long Noncoding RNA FOXF1-AS1 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer Cells Yongsheng Wang, Nanjing Drum Tower Hospital, Medical School of Nanjing University, CN P3.02-088 Enhanced Glycolysis Is Critical for Maintaining Inactivation of JNK and Stability of EGFR Leading to the Survival of EGFR-Mutant Lung Cancer Cells Jae Cheol Lee, Asan Medical Center, University of Ulsan College of Medicine, KR P3.02-089 Establishment of Highly Metastatic Lung Cancer Cell Sublines in Long-term Threedimensional Low Attachment Cultures Tomoyuki Nakano, Jichi Medical University, JP P3.02-090 Hypoxia-Induced Modifications of the Small Non-Coding RNA Transcriptome Delineates Risk of Recurrence in Early-Stage Lung Adenocarcinoma Victor D Martinez, BC Cancer Research Centre, CA P3.02-091 Concurrent Aberrations in G2/M-Phase Transcriptional Programs and Genomic Gatekeepers Highlight Lung Cancer Predisposition in COPD Patients Erin Anne Marshall, BC Cancer Research Centre, CA

92

P3.02-092 CD151-Integrin-C-Kit Axis Plays an Important Role in the Pathogenesis of Non-Small Cell Lung Cancer Zeyi Liu, Institute of Respiratory Diseases, CN P3.02-093 Knockdown of BRM Causes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cell Line H1975 Daisuke Matsubara, Jichi Medical University, JP P3.02-094 Identification of Oncofetal piRNAs in Lung Brenda C. Minatel, British Columbia Cancer Research Centre, CA P3.02-095 Basic Transcription Factor 3 Is Involved in Lung Cancer Growth and Progression Xiongfei Li, Tianjin Medical University General Hospital, CN P3.02-096 The Interaction Between Mast Cells and Lung Cancer Cells Through Extracellular Vesicles Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, IL P3.02-097 Clinicopathological Features and Genetic Landscape of Pulmonary Large Cell Carcinoma under 2015 WHO Classification of NSCLC Renwang Liu, Tianjin Medical University General Hospital, CN P3.02-097a Metabolic Biomarkers in Serum for the Early Diagnosis of Lung Cancer: First Results from the Cancer-Biomarkers in HUNT Initiative Oluf Dimitri Røe, Norwegian University of Science and Technology, NO P3.02-097b Significance of PAK1/CREB Pathway in Lung Adenocarcinoma Oncogenesis Seong Hoon Yoon, Pusan National University Yangsan Hospital, KR P3.02-097c Detection of the EGFR P.(T790M) Mutation by Different Methods: A Small Comparison Case Study Hangjun Wang, McGill University Health Center & McGill University, CA P3.02-097d Pulmonary LCNEC Might Be Aggregated With SCC On the Basis of Different Clinical Features, Overall Survival, and Pathogenesis Ke Chen, Zhongshan Hospital, Fudan University, CN P3.02-097e Prognostic Importance of Tumor Spread Through Air Spaces in Lymph Node Negative Operated Adenocarcinoma Lung Cancers Faith Selcuk Biricik, Koc University Medicine Faculty, TR P3.02-097f Rare Actionable Mutations in a Lung Adenocarcinoma Cohort in Brazil Carlos Gil Ferreira, Koc Neotorax Oncologia D'or, BR P3.02-097g LRIG1 and LMO7 Are Interacting Proteins with Clinical Significance in NSCLC Samuel Kvarnbrink, Radiation Sciences, SE P3.02-097h Mutational Analysis of Multiple Lung Cancers: Discrimination between Primary and Metastatic Lung Cancers by Genomic Profile Taichiro Goto, Yamanashi Central Hospital, JP

P3.03 CHEMOTHERAPY/TARGETED THERAPY

93

P3.03-001 Immunotherapy Toxicity: Are General Practitioner Satisfied About Information Transmitted? A Retrospective Survey Radj Gervais, Centre Francois Baclesse, FR P3.03-002 Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations Tadaaki Yamada, Kyoto Prefectural University of Medicine, JP P3.03-003 ABCB1 3435C≫T Polymorphism Influences the Toxicity and Clinical Outcome of Patients with Taxane-Based Chemotherapy Jia Zhong, Peking University Cancer Hospital & Institute, CN P3.03-004 The Frequency and Clinical Implication of ALK, ROS1, RET and NTRK1 Gene Rearrangements in Adenosquamous Lung Carcinoma Patients Xiaohua Shi, Peking Union Medical College Hospital, CN P3.03-005 Diagnosis and Treatment Analysis of Lung Enteric Adenocarcinoma: 6 Case Report and Review of the Literature Li Lin, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, CN P3.03-006 Efficiency of Anlotinib as 3rd Line Treatment in Patients with Different EGFR Gene Status, an Exploratory Subgroup Analysis of ALTER0303 Trial Baohui Han, Shanghai Chest Hospital, CN P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor Mark G Kris, Memorial Sloan Kettering Cancer Center, US P3.03-008 Organoid Cultures of Lung Squamous Cell Carcinoma for Drug Screening Ruoshi Shi, Ontario Cancer Institute, CA P3.03-009 Concurrent Somatic Mutations in Driver Genes Were Significantly Correlated with Lymph Node Metastasis and Pathological Types in Solid Tumors Yanan Cheng, Tianjin Medical University Cancer Institute and Hospital, CN P3.03-010 Identification of Mechanisms of Drug Resistance in RET-Rearranged Lung Cancer Takashi Nakaoku, National Cancer Center, Research Institute, JP P3.03-011 A Report of BRAF V600E Positive Lung Adenocarcinoma Patient Who Respond Well to Pemetrexed Yoshiko Nakagawa, Nihon University School of Medicine, JP P3.03-012 The Relationship between Efficacy of Wee1 Inhibitor AZD1775 and Mutational Status of TP53 in KRAS-Mutant Non-Small Cell Lung Cancer Bo Mi Ku, Samsung Biomedical Research Institute, Samsung Medical Center, KR P3.03-013 Identification of Proteasomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen Mitsuo Sato, Nagoya University Graduate School of Medicine, JP

94

P3.03-014 Tumor Cavitation in Patients with Primary Lung Cancer Following Apatinib Treatment Man Jiang, The Affiliated Hospital of Qingdao University, CN P3.03-015 ROS-1 Rearranged Non Small Cell Lung Cancer and Crizotinib: An Indian Experience Vikas Talreja, Tata Memorial Hospital, IN P3.03-016 Morphometric Genotyping Identifies Lung Cancer Cells Harboring Target Mutations; CellCT® Platform Detects Gene Abnormalities Alan Nelson, VisionGate, US P3.03-017 Blood Samples NGS for Baseline Molecular Signature of Anotinib Treated Advanced NSCLC Patients in ALTER0303 Trial Baohui Han, Shanghai Chest Hospital, CN P3.03-018 Tumor Cavitation in Lung Metastases in Patients with Solid Tumor Treated with Apatinib Man Jiang, The Affiliated Hospital of Qingdao University, CN P3.03-019 Activity of PARP Inhibitor in NSCLC with Germline and Somatic Mutation and in Silico Chemotherapy Lethality Carmelia Maria Noia Barreto, Avancos em Medicina Institute, BR P3.03-020 Unique Molecular Profile of NSCLC in Thai Population Narumol Trachu, Mahidol University, TH P3.03-021 In Vitro Pharmacogenomic Platform with a High-Purity Patient-Derived Cell Model Hyun Chang, Catholic Kwandong University International St. Mary's Hospital, KR P3.03-022 Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement but Better Survival Nir Peled, Rabin medical center, IL P3.03-023 Nintedanib Selectively Inhibits the Activation and Tumor-Promoting Effects of Fibroblasts from Lung Adenocarcinoma Patients Noemi Reguart, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES P3.03-024 Real-Life Experience and Clinical Characterization of BRAF V600E Mutation in Austrian NSCLC Patients Maximilian Johannes Hochmair, Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, AT P3.03-025 Tumor Biomarkers for the Routine Care of Advanced Non-Small-Cell Lung Cancer: A Decade of Experience in Implementing Predictive Genomic Events Paul Andrew Vanderlaan, Beth Israel Deaconess Medical Center, Harvard Medical School, US P3.03-026 Cell-CT® Differential Detection of Dysplastic Bronchial Epithelial Cells from Patient Explants Daniel J Sussman, VisionGate, US

95

P3.03-027 LKB1 Loss Is Associated with Resistance to Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer Mouse Models Irene Guijarro, The University of Texas M. D. Anderson Cancer Center, US P3.03-028 WINTHER – a Study of Cancer Therapy Based on Tumor and Normal-Matched Biopsies – the Sheba Medical Center Lung Cancer Experience Amir Onn, Sheba Medical Center, IL P3.03-029 ROS1 Alterations in Lung Adenocarcinoma: The Prognostic Role of Rearrangement and Copy Number Variation Jun Chen, The Second Affiliated Hospital of Dalian Medical University, CN P3.03-030 TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs Yun Fan, Zhejiang Cancer Hospital, CN P3.03-031 Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance Yun Fan, Zhejiang Cancer Hospital, CN P3.03-031a The IGFBP-3 Methylation Status Could Define a New Alternative Schedule for NSCLC Treatment Javier De Castro Carpeño, Hospital Universitario La Paz, IDIPAZ, ES P3.03-031b Results of a Phase II Study of Stereotactic Radiosurgery Followed by Erlotinib for Patients with EGFR Mutation and Progression in 5 or Fewer Sites Jared Weiss, Lineberger Comprehensive Cancer Center, University of North Carolina, IDIPAZ, US

P3.04 CLINICAL DESIGN, STATISTICS AND CLINICAL TRIALS P3.04-001 Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer Dawei Yang, Zhongshan Hospital Fudan University, CN P3.04-002 A Randomized Phase II Study of Carboplatin plus Nab-Paclitaxel with or Without Nintedanib for NSCLC with IPF (J-SONIC): Trial in Progress Kohei Otsubo, Kyushu University, JP P3.04-003 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC Helen J Ross, Mayo Clinic Arizona, US P3.04-004 Treatment Rationale and Study Design for the TAKUMI Trial Kentaro Tanaka, Kyushu University Hospital, JP P3.04-005 PD-L1 and Other Immuno-Markers Influenced by Osimertinib Treatment in Advanced NonSmall Cell Lung Cancer Patients (ATHENE Study) Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, CN

96

P3.04-006 SYSTEMS-2: Randomised Phase II Trial of Standard Versus Dose Escalated Radiotherapy for Pain in Malignant Pleural Mesothelioma Miranda Jane Ashton, Beatson West of Scotland Cancer Centre, GB P3.04-007 A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy Yutao Liu, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital，Chinese Academy of Medical Sciences & Peking Union Medical College, CN P3.04-008 A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Rathi N Pillai, Winship Cancer Institute, Emory University, US P3.04-009 Stereotactic Body Radiotherapy to All Sites of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Combined with Durvalumab and Tremelimumab Ticiana A. Leal, University of Wisconsin Carbone Cancer Center, US P3.04-010 Validation of a ctDNA Methylation Assay to Differentiate Benign and Malignant Pulmonary Nodules: A Chinese Nationwide Multi-Center Study Wenhua Liang, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China State Key Laboratory of Respiratory Disease, CN P3.04-011 A Prospective Study to Optimize the Extent of Pulmonary Resection According to DecisionMaking Algorithm in cStage IA NSCLC Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, KR P3.04-012 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC Pasi A Jänne, Dana-Farber Cancer Institute, US P3.04-013 Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC Pasi A Jänne, Dana-Farber Cancer Institute, US P3.04-013a CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma Dean A Fennell, University of Leicester & Leicester University Hospitals, GB P3.04-013b TTFields and Radiosurgery for 1-10 Brain Metastases from NSCLC: The Phase 3 METIS Study Uri Weinberg, Novocure, US

P3.05 EARLY STAGE NSCLC P3.05-001 Breath Analysis for Early Detection of Lung Cancer: The LuCID Study Marc Phillipe Van Der Schee, Academic Medical Center, University of Amsterdam, NL

97

P3.05-002 The Effect of Nodule Size on the Sensitivity of the LuCED® Test for Lung Cancer Michael Meyer, VisionGate, US P3.05-003 Serum Thioredoxin Reductase 1 as a Diagnostic Biomarker for Non-Small Cell Lung Cancer Xiaozheng Kang, Peking University Cancer Hospital, CN P3.05-004 The Impact of EGFR Mutations on Incidence and Survival of NSCLC Patients with Brain Metastasis: a Single Center Retrospective Study Wei-Yuan Chang, National Cheng Kung University Hospital, TW P3.05-005 Hypermethylation of the RASSF1A and SOX1 Genes in Tumor DNA Predicts Unfavorable Overall Survival in Surgically Resected NSCLC Patients Milica Kontic, Clinic for Pulmonology, Clinical Centre of Serbia, RS P3.05-006 Integrated Genomic Analysis to Assess the Molecular Signature of Japanese Patients with Non-Small Cell Lung Cancer Mitsuhiro Isaka, Shizuoka Cancer Center, JP P3.05-007 Potential of CYFRA 21-1 and CEA to Predict Adjuvant Chemotherapy Benefit in Early-Stage Squamous Cell Lung Cancer Achim Escherich, Roche Diagnostics International Ltd, CH P3.05-008 Potential of CYFRA 21-1 and HE4 to Detect Recurrence in Patients with Early-Stage Lung Adenocarcinoma Achim Escherich, Roche Diagnostics International Ltd, CH P3.05-009 Hsa_circ_0044013: A Potential Novel Diagnostic Biomarker of Lung Adenocarcinoma Shuzhen Wei, Zhongda Hospital, Southeast University, CN P3.05-010 NOTCH 1 and NOTCH 3 Expressions for Early Stage of Non-Small Cell Lung Cancer Eun Kyung Cho, Gachon University Gil Medical Center, KR P3.05-012 Clinicopathological Determinants of Circulating Tumor DNA Detection in Early-Stage NonSmall Cell Lung Cancer Jong Ho Cho, Sungkyunkwan University School of Medicine, Samsung Medical Center, KR P3.05-012a Inference of Gene Expressions Associated with Recurrence of Non-Small Cell Lung Cancer Seo Ree Kim, The Catholic University of Korea, KR

P3.06 EPIDEMIOLOGY/PRIMARY PREVENTION/TOBACCO CONTROL AND CESSATION P3.06-001 Tobacco Use, Awareness and Oral Health among Kanchipuram Silk Weavers, Tamil Nadu, India Delfin Lovelina Francis, Tagore Dental College and Hospital, IN P3.06-002 Tobacco Use, Awareness and Oral Health Status among Seafarers in Voc Port, Tuticorin, Tamilnadu, India Delfin Lovelina Francis, Tagore Dental College and Hospital, IN

98

P3.06-003 What Do the Children Think about Smoking and How Are They Helped in Prevention? Domenico Galetta, Clinical Cancer Center “Giovanni Paolo II”,, IT P3.06-004 Role Models “a Tool for Effective Tobacco Control Campaign” Seye O Omiyefa, Youth Action on Tobacco Control and Health, NG P3.06-005 Informational Needs on Smoking Cessation of Cancer Patients Meredith Elana Giuliani, University of Toronto and Princess Margaret Cancer Center, CA P3.06-006 The Government Willingness to Legislate Tobacco Control and Changes on Individual Behavior in Brazil Ana Paula Leal Teixeira, National Cancer Institute-Ministry of Health, BR P3.06-007 Level of Awareness of Various Aspects of Lung Cancer Among College Students in India: Impact of Cancer Awareness Programes Abhishek Shankar, All India Institute of Medical Sciences, IN P3.06-008 Lung Cancer Pathways: A Five-Year Program to Reduce Impact Through Epidemiological Modelling and Investment in Prioritized Interventions Nicole Marion Rankin, The University of Sydney, AU P3.06-009 How Does Screening for the Early Detection of Lung Cancer Facilitate Smoking Cessation? A Qualitative Study of Screened Smokers Ben Young, University of Nottingham, GB P3.06-009a Lung Cancer in the Elderly - Histology, Localization and Gender Distribution in North Romania Lucian Miron, University of Medicine and Pharmacy "Gr. T. Popa", RO

P3.07 IMMUNOLOGY AND IMMUNOTHERAPY P3.07-001 Overcoming Resistance to Anti-PD Immunotherapy in a Syngeneic Mouse Lung Cancer Model Using Adenovirus-Mediated Gene Therapy Xiang Yan, Chinese PLA General Hospital, CN P3.07-002 Blocking of ADAM17 Mitigates Kras-Induced Lung Adenocarcinoma Possibly via Inhibition of IL-6 Trans-Signaling Mohamed I. Saad, Monash University, AU P3.07-003 Analysis of Dendritic Cell Derived Exosomes That Suppressed Tumor Growth Masakatsu Takanashi, Tokyo Medical University, JP P3.07-004 GSDMD Is Required for Effector CD8+ T Cell Responses to Lung Cancer Cell Tang Feng Lv, Jinling Hospital, CN P3.07-005 Activation of Toll-like Receptor-2 Promotes Proliferation in Human Lung Adenocarcinoma Cells Patrick Kohtz, University of Colorado - Denver, US

99

P3.07-006 Pemetrexed Exerts Intratumor Immunomodulatory Effects and Enhances Efficacy of Immune Checkpoint Blockade in MC38 Syngeneic Mouse Tumor Model Ruslan Novosiadly, Eli Lilly, US P3.07-007 Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis Ruben Pio, CIMA-University of Navarra, IDISNA, CIBERONC, ES P3.07-008 Development of Immunomonitoring Assays for Dendritic Cell-Based Lung Cancer Immunotherapy Ondřej Palata, Sotio a.s., CZ P3.07-009 PI3K/mTOR Pathway Altertions May Mediate PD-1/PD-L1 Blockade Resistance in Non-Small Cell Lung Cancer Tao Shou, First People’s Hospital of Yunnan Province, CN P3.07-011 Investigation of Autologous Tumor-Killing Effect of Effusion-Associated Lymphocytes in Malignant Pleural Effusion of Lung Cancer Yung-Hung Luo, Taipei Veterans General Hospital, TW P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases Lucio Crinò, Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori (IRST) IRCSS, IT P3.07-013 Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced NonSmall Cell Lung Cancer Alexander Kuhlmann, Leibniz Universität Hannover, DE P3.07-013a PD-L1 Expression, Using SP142 and 22C3 Antibody Clones, in NSCLC Patients with Known Status of EGFR and ALK Genes Pawel Krawczyk, Medical University of Lublin, PL P3.07-013b The Comparison Analysis of PD-1 Status Between 22C3 and 28-8 IHC Assay in Clinical Practice: A Single Institutional Experience Yuki Nakamura, Matsusaka Municipal Hospital, JP P3.07-013c Computational Simulations for Investigating Electric Field Distributions When Delivering Tumor Treating Fields (TTFields) to the Lungs Uri Weinberg, Novocure, US P3.07-013d Tumor Treating Fields Induce Immunogenic Cell Death and Enhance Antitumor Effects of Anti-PD1 in NSCLC In-Vivo Models Uri Weinberg, Novocure, US

P3.08 LOCALLY ADVANCED NSCLC P3.08-001 Concurrent Chemoradio-therapy with Weekly Carboplatin-Paclitaxel May Be Feasible Option in inoperable Stage III NSCLC Fatih Kose, Baskent University, TR

100

P3.08-002 Lymphovascular Invasion Is Not a Postoperative Prognostic Factor for Large-Sized Lung Cancer Atsushi Tajima, Saiseikai Utsunomiya Hospital, JP P3.08-003 Multimodal Treatment in the Initially Inoperable Stage III N2 Non-Small Cell Lung Cancer Patients Eun Kyo Joung, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, KR P3.08-004 Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC Aaron Laine, UT Southwestern Medical Center, US P3.08-005 Hereditary Familial Overlap Syndrome with Multiple Synchronous Lung Tumors Andrés F. Cardona, Foundation for Clinical and Applied Cancer Research - FICMAC, CO P3.08-006 Treatment Response and Survival Outcomes Are Associated with Histologic Type in NonSmall Cell Lung Cancer Treated with Trimodal Treatment Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, KR

P3.09 MESOTHELIOMA P3.09-001 The Dosimetric Advantages of Intensity Modulated Proton Therapy (IMPT) for Mesothelioma after Pleurectomy/Decortication Jean-Claude M Rwigema, Mayo Clinic Arizona, US P3.09-002 Can We Do Better? Feasibility Dosimetric Study for Upfront Radical Radiotherapy in Mesothelioma Timothy Mitchell, Beatson West Of Scotland Cancer Center, GB P3.09-003 Heart Radiation Dose as a Risk Factor for Dyspnea Worsening After Multimodality Treatment for NSCLC and MPM: An Exploratory Analysis Angela Botticella, KU Leuven, BE P3.09-004 Routine Clinical Parameters Can Stratify Survival Characteristics in Mesothelioma Patients Undergoing Surgery Fraser Brims, Sir Charles Gairdner Hospital, AU P3.09-005 The Results of Trimodality Treatment Strategy for Malignant Pleural Mesothelioma Kazunori Okabe, Yamaguchi Ube Medical Center, JP P3.09-006 Preoperative Six-Minute Walk Distance and Desaturation in Patients with Malignant Pleural Mesothelioma Motoki Nagaya, Department of Rehabilitation, Nagoya University Hospital, JP P3.09-007 Thoracic Asymmetry and Its Impact on Survival after Radiation and Surgery for Malignant Pleural Mesothelioma John Cho, University Hospital Network, Princess Margaret Cancer Centre, CA P3.09-008 Role of Surgery in the Multimodality Treatment of Malignant Pleural Mesothelioma Bub-Se Na, Seoul National University Hospital, KR

101

P3.09-009 Fourteen Cases Study of 5 Year Survivors of Malignant Pleural Mesothelioma Following Extrapleural Pneumonectomy Ayumi Kuroda, Hyogo College of Medicine, JP P3.09-010 18 Years Single Center Experience of Surgical Resection of Malignant Pleural Mesothelioma After Induction Chemotherapy Michaela B Kirschner, University Hospital Zurich, CH P3.09-010a: Late Response to Pembrolizumab in Advanced Biphasic Pleural Mesothelioma Timothy Clay, St John of God Hospital, AU

P3.10 NURSING/PALLIATIVE CARE/ETHICS P3.10-001 Prognostic Factors of Survival in Malignant Pleural Effusion Fernando Conrado Abrão, Hospital Santa Marcelina, BR P3.10-002 Implementing an Innovative Distress/Supportive Care Screening Tool in a Lung Cancer Clinic Lawrence Eric Feldman, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, US P3.10-003 Assessing and Addressing Knowledge Gaps to Improve Lung Cancer Screening Rates Lawrence Eric Feldman, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, US P3.10-004 Immunotherapy: Emergency Department Provider Needs Assessment Survey Lavinia Dobrea, St. Joseph Hospital, US P3.10-005 National UK Thoracic Surgery PPI Group Identify Key Questions in Routine Clinical Care for Further Research Amy Kerr, Heart of England NHS Foundation Trust, GB P3.10-006 The Efficacy of Pistacia Terebinthus Soap in the Treatment of Erlotinib-Induced Skin Toxicity in Non-Small Cell Lung Cancer Patients Didem Tastekin, Department of Medical Oncology, Institute of Oncology, Istanbul University, Capa, TR P3.10-007 Sudden Death of the Patients with Lung Cancer Yasushi Nakano, Kawasaki Municipal Ida Hospital, JP

P3.11 PATIENT ADVOCACY P3.11-001 Factors Correlated With Time and Cost Diagnostic Lung Cancer Inggar Pertiwi, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Refferal Hospital, ID P3.11-002 Immunotherapies and Lung Cancer: Educating the Global Lung Cancer Community Maureen Rigney, Lung Cancer Alliance, US

102

P3.12 PULMONOLOGY/ENDOSCOPY P3.12-001 Lung Cancer in Patients with Interstitial Lung Disease: Clinical Characteristics and Impact on Survival Shunsaku Hayai, Tosei general hospital, JP P3.12-002 Patients with Malignant Pleural Effusion who Succeeded Pleurodesis have a Longer Survival Rate - a 10-year Follow-up Li-Han Hsu, Sun Yat-Sen Cancer Center, TW P3.12-003 Optimised Inhaler Therapy Is Superior to Supportive Care Alone for Dyspnoea in Patients with Coexisting COPD and Lung Cancer David Peter Walder, Institution for Cancer Research, GB P3.12-004 Maidong on the Prevention and Treatment of Radiation Pneumonitis in Mice C57BL/6 Jiancheng Li, Fujian Cancer Hospital, CN P3.12-004a The Demonstration of the Possibility of the Mediastinal Mass Diagnosis by Means of the Cryo Biopsy Jaroslaw Pierog, Pomeranian Medical University, PL P3.12-004b All Cause In-Hospital Mortality on Diagnostic Bronchoscopy in Lung Cancer Patients: Data from the Japanese DPC Database Yoshihisa Hiraishi, Pomeranian Medical University, PL

P3.13 RADIOLOGY/STAGING/SCREENING P3.13-001 – P3.13.038 DIAGNOSTIC RADIOLOGY P3.13-001 Clinical Significance of Chest Tomography Characteristics in Non Small Cell Lung Cancer Patients Who Received Anatomic Resection Ching-Yang Wu, Chang Gung Memorial Hospital, Linkou, TW P3.13-002 Reduced Dose Perfusion CT of Lung Cancer using a 16-cm Coverage Scanner: Effects of Respiratory Motion Correction on Perfusion Assessment Yeon Joo Jeong, Pusan National University Hospital, KR P3.13-003 The Lung Cancer Prognostic Index – a Risk Score to Predict Overall Survival after the Diagnosis of Non-Small Cell Lung Cancer Marliese Alexander, Monash University, AU P3.13-004 Prospective Study of Sequential Ultra-Low then Standard Dose 18F-FDG PET/CT Scans for Lung Lesion Detectability Ivan WK Tham, National University Cancer Institute, Singapore, SG P3.13-005 Characteristics of Primary Lung Cancer on PET/CT Imaging in the South African Population Osayande Evbuomwan, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, ZA

103

P3.13-006 Correlation between CT Morphology at the Diagnosis and EGFR Status in Patients with Adenocarcinoma of the Lung Manlio Mencoboni, Villa Scassi Hospital, ASL 3 Genovese, IT P3.13-007 A Feasible Follow-Up Program Using FDG-PET/CT for Asymptomatic Postoperative NonSmall-Cell Lung Cancer Patients Hiroaki Toba, Institute of Biomedical Sciences, Tokushima University Graduate School, JP P3.13-008 Lung Cancer Associated with Cystic Airspaces: Clinical, Imaging, Histopathological and Molecular Correlation Annemie Snoeckx, Antwerp University Hospital and University of Antwerp, BE P3.13-009 Rapid Detection of Lung Cancer by Fluorescent Imaging using a γ-Glutamyltranspeptidaseactivatable Fluorescent Probe Mingyon Mun, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, JP P3.13-010 Correlation between HRCT Features of Pulmonary Pure Ground-Glass Nodules and the New Pathologic Classification of Lung Adenocarcinoma Jindong Guo, Shanghai Chest Hospital, CN P3.13-011 Use of Volume Growth and Fluor-Deoxy-Glucose Positron Emission Tomography in Evaluating Indeterminate Lung Nodules in Lung Cancer Screening Zaigham Saghir, Copenhagen University Hospital, Gentofte Hospital, DK P3.13-012 Fast Fourier Transform Analysis for the Outline of Pulmonary Nodules on Computed Tomography Images Tatsuya Yoshimasu, Wakayama Medical University, JP P3.13-013 Association of Pleural Tags with Visceral Pleural Invasion of Peripheral Lung Cancer Mayumi Higashi, Yamaguchi University, JP P3.13-014 Prediction of Survival with 18F-FDG-PET/CT Early during Erlotinib Treatment in NSCLC Patients – a Comparison of Four Evaluation Methods Joan Fledelius, Herning Hospital, DK P3.13-015 18F-FDG-PET/CT after Induction Chemotherapy for Prediction of Survival after Radical Chemo-Radiotherapy in Locally Advanced NSCLC Patients Joan Fledelius, Herning Hospital, DK P3.13-016 18F-FDG-PET/CT for Prediction of Survival after Induction Chemotherapy in Locally Advanced NSCLC – a Comparison of Methods Joan Fledelius, Herning Hospital, DK P3.13-017 Review of Lung Cancers on the Stage and Growth Rate, Matched with Lung RADs Category, in Previously Treated with Breast Cancer Patients Soo-Youn Ham, Korea University Anam hospital, KR P3.13-018 CT-Guided Percutaneous Barium Marking Prior to Video-Assisted Thoracoscopic Surgery (VATS) for the Localization of Small Pulmonary Nodules Ana Caroline Zimmer Gelatti, Hospital do Câncer Mãe de Deus, BR

104

P3.13-019 Preoperative Needle Biopsy Does Not Increase the Risk of Pleural Recurrence in ≤3cm Lung Adenocarcinoma Koji Kameda, Memorial Sloan Kettering Cancer Center, US P3.13-020 A Pilot Study of the Autoantibodies to Tumor Antigens in Lung Cancer Using the EarlyCDTLung Test in Hong Kong Chu Leuk Lau, Quality HealthCare Medical Service, HK P3.13-021 Can Lymph Nodes Visualised on PET/CT Predict the Outcome of Patients with Lung Cancer? Mboyo Di Tamba Vangu, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, ZA P3.13-022 3D CNNs for Recognition of Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma Junfeng Xiong, Shanghai Jiao Tong University, CN P3.13-023 Clinicopathological Impacts of the Small Ground-Glass Opacity Surrounding the Solid Type Lung Adenocarcinoma Kazutoshi Hamanaka, Shinshu University, JP P3.13-024 Is Alveolar Spread May Be Predictive with PET CT Scanning? Nil Molinas Mandel, Koc University Medicine Faculty, TR P3.13-025 Spinal Cord and Cauda Equina Compression in Lung Cancer Henda Neji, Abderrahmen Mami Hospital, TN P3.13-026 Non-Small Cell Lung Cancer: Imaging of Recurrences After Surgery Henda Neji, Abderrahmen Mami Hospital, TN P3.13-027 Utilization of PET Scan in Advanced Stage Non-Small Cell Lung Cancer in the United States Madhusmita Behera, Winship Cancer Institute of Emory University, US P3.13-028 Controversies on Lung Cancers Manifesting as Part-Solid Nodules Rowena Yip, Icahn School of Medicine at Mount Sinai, US P3.13-029 Imaging Guideline-Recommendations Prior to Treatment for Non-Small Cell Lung Cancer Demonstrates Variable Compliance Joshua Robert Rayburn, Swedish Cancer Institute, US P3.13-030 Metabolic Parameters of FDG PET at Early Evaluation of NSCLC Differ with Histological Subtypes Yosef Landman, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, IL P3.13-031 Predicting Factor for the Dissociation of the Diameter Between Radiographical Solid Part and Pathological Invasive Part in Lung Adenocarcinoma Yota Suzuki, Keio University School of Medicine, JP P3.13-032 The Impact of Tobacco Exposure on Lung Nodules and Emphysema in a Pilot Silesian Study of Early Lung Cancer with LDCT

105

Mariusz Adamek, Department of Thoracic Surgery, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, PL P3.13-033 DNA Methylation of PTGER4 and SHOX2 in Liquid Biopsies Facilitates the Diagnosis of Lung Malignancy After Chest CT-Scan Lea Maria Schotten, University Medicine Essen - Ruhrlandklinik, Essen, Germany, DE P3.13-034 Comparison of Cytological Smears and Cell Blocks of Pleural Fluid Diagnosing Malignant Pleural Effusion in Lung Cancer Giedrė Cincilevičiūtė, Center of Pulmonology and Allergology of Vilnius University Hospital Santaros Klinikos., LT P3.13-035 Automatic Estimation of Measurement Error on CT Imaging Ricardo S Avila, Accumetra, LLC, US P3.13-036 Immunohistochemical and Genetic Characteristics of Lung Cancer Mimicking Organizing Pneumonia Tomohiro Ichikawa, National Cancer Center Hospital East, JP P3.13-037 Deep Learning System for Lung Nodule Detection Dawei Yang, Zhongshan Hospital Fudan University, CN P3.13-038 The RoaDmaP Study: Feasibility of Implementing a Primary Care Intervention for Referral of Potential Lung Cancer Cases to Specialist Care Nicole Marion Rankin, Cancer Council NSW, AU P3.13-038a Metastases in T1-T2 classed Lung Cancer Henda Neji, Abderrahmen Mami Hospital, TN

P3.14 RADIOTHERAPY P3.14-001 Impact of PCI on Prognosis of LD-SCLC Through Pattern of Brain Metastases as a First Recurrence Site Masaki Nakamura, National Cancer Center Hospital East, JP P3.14-002 Multimodality Management of Pancoast Tumors; Does Surgical Resection Need to Be Included? Mojgan Taremi, Princess Margaret Hospital, CA P3.14-003 Patterns of Follow-Up Care After Curative Radiotherapy for Stage I-III Non-Small Cell Lung Cancer Sharanya Mohan, University of NSW, AU P3.14-004 Pathological Study on the Clinical Target Volume (CTV) in Limited-Stage SCLC for CTSimulation Based Thoracic Radiotherapy Planning Xiao Hu, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, CN

106

P3.14-005 Treatment Response Measured on Conebeam-CT During Concurrent Chemoradiation for NSCLC Patients Margriet Kwint, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, NL P3.14-006 Slow CT Simulation for GTV Delineation and Planning of Radiotherapy to Lung Cancer Patients; A Sunshine to Developing Countries Sharif Ahmed, United Hospital Limited, BD P3.14-007 A Functional Equivalent Uniform Dose Correlates with Radiation Pneumonities in Radiation Therapy Li Yan Dai, Renji Hospital, Shanghai Jiaotong University School of Medicine, CN P3.14-008 Clinical Characteristics Matrix of Lung Tumor Under Stereotactic Ablative Body Radiotherapy (SABR) Kaile Li, John R Marsh Cancer Center, US P3.14-009 Thoracic Re-Irradiation of Lung Cancer Using Highly Conformal Radiotherapy Is Effective as Salvage Treatment Option Yeon Sil Kim, Seoul St.Mary's Hospital, KR P3.14-010 Magnetic Resonance Imaging (MRI) for Lung Cancer Radiotherapy Planning and Treatment Michael Dubec, The Christie NHS Foundation Trust, GB P3.14-011 Mean Heart Dose Is an Independent Risk Factor for Early Mortality After Chemoradiotherapy Treatment for Lung Cancer Dirk K De Ruysscher, Maastricht University Medical Centre, NL P3.14-012 Risk of Developing Pneumonitis Increases in Patients Receiving Immunotherapy with a History of Lung Irradiation Feliciano Barron, Instituto Nacional de Cancerologia, MX P3.14-013 Outcomes According to Marginal Tumor Dose Prescription for Small- to Medium-Sized Brain Metastases from Lung Cancer Fabio Y Moraes, University of Toronto - Princess Margaret Cancer Center, CA P3.14-014 Lung Stereotactic Body Radiotherapy (SBRT): Patient's Outcome and Prognostic Factors Margarita Majem, Hospital de la Santa Creu i Sant Pau, ES P3.14-015 A Propensity Matched Analysis of SBRT and Sublobar Resection for Stage I Non-Small Cell Lung Cancer in Patients at High Risk for Lobectomy Yaping Xu, Zhejiang Cancer Hospital, CN P3.14-016 Research About Different Administration Mode of Endostar for Combining with Concurrent Chemoradiotherapy in Local Advanced NSCLC Jiancheng Li, Fujian Cancer Hospital, CN P3.14-017 Dosimetric Evaluation of Lung SBRT Treatment Margarita Majem, Hospital de la Santa Creu i Sant Pau, ES

107

P3.14-017a Extra-Cranial Oligo-Progression upon 1st Line EGFR TKI in Advanced Non-Small Cell Lung Cancer Patients: Outcomes of Local Ablative Radiotherapy Florence Siu Ting Mok, Prince of Wales Hospital, HK

P3.15 SCLC/NEUROENDOCRINE TUMORS P3.15-001 The Impact of MET Inhibition on Small-Cell Lung Cancer Cells Exhibiting Aberrant Activation of the HGF/MET Pathway Hirokazu Taniguchi, Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, JP P3.15-002 Molecular Profiling and Networks Relevant to Disease Mechanisms in Small Cell Lung Cancer and Lung Carcinoid Tumor Kiyonaga Fujii, St. Marianna University School of Medicine, JP P3.15-003 Second Line Chemotherapy in SCLC: The West of Scotland Experience Sarah Jane Slater, Beatson West of Scotland Cancer Centre, GB P3.15-004 Distinct Role of FAK Kinase and C-Terminal Domains on Small-Cell Lung Cancer Proliferation Sebahat Ocak, Cliniques Universitaires UCL Mont-Godinne, BE P3.15-005 Third Line Chemotherapy in SCLC: The West of Scotland Experience Sarah Jane Slater, Beatson West of Scotland Cancer Centre, GB P3.15-006 Comprehensive Analysis of EMT Gene Signature in Primary and Metastatic Small Cell and Non-Small Cell Carcinomas of the Lung Tabatha Gutierrez Prieto, Faculdade de Medicina da USP, BR P3.15-007 A Retrospective Review of Small Cell Lung Cancer (SCLC) Patients Treated at Marmara University Hospital Faysal Dane, Marmara University Medical School, Marmara University Pendik Training & Research Hospital, TR P3.15-008 [F18]PARPi PET as an In Vivo Pharmacodynamic Biomarker of PARP Inhibitor Therapy in Patient-Derived Xenografts of Small Cell Lung Cancer Benjamin Lok, Princess Margaret Cancer Centre, CA P3.15-009 Impact of Interstitial Lung Disease on Clinical Outcomes in Small Cell Lung Cancer Patients Kimitaka Akaike, Kumamoto University Hospital, JP P3.15-010 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Natural History of the Disease Progression and Management Zin Myint, University of Kentucky, US P3.15-011 Contemporary Treatment and Prognosis of Non-Metastatic Atypical Bronchopulmonary Carcinoid Tumors Abraham J. Wu, Memorial Sloan Kettering Cancer Center, US

108

P3.15-012 Surgical Outcome in Early Stage Small Cell Lung Cancer Kenji Inafuku, Kanagawa Cancer Center, JP P3.15-013 The Addition of Antiangiogenic Agents to Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Meta-Analysis Min Peng, Renmin Hospital of Wuhan University, CN P3.15-014 Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Chong-Kin Liam, University of Malaya, MY P3.15-015 LCNEC Tumor Location, Divided into Central and Peripheral Type, Has Distinct Clinicopathologic Feature, Genomic Characteristics and Survival Fei Zhou, Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, CN P3.15-016 The Role of Surgery in Combination Treatment of Patients with Small Cell Lung Cancer Aleksei Aleksandrovich Aksarin, Surgut District Clinical Hospital, RU P3.15-016a Prediction of Potential Biomarkers for Personalized Treatment in Pulmonary Large-Cell Neuroendocrine Carcinoma Takashi Makino, Toho University School of Medicine, JP

P3.16 SURGERY P3.16-001 – P3.16-036 RISK ASSESSMENT AND PROGNOSTIC FACTORS P3.16-001 Feasibility of 20 mL of Saline for Pleural Lavage Cytology in Non-Small Cell Lung Cancer Toru Nakamura, Seirei Hamamatsu General Hospital, JP P3.16-002 Postoperative Prognostic Factors in Non-Small Cell Lung Cancer Patients with Lymph Node Metastasis Tatsuya Goto, Niigata University, JP P3.16-003 The Clinical Significance of Immune-Nutritional Parameters in Surgically Resected Elderly Patients with Non-Small Cell Lung Cancer Fumihiro Shoji, Kyushu University, Graduate School of Medical Sciences, JP P3.16-004 Surgery for Patients with Lung Cancer Associated with Interstitial Pneumonia Yoko Azuma, Toho University School of Medicine, JP P3.16-005 Outcome, Mortality and Morbidity after Lung Cancer Thoracic Surgery Fadil Gradica, University Hospital Shefqet Ndroqi, AL P3.16-006 Impact of Limited Resection or Omitted Adjuvant Therapy in Patients with Pathologic Stage II and III Non-Small-Cell Lung Cancer Jeong Su Cho, Pusan National University Hospital, KR

109

P3.16-007 Incidence and Outcomes of Positive Parenchymal Margins after Lung Resection – an Analysis of 1428 Cases Patrick James Villeneuve, The Ottawa Hospital, CA P3.16-008 Thymidine Phosphorylase Influences Clinical Outcome Following Surgery in Patients with Stage I and II Non-Small Cell Lung Cancer Naoya Himuro, Showa University School of Medicine, JP P3.16-009 Reoperation for Hemostasis within 24 Hours Can Get a Better Short-Term Outcome When Indicated after Lung Cancer Surgery Qiang Li, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, CN P3.16-010 Preoperative Six-Minute Walk Distance Is Associated with Complications of Pneumonia after Lung Resection Keiko Hattori, Department of Rehabilitation, Nagoya University Hospital, JP P3.16-011 Correlation Between Pulmonary Vein Stump Thrombus and Cerebral Infarction After Left Upper Lobectomy of the Lung Yoshiyuki Yasuura, Shizuoka Cancer Center, JP P3.16-012 Lung Cancer: System Approach Oleg Kshivets, Roshal Hospital, RU P3.16-013 Prognostic Effect of EGFR Gene Mutation for Recurrence in Completely Resected Lung Adenocarcinoma In Kyu Park, Seoul National University Hospital, KR P3.16-014 Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer-Prognostic Significance of Local Treatment Hyeong Ryul Kim, Asan Medical Center, University of Ulsan College of Medicine, KR P3.16-015 Rapid Identification of Micropapillary or Solid Component for Early-Stage Lung Adenocarcinoma Ze-Rui Zhao, Prince of Wales Hospital, Chinese University of Hong Kong, HK P3.16-016 Prognosis of Patients with Remnant Tumor at Bronchial Stump After Pulmonary Resection for NSCLC: Based on Case Series Study Hye-Seon Kim, Hanyang University Seoul Hospital, KR P3.16-017 The Role of Skip Metastases and the Number of Metastac Lymp Nodes in the Survival of Operated Patients Mark Krasnik, Copenhagen University Hospital Rigshospitalet / Gentofte Hospital, DK P3.16-018 Null 30-Days Mortality After 72 Consecutive Left Open Pneumonectomies for Lung Cancer Veronica Manolache, Oncology Institute Bucharest, RO P3.16-019 Prognostic Factors for Resected Non-Small Cell Lung Cancer in Patients with Type 2 Diabetes Mellitus Woo Sik Yu, The Graduate School of Yonsei University, KR

110

P3.16-020 Long Term Changes of Pulmonary Function After Lobectomy Kook Nam Han, Korea University Guro Hospital, KR P3.16-021 Thoracic Morbidity and Mortality System in Analysis of Postoperative Complications after Pneumonectomy in NSCLC Patients Oleg Pikin, P. Hertzen Research Institute of Oncology, RU P3.16-022 Surgery for Non-Small-Cell Lung Cancer with Malignant Minor Pleural Effusion Detected on Thoracotomy Toshiya Yokota, Mitsui Memorial Hospital, JP P3.16-023 Intrapulmonary Lymph Node Metastasis of Non-Small Cell Lung Cancer: Distribution Pattern and Therapeutic Relevance Nan Wu, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), CN P3.16-024 Feasibility of the Fit4Surgery App - Can It Replace Conventional Pulmonary Rehabilitation in the Surgical Population? Nicola Oswald, University of Birmingham, GB P3.16-025 Tumor Doubling Time Is the Most Important Predictor of Survival and Pathological Diagnosis in Metachronous Lung Cancer Keisuke Asakura, National Cancer Center Hospital, JP P3.16-026 Clinical Implication of Occult Lymph Node Metastasis in the Remaining Lobes After Lobectomy in Non-small Cell Lung Cancer Young Tae Kim, Seoul National University Hospital, KR P3.16-027 Effects of Surgical Waiting Time on Prognosis in Patients with Lung Cancer Yuriko Terada, Japanese Red Cross Medical Center, JP P3.16-028 Necrosis Is a Predictor of Recurrence in Patients with Small Lung Adenocarcinoma ≦2cm Yuriko Terada, The University of Tokyo Hospital, JP P3.16-029 Recurrence within a Year after Complete Resection of Primary Lung Cancer Takashi Ibe, Maebashi Red Cross hospital, JP P3.16-030 Venous Thromboembolism After Lung Cancer Surgery and Its Risk Factors: A Single Center, Retrospective, Cohort Study from China Bo Tian, Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, CN P3.16-031 Survival and Prognostic Factors of Synchronous Multiple Primary NSCLC and Further Differentiation from Intrapulmonary Metastasis Fei Xiao, National Clinical Research Center for Respiratory Diseases, Center for Respiratory Diseases, China-Japan Friendship Hospital, CN P3.16-032 Prediction of Postoperative Lung Function in Patients with Lung Cancer by Lung Lobe Kantaro Hara, Osaka City University Hospital, JP P3.16-033 Significance of Spread through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma Gouji Toyokawa, Graduate School of Medical Sciences, Kyushu University, JP

111

P3.16-034 Impact of Travel Distance to Treatment Institution on Survival from Stage I to III Lung Cancer Ana Caroline Zimmer Gelatti, Hospital do Câncer Mãe de Deus, BR P3.16-035 The Unknown: Does Body Mass Index (BMI) Influence Outcomes Post Lung Cancer Resection Surgery? Prakash Balakrishnan, Wellington Regional Hospital, NZ P3.16-036 Feasibility of Lung Cancer Surgery in Septuagenarians Prakash Balakrishnan, Wellington Regional Hospital, NZ P3.16-037 – P3.16-049 SURGERY FOR LOCALLY ADVANCED AND ADVANCED NSCLC P3.16-037 Superior Vena Cava Replacement Combined with Veno-Venous Shunt for Lung Cancer and Thymoma: Case Series Qiang Li, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, CN P3.16-038 Experience of 180 Bronchial Sleeve Resections for Malignant Tumors Evgeny Levchenko, N. N. Petrov Research Institute of Oncology, RU P3.16-039 Right Upper Lobectomy with SVC Reconstruction after Induction Chemoradiotherapy for a Patient with Bulky N2 NSCLC Hideo Ichimura, University of Tsukuba, Hitachi Medical Education and Research Center, JP P3.16-040 Intrapleural Perfusion Thermo-Chemotherapy for Pleural Effusion Caused by Lung Carcinoma under VATS Runlei Hu, Hangzhou First People’s Hospital, CN P3.16-041 Pleural Photodynamic Therapy and Surgery for Pleural Metastasis by Non-small Cell Lung Cancer Ke-Cheng Chen, National Taiwan University Hospital, TW P3.16-042 Intraoperative Hyper-Thermotherapy with Distilled Water for StageIV Lung Cancer Ayumi Suzuki, Kariya Toyota General Hospital, JP P3.16-043 Resection and Reconstruction of Tracheal Carina in Lung Cancer Surgery Evgeny Levchenko, N. N. Petrov Research Institute of Oncology, RU P3.16-044 Feasible Outcome of Radical Extended Surgery in T4 Locally Advanced NSCLC; 23-Year Japanese Single Center Experience Ryuichi Waseda, Fukuoka University, JP P3.16-045 Evaluation of the Safety and Efficacy of VATS Pneumonectomy in the Treatment of Locally Advanced Lung Cancer Joshua Goldblatt, St Vincent's Hospital, AU P3.16-046 Pneumonectomy After Induction/Neoadjuvant Treatment for NSCLC: Morbidity, Mortality and Long-Term Survival Cengiz Gebitekin, Uludag University, TR

112

P3.16-047 Salvage Surgery for Locoregional Recurrence or Persistent Residual Tumor After Definitive Chemoradiation Therapy Junichiro Osawa, Kanagawa Cancer Center, JP P3.16-048 The Role of Pulmonary Resection in Stage IVa Non-Small Cell Carcinoma Patients Tomoyuki Igarashi, Shiga University of Medical Science, JP P3.16-049 Surgery with Continued TKI Therapy After Acquiring Resistance to EGFR or ALK TKI Shuta Ohara, Kindai University, JP P3.16-050 – P3.16-053a TRANSLATIONAL STUDIES P3.16-050 Stromal PDGFR-β Expression Influences Postoperative Survival of NSCLC Patients Receiving Preoperative Chemo- or Chemo-Radiotherapy Ryu Kanzaki, Osaka University Graduate School of Medicine, JP P3.16-051 Implications of Preoperative Serum Tumor Levels on Pathological Characteristics in Patients with Lung Adenocarcinoma Terumoto Koike, Niigata University, JP P3.16-052 Use of Decellularised Porcine Intestinal Submucosa Extracellular Matrix in Airway Reconstruction to Enable Lung-Sparing Oncological Surgery Michelle Lynne Kim, Barwon Health, AU P3.16-053 Genomic Challenges for Lung Cancers with Multiple Pulmonary Sites of Involvement Xiaozheng Kang, Peking University Cancer Hospital, CN P3.16-053a Surgical Outcome of Bronchoplasty in Non-small Cell Lung Cancer Patients Katsuyuki Suzuki, Yamagata Prefectural Central Hospital, JP

P3.17 THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES P3.17-001 The Prognostic Analysis of Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma with Different Status of Lymph Node Metastasis Xin Xu, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, CN P3.17-002 Comparison of Single- and Multi-Incision Minimally Invasive Esophagectomy for Treating Esophageal Cancer: A Propensity-Matched Study Mong-Wei Lin, National Taiwan University Hospital, TW P3.17-003 A Selective Small Molecule Inhibitor of C-Met Kinase, BPI-9016M, Has Synergistic Effects with Radiation on Esophageal Squamous Cell Carcinoma Yaping Xu, Zhejiang Cancer Hospital, CN

113